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SUMMARY
An investigation into the presence of plasmids in 
Mycobacterium tuberculosis was conducted. No extrachromosomal 
DNA was found although some evidence for their presence were 
detected.
Plasmid-related sequences were however found in the 
genomic DNA of M. tuberculosis.
Isolation of plasmid-related sequences from a strain of 
M. tuberculosis resulted in two different DNA probes which 
showed high specificity for M. tuberculosis and related 
species. One of these probes gave banding patterns which 
suggest the presence of restriction fragment polymorphism in 
M. tuberculosis. The other probe gave banding patterns which 
were unique for each strain tested. The use of these probes 
for epidemiological studies is suggested.
An E, coll plasmid, pIJ666, was successfully introduced 
into Mycobacterium smegmatls ATCC607 and stably maintained 
through several subcultures. One of the selective markers, a 
chloramphenicol resistance gene from Tn9, was efficiently 
expressed in M. smegmatls ATCC607. The development of a 
transformation system in M, smegmatls from this initial study 
is indicated.
INTRODUCTION
CHAPTER 1
The Mycobacteria 
Section 1.0 A short history
The disease that is known as tuberculosis is an old one. 
Ancient Hindu texts have referred to it as the king of 
disease and the disease of kings and thus emphasising the 
indiscriminate nature of this disease.
Another disease of kings is leprosy. Both are caused by 
members of the genus Mycobacterium. When originally named in 
1896, in an Atlas of Bacteriology, by Lehmann and Neumann, 
this genus contained the leprosy bacillus 
(Mycobacterium leprae), observed by Armauer Hansen in 1874, 
and the tubercle bacillus, first described by Robert Koch in 
1882. The name Mycobacterium means fungus-bacterium arising 
from the characteristic fungus-like pellicle produced by the 
tubercle bacillus when grown in liquid media.
The genus Mycobacterium has been dominated by the 
species M. tuberculosis. This organism, its variants and the 
diseases with which they have been associated with were so 
important in medicine and public health that for a long time 
any other acid fast bacteria, apart from M. leprae, were 
dismissed as saprophytes of little consequence. Den Doreen De 
Jong (1939, quoted by Collins et al, 1984) warned that the 
tubercle bacillus was "the wayward son of a deserving family" 
while Wayne (1964) remarked that it was "not the sun but
merely one of the planets" but still this "tuberculocentric" 
philosophy (Collins, 1965) persisted until recently.
The infective potential of other mycobacterial species 
has now been recognised. The relatively high incidence of 
M. avium-Intracellulare in Acquired Immune Deficiency 
Syndrome (AIDS) patients have created interest in this 
species (Farhi et al, 1985, Kiehn et al, 1985, Kiehn and 
Cammarata, 1986). Disseminated infection with M. kansasll 
were reported in AIDS patient by Sherer et al (1986). These 
and other reports, starting from the 1950’s which suggested 
that the atypical mycobacteria can also be clinically 
significant, stimulated changes in attitudes and interest 
towards mycobacterial species other than M. tuberculosis 
(Grange, 1980) (see Section 3.2 for further discussions on 
atypical mycobacterial diseases).
Section 1.1 Acid Fastness
The characteristic (although not unique) and most well 
known property of this genus is acid fastness. Mycobacterial 
acid fastness is defined as the ability of mycobacteria to 
resist decolourization in the presence of a weak mineral acid 
after staining with an arylraethane dye such as fuchsin, 
crystal violet or auramine (Barksdale and Kim, 1977; Collins 
et al, 1985) and the staining procedure used to identify 
mycobacterial species is called the Ziehl-Neelsen stain (the 
full details of this procedure is given in Collins et al, 
(1985).
The acid fastness is due to the fuchsin being trapped 
intracellularly by a barrier formed by mycolic acid-fuchsin 
complexes in the peptidoglycolipid layer of the outer cell 
wall (Barksdale and Kim, 1977).
Section 1.2 Morphology
Mycobacteria are Gram positive bacilli with sizes 
ranging from 1 to 10pm long and about 1 to 0.5pm in width. 
M. tuberculosis usually, but not always, forms characteristic 
serpentine cords or rope-like structures under the 
microscope. Some mycobacteria appear almost coccoid while 
others fusiform.
The cord-like structures observed in M. tuberculosis are 
due to a component in the outer cell wall called the Cord 
Factor (CF). CF is a glycolipid consisting of two mycolic 
acid molecules (alpha branched and beta-hydroxy1ated acid 
with 90 carbon atoms) linked with trehalose (Noll et al, 
1956; Silva 1985). The cord factor was shown to play an 
important role in host-parasite relationship. It was found to 
be associated with virulence, is involved in inhibiting 
leukocyte migration, confers hydrophobicity to the cell and 
acts as an immunostimulant (Silva et al, 1985). Other 
mycobacteria too produce CF but with variations in the number 
of carbon atoms in the mycolic acid molecules.
Mycobacteria usually form;, smooth or rough colonies on 
solid media although colonial variation can occur (Collins 
et al, 1985). Virulent strains of the M. tuberculosis and
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M. avium-intracellular e complexes are usually associated with 
rough colonies (Silva et al, 1985; Collins, 1988). The colour 
of the colonies ranges from white, to buff, to bright orange. 
Some species are also photochromogenic such as M, kansasll.
CHAPTER 2
Taxonomy and Identification 
Section 2.0 Taxonomy
Since the time when the genus Mycobacterium was first 
recognised by Lehmann and Neumann in 1896, more and more 
members of this genus have been isolated and recognised. The 
history of the classification of mycobacteria is similar to 
many of that of other bacterial genera. Initially the genus 
and the few species were differentiated on the basis of a 
small number of simple cultural properties. Later when 
interest grew, more and more distinguishing properties were 
found and many workers described apparently new species 
unfortunately sometimes without comparison with all 
previously described ones. Consequently, a plethora of names 
emerged so that some species were known by a considerable 
number of names.
Fortunately, order has now replaced the chaos that was 
the genus Mycobacterium. An approved list of mycobacterial 
names has now been published in the International Journal of 
Systematic Bacteriology in January 1980 (Skerman et al,1980).
Table 2A shows the current list of species (from Collins 
et al, 1985).
Table 2A Approved names for mycobacteria, synonyms
and "popular" names
Approved names Other names
M. afrlcanum (a) M.tuberculosis African variantM. aslaticumM. aunmM. avium (b,c,d) M. avium-IntracellulareAvian tubercle bacillus, MAIS bacillusM. bovls (b,c) M. tuberculosis bovine variant Bovine tubercle bacillusM. chelonel (b,c) M. abscessus, M. borstelense Turtle tubercle bacillusM. chltaeM. duvalllM. farclnogenes (c)M. flavescensM, fortultum (b,c) M. ranae, M. glae, M. perlgrlnum Frog tubercle bacillusM. gadlumM. gastrlM. gllvumM. gordonaeM. haemophllum (b)M. Intracellulare (b,c,d) M. avium-Intracellul are Battey bacillus, MAIS bacillusM. kansasll (b) M. luclflavumM. komossenseM. leprae (b) Leprosy bacillus, Hansen's bacillusM. lepraemurlum (c) Rat leprosy bacillusM. malmoense (b)M. marlnum (b,c) M. Jbalnae, M. platypoecllusM. microti (c) M. tuberculosis vole variant Vole tubercle bacillusM. nonchromogenlcumM. neoaurumM. parafortultumM. paratuberculosls (c,d) M. jobnel, Johne's bacillusM. phlel Timothy grass bacillusM. scrofulaceum (b) M. marlanum, MAIS bacillusM. senegalense (c)M. slmlae (b,c) M. JiabanaM. smegmatls Smegma bacillusM. szulgal (b)M. terrae Radish bacillus
continued....
Table 2A (continued)
Approved names Other names
M. thermoreslstlblleM. trivialeM. tuberculosis (b,c) Human tubercle bacillusM. ulcerans (b) M. burullM. vaccaeM. xenopl (b) M. xenopel, M. littorale
(a) Skerman et al, 1980(b) Well documented human pathogen(c) Well documented animal pathogen(d) Member of the MAIS {M. avium-Intracellulare-scrofulaceum) complex. 
(From Collins et al (1985)
The Mycobacterium genus can be divided into two main 
groups: (1) Fast growers and (2) Slow growers. M. smegmatls,
M. phlel and M. fortultum are examples of fast growers. On 
solid media, the colonies start becoming visible after 1 to 3 
days of incubation. M. tuberculosis, M. xenopl and M. avium 
are examples of slow growers. Colonies of M. tuberculosis 
start becoming visible after 10 days of incubation. Other 
species belonging to this group may require an even longer 
time than this. So far no one has been able to grow M. leprae 
in vitro.
There have been a number of more rational and 
fundamental approaches to the taxonomy of the genus. Baess 
(1979) studied the relationship of the different species on 
the basis of DNA homology. Stanford and Grange (1974) and 
Andersen et al (1986) compared species and strains using 
antigenic analysis of their soluble cytoplasmic antigens. 
This technique showed that mycobacterial antigens occur in
four main groups (Table 2B). Table 2B shows that there is 
a large group of antigens. Group (i), that occur in all 
mycobacteria and is shared to some extent with related genera 
such as nocardia and corynebacteria. Group (ii) antigens were 
only found in slow growing mycobacteria. The third group was 
found in the fast growing mycobacteria and was also present 
in some nocardia. Group (iv) antigens were only found in 
mycobacteria. Furthermore these antigens show species and 
strain variations.
Table 2B The distribution of the four groups of antigens
among mycobacteria and related genera
Antigenic Group
i ii iii iv
Slow growers //////////////////// //////////////////// /unique/// ////////// ////////// to each//
//////////////////////////////species//
M. leprae M. vaccae ////////////////////
Fast growers //////////////////// ////////////////////
Norcardia . //////////// ///////////
ListeriaCorynebacteria ////
The most important mycobacterial disease is caused by 
M. tuberculosis. This species contains a number of variants. 
Some of the variants have been given their own species name, 
for example M. afrlcanum and M. bovls. This classification 
have been disputed by some workers who prefer to call all the
variants as M. tuberculosis followed by variant specification 
if required. From a clinical point of view it would be 
sufficient to determine whether a mycobacterium is 
M. tuberculosis or not. Further division into variants does 
not provide information which would affect patient management 
but is for epidemiological interest only. In fact designating 
the variants with their own species name may cause confusion.
For epidemiological purposes M. tuberculosis is 
subdivided into the following variants:
Classical human.
Asian human (Grange et al 1977)
African human 
bovis
BCG (Bacille Calmette-Guerin)
BCG is included because it may cause disseminated 
disease in vaccinated neonates or immunosuppressed patients. 
BCG is the anti-tuberculosis vaccine prepared by Calmette and 
Guerin by passaging a strain of M. bovls 231 times over a 
period of 13 years. Most workers refer to BCG as M. bovls 
BCG, thus indicating BCG as a variant of M. bovls, but 
significant differences between BCG strains and M. bovls 
(reviewed by Grange et al, 1983) have led to other workers to 
consider BCG as a separate variant of M. tuberculosis rather 
than M. bovls and thus should be referred to as BCG only 
(Malcolm Yates, personal communication).
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Section 2.1 Identification of Mycobacteria
Although many non-tuberculous mycobacteria have been 
shown to be pathogenic to man, the most common mycobacterial 
diseases are leprosy and tuberculosis. Leprosy however is 
much rarer in developed countries. Furthermore, the symptoms 
shown by leprosy are more easily identified. Tuberculosis 
therefore is the single most important mycobacterial disease 
in this and most developed countries. The first task for a 
Mycobacterium diagnostic laboratory is to identify the 
Mycobacterium as either a tubercle or non—tubercle 
Mycobacterium, If the mycobacterium is identified as 
M. tuberculosis, the treating hospital is immediately 
notified. Drug sensitivity tests are then performed and the 
variants are further identified.
Non- tubercle mycobacteria, after the first screening, 
are identified using a number of cultural and biochemical 
test.
The screening methods of Marks (1972 and 1976) as used 
by the Regional Tuberculosis Reference Unit at Dulwich 
Hospital are shown below.
Section 2.1.1 The first screening test?
Tubes of Lowenstein Jensen media (see Materials and 
Methods) containing glycerol (LJG) are used to test the 
following:
1. The rate of growth at 37°C
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2. Pigment production if any, with or without light 
induction *
3. Growth at 25°C.
4. Growth on LJG containing SOOmg/litre of p-nitrobenzoic 
acid (PNB).
The details of the screening procedure are shown in 
Collins et al (1985).
The tubes are examined after 3, 7, 14 and 21 days of 
incubation. Tubercle bacilli require about 10 days of 
incubation to give visible colonies. No pigments are produced 
and they do not grow at 25°C nor in the presence of PNB. 
After 21 days Classical human and Asian human variants show 
characteristic, dry, crumbly colonies, greyish white or buff 
in colour on LJG (or LJP) at 37^ C. The bovine and African 
variants usually grow better in LJP. Their colonies are 
flatter and may appear to be less rough than the previous two 
variants.
Mycobacteria that grow within three days, produce 
yellow, orange or pink colonies, able to grow at 25®C or on 
PNB or any combination of these characteristics are not 
tubercle bacilli.
Section 2.1.2 Identification of variants of
M. tuberculosis and BCG
Suspensions of organisms identified as tubercle bacilli 
after the first screening, are used for the following tests:
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1. Sensitivity to thiopen-2-carboxylic acid hydrazine (TCH)
2. Nitratase production test
3. Oxygen preference
4. Pyrazinamide sensitivity
5. Cycloserine sensitivity
6. Pyruvate preference (bovine strains grow better on LJP 
than LJG).
(See Collins et al 1985 for details of the tests)
There are six variants of the M. tuberculosis complex 
which are considered clinically important and are identified 
by the tests described above.
There are other variants of the tubercle complex but 
they are not clinically important. M, microti is included in 
the tubercle complex because of cultural similarities. Yates 
(1984) reported that it had the characteristics of the 
African I variant although M. microti is not pathogenic to 
man.
Hein and Tomasovic (1981) isolated 25 strains of 
M. bovls from Australian water buffaloes. These strains had 
no preference for pyruvate. Kotian et al (1983) reported the 
isolation of tubercle bacilli from patients which had 
characteristics intermediate in their properties between 
M. tuberculosis and M. bovls.
Table 20 shows the reactions of the various clinically 
important strains and variants to the tests.
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Table 2C Species and variants of the tubercle bacilli
Species (a) Variants (b) TCH Nitratase Oxygen pref. Pyr. Cyclo.
M. tuberculosis Classical human R + A S SAsian human S + A S SM.afrlcanum African I S - M S SAfrican II S + M S SM. bovls Classical bovine S - M R SBCG (c) S A R R
TCH- Thiopen-2-carboxylic acid hydrazide, Pyr.- pyrazinamide.
Cycle.- cycloserine.
S - Sensitive R - Resistant A - Aerobic M - Microaerophilic(a) - Species according to Skerman et al (1980)(b) - Variants according to Collins et al (1982)(c) - Not recognised as a separate species.
(After Collins et al 1985)
Section 2.1.3 Identification of non-tubercle mycobacteria
The methods for identifying non-tubercle mycobacteria 
are used by members of the International Working Group of 
Mycobacterial Taxonomy and the European Society of 
Mycobacteriologists. The organisms were subjected to the 
following tests:
1. Growth at different temperatures. The organisms were 
tested for growth at 20, 25, 37, 42 and 44°C.
2. Pigment production. Production of yellow or orange 
pigments indicate a scotochromogen. Photochromogens only 
produce pigments in the presence of light. Potocromogenicity 
however may be temperature dependent.
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3. Sensitivity to thiacetazone (TZ)
4. Nitratase production
5. Arylsulphatase production. The production of arylsulpha­
tase was checked after 3 and 21 days.
6. Catalase production
7. Tween hydrolysis
8. Tellurite reduction
9. Growth in N medium. The medium used contains ammonium 
sulphate as the sole source of nitrogen.
10. Resistance to antituberculous drugs. Streptomycin, 
ethambutol, ethionamide and rifampicin are the main drugs 
used for tuberculosis therapy.
Table 2D shows the typical reactions of the various 
mycobacterial species to the tests.
Minnikin and Goodfellow (1980) and Jenkins (1981) showed 
that mycobacteria could be identified by using thin layer 
chromatography to determine their lipid patterns. This method 
was found to be particularly useful to identify unusual 
species and for distinguishing the species in the fast- 
growers group. Other methods for more discriminative 
identification are available such as immunology, gas-liquid 
chromatography of lipids and pyrolysis mass spectroscopy. 
These methods however are not used for normal diagnostic 
procedures.
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Table 2D Identification of non-tubercle Mycobacteria
Species Pig. TZ Nit . TwH
20
Growth 
25 33
at
42 44
Su .
3d
«
21d
Cat" Tel ' N . RG
M .kansasii P S V
M .marinum P R - + + + + - - 4- + V +M .xenopi -/Sc R - - - - - + + + + + _MAIS -/Sc V - - V + + + V V _ +M .malmoense - R 4- + - + + - - _ _
M .simiae P R - - - + - -
M .szulgai Sc/P R + + - - _ + + + +
M .fortuitum - R + - + + + V - + + + V + +M. chelonei - R - - + + + - - + + + VM .gordonae Sc R - + + + + _ - + _
M.flavescensSc R + + + _ _ +
M .gastri - R - + + _
M .t errae - R + + V + + - _ _
M .triviale - R — + - + + _ _ _
M .nonchro- - R - + V — - + _
mogenicum
M .smegmatis - R + + + _ 4-M . phlei Sc R + + •f + + + _ +
M .ulcerans - /Sc R - - - - - - - - -
Pig.- Pigmentation test TZ- Thiacetazone Nit.- Nitratase test 
T w H .- Tween hydrolysis Su - Arylsulphatase test Cat - Catalase test
Tel - Tellurite reduction N .- nitrogen test R G — Rapid growth 
P-Photochromogen Sc-Scotochromogen S-Sensitive R-Resistant
3d-3 days 21d-21 days
* Sulphatase test- pink colour shows the presence of sulphatase 
+++ deep pink, ++ p i n k , + pale pink
Catalase test- amount of foam, +++>20mm, ++ 10-20mm, + 5- 10mm, - <5mm
Tellurite reduction test is not done with pigmented strains.
(After Collins et al, 1985)
Section 2.1,4 Drug sensitivity tests
Tuberculosis is a highly infectious disease especially 
in conditions of social deprivity. Fortunately, the majority 
of M. tuberculosis strains respond to drug treatments. The
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major antituberculous drugs used in this country are 
Streptomycin (S), Isoniazid (I), Pyrazinamide (Z), Ethambutol 
(E) and Rifampicin (R).
There are at least five methods of drug sensitivity tests 
used throughout the world:
1. The absolute concentration method (Meissner, 1964). This 
is essentially the determination of the minimum inhibitory 
concentration (MIC) of each drug for the test. The 
concentration of the drug must be exact therefore the media 
cannot be heated. This excludes the use of inspissated egg 
based media such as LJG. Middlebrook 7H10 or 7H11 are the 
media of choice for this method. This method is popular in 
some parts of Europe.
2. The proportion method. Also used in Europe and popular in 
the USA (Canetti, 1969, Vestal 1975). In principle, the 
number of colonies growing on drug containing and drug free 
media are compared. The organisms are considered as resistant 
if the number of colonies on the drug containing media is 1 
per cent or more of the number on the control media.
3. The resistance ratio method. This method is used 
throughout the UK and other countries influenced by British 
bacteriologists (Leat and Marks, 1970, Collins and Lyne, 
1984). In this method the MIC of a test strain is compared to 
the mean result of a number of control strains using the same 
batch of medium. Within reason therefore, the exact amount of 
the drug in the medium is not important and inspissated egg
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based media can be used. The resistance ratio is measured by 
dividing the MIC of the test strain by the Modal MIC (average 
MIC of the control strains). Strains with Resistance Ratio of 
1 or 2 are reported as sensitive. Resistance Ratios higher 
than this are considered resistant,
4. The disc diffusion method (Wayne and Krasnow, 1966). 
Essentially the MIC of each strain »s tested for each drug. 
This method was found to be useful for field work by Griffith 
et al (1971). One paper disc impregnated with the required 
drug is placed in each quadrant of a Felsen plate and the 
medium (usually Middlebrook 7H11 agar) is poured over it and 
allowed to set. The quadrants are inoculated with the test 
or control strains and the zones of inhibition in the test 
strains are compared to that of the controls.
5. The radiometric method (Vinke et al, 1982). This method 
(using the BACTEC instrument: Johnston Laboratories) can be 
used to measure the metabolic activity of mycobacteria in the 
presence of antituberculous drugs. This method gives very 
rapid results but the materials and equipments used are too 
expensive for routine diagnostic use in most laboratories. 
Furthermore, physicians in most countries commence drug 
treatment on clinical rather than bacteriological evidence 
using standard drug therapy regimen, therefore, rapid results 
are not usually required. Modifications to the treatment are 
made after the results of drug sensitivity tests are known.
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CHAPTER 3
Mycobacterial Diseases 
Section 3,0 Leprosy
Leprosy is caused by Mycobacterlim leprae also known as 
Hansen's bacillus. About 11 million sufferers of the disease 
throughout the world are present at this time as estimated by 
the World Health Organization (W.H.O. ). So far there has been 
no conclusive proof of M. leprae being cultured in vitro. 
Limited growth can be obtained in nude mice and mouse 
footpads and until recently these were the methods of choice 
for growing this organism. To grow "large" amounts of the 
organism, the nine-banded armadillo is now the method of 
choice, where M. leprae multiplies well. Although expensive, 
this animal has been used to supply large numbers of bacilli 
for research purposes. Nude mice and mouse footpads are still 
used for immunological studies and sensitivity testing. Three 
species of monkeys have also been found to be susceptible to 
M. leprae (Wolf et al, 1985). Monkeys may provide a better 
model of the human disease, being physiologically closer to 
Man than other animals.
Leprosy is principaly a disease of the skin and 
superficial nerves. It also affects the nose from which 
numerous bacilli are shed. The main mechanism involved in 
protection against leprosy (and tuberculosis) is the cell- 
mediated immunity (CMI) response (involving the T-lymphocytes
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which are sometimes referred to as T-cells) (Ridley and 
Jopling, 1966; Sharp et al, 1985). The humoral immune 
response, which is mounted by the B-lymphocytes, are also 
stimulated, resulting in high antibody titres but do not 
appear to have any or little protective effect (Ridley and 
Jopling 1966).
Ridley and Jopling (1966) classified the different forms 
of the disease according the spectrum of immune responses. 
The position of the patient within the spectrum is determined 
by the degree of expression of that individual's immune 
system especially that of the CMI. At one end of the 
spectrum, called tuberculoid leprosy, there is a high degree 
of ce11-mediated immunological activity (involving T-cells 
and macrophages) with the formation of granulomas containing 
numerous lymphocytes and very little bacilli, similar to 
tuberculosis (see Section 3.1). At this end of the spectrum 
the response to therapy is good.
At the other end of the disease, the relevant T-cell 
immune responses are suppressed and the response to therapy 
is poor. The antibody level in the blood however, is high 
which also includes other non-leprae related antibodies due 
to polyclonal B-cell activation. This part of the spectrum is 
called lepromatous leprosy. Lesions found on thesz patients 
teem with the bacilli.
Between these two poles of the spectrum, a wide range of 
intermediate forms exist and these are divided into
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borderline tuberculoid, mid borderline and borderline 
lepromatous. The number of lesions and the number of bacilli 
in them as well as the infactivity of the patients increase 
as the lepromatous end of the spectrum is approached.
Apart from the damage caused by sheer numbers of bacilli 
in the superficial nerve tissues and the formation of nodules 
and lesions, patients also tend to cause damage to themselves 
by physical abrasions due to the fact that they can no longer 
feel the pain. Cuts, burns and bruises therefore, if 
undetected may soon become infected leading to all sorts of 
opportunistic infections.
Leprosy is further complicated by the occurrence of two 
other types of tissue-damaging reactions known as Jopling 
Types I and II (Jopling, 1978).
Type I reaction is also known as erythema nodosum 
leprosum (ENL). This occurs in patients at or near the 
lepromatous pole of the spectrum. This is due to complexes 
formed between antibodies and antigens liberated by the 
bacilli often occurring shortly after therapy.
Type II reaction is a delayed hypersensitivity type and 
indicates the shifting of the disease toward the tuberculoid 
pole of the spectrum. This reaction is also known as a 
reversal or upgrading reaction. Unfortunately this 
immunological activity often leads to rapid and severe nerve 
damage leading to crippling of the joints.
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The CMI response of leprosy patient can be measured 
using two in vitro tests: the lymphocyte transformation test 
(LTT), in which T-cells are stimulated to proliferate 
following contact with M. leprae, and the leucocyte migration 
inhibition test (LMIT) which measures the capacity of T-cells 
to produce migration inhibition factor (MIF) after antigenic 
stimulation (Ridley, 1976), Lepromatous leprosy patients show 
negative results to both tests while tuberculoid leprosy 
patients give strongly positive reactions. Patients in the 
middle of the spectrum show intermediate results. However, 
the tests are not always reliable since some patients at the 
borderlines of the two poles of the spectrum sometimes gave 
results which are opposite to expected reactions.
Another test used to measure the CMI response of leprosy 
patients is the lepromin skin test. A number of reagents have 
been described and used: The Mitsuda lepromin consists of 
heat-killed M. leprae bacilli extracted from tissue. The 
Dharmendra lepromin is a more purified form of the Mitsuda 
lepromin while lepromin A consists of a suspension of 
M. leprae infected armadillo tissue which has been 
autoclaved.
A positive lepromin skin test is biphasic consisting of 
an early and late reactions. The early, or Fernandez 
reaction, appears within 24 to 48 hours of injection of the 
lepromin, and is best seen with the Dharmendra lepromin. The 
late reaction is also called the Mitsuda reaction and occurs
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between 2 to 4 weeks after the injection (most noticeable 
with the Mitsuda and lepromin A preparations).
Again, tuberculoid leprosy patients produce strong 
reactions while lepromatous leprosy patients are negative. 
Borderline patients give intermediate results. The lepromin 
skin test cannot be used in leprosy diagnosis however, 
because healthy individuals often produce positive reactions 
even in areas where leprosy is not endemic. This may be due 
to prior contact to other mycobacteria in the environment.
Section 3.0.1 Therapy of leprosy
Tremendous progress has been achieved in the 
chemotherapy of disease during the last 40 years. One of the 
important preconditions for the development of chemotherapy 
in any disease is the availability of an in vitro system to 
test the drugs to be used. The lack of such a system for 
M. leprae is the major drawback in the development of a 
rational chemotherapeutic regimen in the treatment of the 
disease.
Seydel and Wempe (1982) however, has suggested the use 
of "Mycobacterium lufu (Portaels, 1980), a newly discovered 
species, as a model system due to its sensitivity profile 
which resemble that of M. leprae (Kulkarni and Seydel, 1983),
Chemotheraphy of leprosy started in the early 1940's 
with the use of sulphone-derived antibiotic called Promin. 
This was replaced in the late 1940’s with dapsone (4,4’
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diaminophenyl sulphone) which inhibits the growth of 
M. leprae. Dapsone has this effect by inhibiting the enzyme 
dihydropteroate synthase (Ellard et al, 1971). Due to its 
effectiveness, low toxicity and low cost (Bloom and Godal,
1983), the eradication of leprosy was thought possible. This 
however, has not happened due to a number of factors.
In contrast to antituberculous regimens, monotherapy has 
generally been applied in the therapy of leprosy. This has 
created problems of less effective therapy and has resulted 
in some cases to the rise of resistant mutants especially 
against dapsone (Waters et al, 1976). Secondary resistance 
(resistance arising during treatment) to dapsone as high as 
25 cases per 1000 has been reported (Waters et al, 1976). 
Pearson et al (1977) documented the first evidence of primary 
dapsone resistance (the occurrence of resistant bacilli in 
patients previously untreated with dapsone).
Another factor contributing to the problem is poor 
patient compliance due to the rigorous demands of the therapy 
regimens (involving dapsone monotherapy) which usually last 
from 3 years (for tuberculoid leprosy patient) to life (for 
lepromatous leprosy patients). Poor patient compliance is 
usually a problem in Third World countries due to the lack of 
monitoring resources. However, even in places where patient 
compliance is good the rise of dapsone resistant bacilli 
still occurs (Meade et al, 1973).
The World Health Organization convened a Study Group in
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1981 to review and rationalise drug therapy regimens to 
combat the problem of drug resistance. A new regimen was 
recommended consisting of dapsone, rifampicin (which inhibits 
RNA synthesis by binding to RNA polymerase) and clofazimine. 
Clofazimine however, has a side-effect which results in 
abnormal skin pigmentation ; this is particularly noticeable 
in light-skinned patients and thus the Study Group suggested 
the use of ethionamide in this group of patients.
The triple-drug regimen was recommended for lepromatous 
leprosy patients (administered for two years) while dapsone 
and rifampicin was suggested for tuberculoid leprosy patients 
who should be treated for 6 months.
A combined therapy method was used in Malta (Freerksen 
et al, 1978) and has also proved to be effective. This uses a 
combination of dapsone, isonicotinic acid hydrazide, 2- 
propylisonicotinic acid thioamide (PTH) and rifampicin.
Section 3.0.2 Vaccine Development
Chemotherapy alone is unlikely to result in a complete 
eradication of leprosy. A more rational strategy would 
require two concerted approaches: Chemotherapy, to treat
infected individuals (involving an active case-finding 
programme) and reduce the chances of these individuals to 
infect others, and vaccination, to protect the uninfected 
population.
Vaccination against leprosy has been attempted by
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several workers such as Fernandez (1939), De Souza Campos 
(1953), Chatterjee (1958) and Yanigasawa (1960) (cited by 
Lwin et al, 1985) using BCG as the vaccine. Protection 
against leprosy, as indicated by conversion from lepromin 
negative to lepromin positive in healthy individuals, was 
reported ranging from 26% to 90% in each test group although 
these early trials were not large enough or well enough 
controlled for definitive conclusions on the value of BCG as 
a leprosy vaccine.
Other, better designed trials involving larger groups 
of individuals have been undertaken to evaluate the 
usefulness of BCG as a leprosy vaccine (Brown and Stone, 
1966; Stanley et al, 1981; Lwin et al, 1985; Tripathy, 1984; 
Fine et al 1986). The protection was reported to vary from 
20% to 80%. Thus, BCG appear to be a useful but not 
completely reliable vaccine against leprosy.
A more specific anti-leprosy vaccine was the next goal. 
The availability of large numbers of M. leprae since 1971 
with the use of the nine-banded armadillo for large scale 
cultivation of the bacilli resulted in studies using heat 
killed, gamma irradiated, whole M. leprae bacilli as vaccine 
against leprosy. This vaccine is also known as the IMMLEP 
vaccine because it was developed by the International 
Scientific Working Group on the Immunology of Leprosy 
(UNDP/World Bank/W.H.O. Special Programme for Research and 
Training in Tropical Diseases).
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Convit et al (1979, 1982) showed that a combined IMMLEP 
and BCG vaccine preparation produced a therapeutic effect in 
leprosy patients including those with lepromatous leprosy 
resulting in skin-test conversion, degradation and clearance 
of bacilli from skin lesions and marked improvement in 
clinical symptoms. The potential of this preparation as a 
vaccine is indicated by these results but the true value will 
not be known until all follow up tests, which will continue 
for several years have been collected and evaluated. Other 
large scale trials using the IMMLEP and BCG vaccines, used 
singly or in combination are being evaluated in different 
parts of the world ; Venezuela (Zuniga and Convit, 1985) and 
Malawi (Williams, 1985).
Recently, Emmrich and Kaufmann (1986) reported that a 
cultivable MAIS related mycobacterium, called the ICRC 
bacillus, was able to stimulate T—cell clones from 
tuberculoid leprosy patients to a greater degree than either 
BCG or the IMMLEP vaccine. Significant skin-test conversion 
rates, over 90%, were achieved by Deo et al (1981) earlier 
using this bacillus in lepromin negative, healthy individuals 
and borderline lepromatous patients. Similar results were 
achieved by Chaudhuri et al (1983) with another MAIS related 
bacillus called Mycobacterium W.
The potential of these two cultivable mycobacteria as 
anti-leprosy vaccines is tremendous because the IMMLEP 
vaccine is relatively much more difficult and expensive to 
produce. A large-scale trial of the ICRC vaccine is currently
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being conducted in India. Molecular biology techniques have 
recently been included in vaccine development programmes 
initiated in 1983 by IMMLEP and IMMTUB scientists under the 
auspices of the W.H.O.
The search for an effective vaccine against leprosy 
therefore is underway and hopefully will yield good results 
in the not too distant future.
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Section 3.1 Tuberculosis
Tuberculosis is by far the most frequently encountered 
mycobacterial disease. The importance of the disease in 
industrially more developed countries has diminished 
considerably but it remains a major public health problem in 
most developing nations.The high level of infection in these 
countries shows little or no downward trends.
It is estimated that every year, between 50 to 100 
million are infected by the tubercle bacillus, and of these, 
10 to 20 million will develop the symptoms. A significant 
proportion,about 3 million, will die (Collins et al, 1985).
The lung is the most frequently infected organ. Other 
sites can also be infected such as the lymph nodes, bone, 
kidneys, the reproductive systems, intestines, skin and the 
central nervous system. However, all sites in the body are 
vulnerable and infection in unusual sites may cause serious 
diagnostic problems.
Tuberculosis is usually aquired by the inhalation of 
small cough droplets containing a few bacilli. These 
particles lodge in a peripheral part of the lungs. The events 
which follow this initial infection vary enormously from 
patient to patient. A general pattern of progression however 
can be seen and has been desribed (Wallgren, 1948; Collins et 
ai, 1985).
In people with innate immunity, bacilli at the site of
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infection are ingested and removed from the lungs by 
resident alveolar macrophages whose primary function is to 
clear the lungs of foreign material. In this way the exposed 
individuals are protected from the disease and no 
colonization occurs and hence no primary infection and 
disease.
In most cases a primary disease occurs. At the site of 
initial infection local multiplication of the bacilli occurs 
leading to the formation of a small lesion called the Ghon 
focus. From this focus bacilli are carried to the regional 
lymph nodes by the lymphatic system. At this site additional 
bacillary multiplication may occur. The lesions consisting of 
the Ghon focus and the enlarged regional nodes are known as 
the primary complex of Ranke. In most cases sufficient local 
immunity may develop which limits the infection. The 
protective immune response in tuberculosis is of the cell 
mediated type (involving T-lymphocytes). Lymphocytes upon 
contact with the appropriate antigens release chemical 
mediators called lymphokines which among others activate 
macrophages.
Activated macrophages and lymphocytes form a compact 
aggregate around the bacilli, forming the histological 
structure called a granuloma. There is no spreading beyond 
the primary focus (granuloma) or tubercle and the lymph 
nodes. This cell-mediated immunity takes about 10 days to 
develop. There is also no sign of an active infection. The 
individual is said to be tuberculin converted because they
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show a positive response to tuberculin challenge in a skin 
test. Tuberculin is a mixture of proteins derived from 
culture filtrates of M. tuberculosis and is also known as 
purified protein derivative (PPD).
In a small proportion of cases, 3% to 5% (Collins, 
1988), the infection will eventually spread leading to 
detectable symptoms. The bacilli may spread via the blood 
stream to other organs such as the spleen and liver and even 
the brain. Other parts of the lungs develop lesions. 
Caseation and cavitation of the lesions results in the 
bacilli being expelled from the lungs via cough droplets and 
thus leading to more infection. These patients will 
eventually die although cell-mediated immune responses are 
still present as indicated by the positive tuberculin 
response. Antibodies are also produced but do not seem to be 
effective. This response however may eventually disappear as 
the disease progresses. Frequently however, the disseminated 
bacteria may lie dormant for many years at the sites of the 
secondary infection but will eventually reactivate.
Some patients who develop primary infection but in whom 
the disease is limited to the site of initial infection by 
the immunity response as described previously, may also 
sometimes develop the full blown disease due to reactivation. 
Dormant tubercle bacilli may be reactivated by several 
stimuli such as age, immunosuppresive therapy or a new 
tubercle infection.
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Some individuals however are incapable of mounting any 
response at all. These individuals develop a rapidly fatal, 
miliary form of the disease leading to early death. Infants 
born of tuberculous mothers usually have this type of 
infection. Excessive antibody levels can be detected but 
again do not appear to be effective in controlling the 
disease.
Table 3A gives a summary of the spectrum of the disease 
which occur in normal individuals.
Table 3A Tuberculosis and immunological response
Disease spectrum response Infectious response Immune
A.No infection No disease Innate immunity No colonization No primary infection
No tuberculin
B.Infection No disease Mucosal colonization Alveolar infection Primary tubercle No spread beyond draining lymph nodes
Tuberculin conversion Cell mediated immunity (CMI)
C.InfectionChronic disease Primary tubercle Hilar lymph nodes Spleen and liver Secondary lung lesions Caseation and cavitation Eventual death
TuberculinconversionCMIAntibodyproduction
D.InfectionMiliary disease Primary tubercle Rapid spread to spleen, liver, bone Diffuse granuloma formation
Tuberculin anergy. No CMI Excessive antibody production
32
Section 3.1.1 Chemotherapy of tuberculosis
Chemotherapy of tuberculosis must take into account the 
fact that the bacilli population in the patient can be 
divided into three functional groups (Mitchison, 1980).
First, there is a large group consisting of about 10^ to 
10^ cells which are metabolically active and are 
extracellular.
The second group of about 10^ to 1Q5 cells are 
intracellular and are only moderately active metabolically. 
This part of the bacillary population are found in non- 
specifically activated macrophages that enter the lesions 
during the initial infection. Although these macrophages can 
engulf tubercle bacilli, these are not strongly 
mycobactericidal and can only slow the growth of the virulent 
pathogen. Killing occurs only after the macrophages have been 
immunological ly activated by T—cells which have been 
specifically sensitized after entering the lesions later in 
the infection.
The final group, consisting of about 10^ to 10^ cells, 
can be found in both environments but show only sporadic 
bursts of activity. Thus different drugs must be used which 
will be active at the different environments and effective 
against the variety of physiological states of the cells in 
a host.
Streptomycin for example is inactivated by low pH and
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thus will only be effective against bacilli that are situated 
extracellularly (Erdos and Ullman, 1960). Pyraz inamide by 
contrast can only work at low pH and therefore is very 
effective against bacilli situated in the macrophages 
(Collins et al, 1985).
Isoniazid is effective against the pathogens in both 
types of environments (Dickinson and Mitchison, 1976; Shoeb 
et al, 1985a, 1985b, 1985c). All three drugs however, will 
only act against actively growing bacteria (McClatchy, 1980).
Rifampicin on the other hand can kill bacilli that are 
actively growing as well as those showing only short bursts 
of activity (Dickinson and Mitchison, 1976, Gangadharam,
1984).
Isoniazid, rifampicin, pyrazinamide, streptomycin, 
ethambutol and para-amino salicylic acid constitute the first 
line of defence in antituberculous chemotherapy. Other drugs 
that are also used include kanamycin, cycloserine, viomycin, 
capreomycin, thioacetazone and ethionamide.
Many treatment regimens have been devised over the 
years. Older regimens usually require durations of up to two 
years. The introduction of rifampicin allowed the development 
of intensive short course treatments which lasts for 9 months 
or even shorter. Thus, for example. The British Thoracic and 
Tuberculosis Association (1976) recommended a 9 month regimen
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in which isoniazid and rifampicin were given daily with the 
addition of ethambutol for the first two months.
The addition of pyrazinamide with ethambutol during the 
first two months reduces the duration of the treatment to 6 
months. A number of intermittent short course regimens have 
also been tried (Fox, 1981). These usually involve a short 
intensive phase with rifampicin, isoniazid, pyrazinamide and 
streptomycin, followed by a phase in which only rifampicin 
and isoniazid are given at intermittent intervals.
These types of treatments allow better supervision and 
encourage patients to co-operate in implementing the 
treatment. This is an important factor especially in Third 
World countries where non-compliance is a major reason for 
the failure of chemotherapy.
Section 3.1.2 Antibiotic Resistance in Mycobacteria.
Two forms of drug resistance in mycobacteria are 
recognised: Primary resistance, in which the patient with no 
previous record of antituberculous chemotherapy, is infected 
with a strain already resistant to one or more drugs, and 
acquired or secondary resistance which emerges during 
chemotherapy (Gangadharam, 1984; Suwanogool et al, 1984). 
A third category is also sometimes recognised and this is 
called initial drug resistance where the patient den»«?and has 
no recorded history of chemotherapy (Mitchison, 1968). This 
category is used in places where medical records are not 
easily available or are non-existent.
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The phenomenon of drug resistance in M. tuberculosis has 
serious consequences for the success of chemotherapy 
especially in the light of increasing number of patients 
suffering from the disease in the less developed countries.
Table 3B shows the prevalence of primary drug resistance 
and Table 3C shows the prevalence of acquired drug 
resistance in some developed and developing countries.
Primary drug resistance tends to be lower in developed 
countries than in developing countries while in acquired drug 
resistance wide differences occur between countries 
irrespective of development status probably reflecting usage 
of specific drugs.
However, the significance of these figures differ in the 
two cases. Patients with acquired drug resistance form the 
infector pool from which the majority of patients with 
primary drug resistance develop. Infection is dependent upon 
the random chance of exposure. Unfortunately social and 
economic factors tend to increase the chances of a patient 
with acquired drug resistance to infect fresh cases in 
developing countries compared to developed countries.
Section 3.1.3 The Mechanism of Resistance in Mycobacteria.
Knowledge of the mechanisms of resistance to 
antituberculous drugs are sparse at best. In the resistance 
to isoniazid experiments have shown that several factors may 
contribute towards resistance. This includes changes in cell
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Table 3B Primary drug resistance in various countries
Primary resistance (%) to
Country Year No.studied Isoniazid Streptomycin PAS
Algeria 1966 125 15.2 14.4 2.4East Africa 1964 365 8.0 0.6 —Hong Kong 1964 302 14.0 11.0 3.0India 1969 1175 15.5 13.8 -Sudan 1965 181 23 10.0 5.0Australia 1968 1150 1.8 1.7 1.6Canada 1965 2064 1.5 2.7 2.2Britain 1963 759 1.3 2.8 0.9U.S.A. 1966 1089 2.2 2.0 0.7
(After Gangadharam (1984), pp 129)
Table 3C Acquired drug resistance in various countries
Resistant
Country Isoniazid Streptomycin PAS
Austria 40.0 20.0 8.2Belgium 40.0 38.0 14.0Brazil 60.0 75.0 9.0Canada 65.0 69.0 23.0Czechos1ovakia 17.5 5.1 8.5India 46.0 25.0 11.0Spain 71.0 43.0 -United Kingdom 25.0 20.0 16.0USA 34.0 23.0 18.0
(After Gangadharam (1984), pp 153)
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wall permeability barriers (Barclay et al, 1953; Lorien and 
Finland 1969). Some suggestions have also been made of the 
occurrence of isoniazid destroying substances (Toida, 1962). 
Changes in biochemical requirements have also been observed 
in isoniazid resistant mutant, suggesting that the 
development of alternative biosynthetic pathways may also be 
responsible for antibiotic resistance (Cohn et al, 1954).
Resistance to aminoglycoside antibiotics such as 
streptomycin have been attributed to changes in the ribosome 
which has become insensitive to the drugs, although whether 
the changes occurred in the ribosomal proteins as is the case 
in other bacteria have not been established yet (Masuda and 
Yamada, 1976; Yamada et al 1985; Wallace et al, 1985).
The presence of aminoglycoside modifying enzymes have 
been demonstrated in M. fortultum (Hull et al, 1984). In 
M. tuberculosisr permeability barriers have also been 
implicated to play a part in drug resistance (Bonicke and 
Bonicke, 1970; McClatchy 1971 and 1980).
Resistance to rifampicin also appears to be due to the 
development of permeability barriers (Rastogi et al, 1981) or 
to conformational changes in the target i.e. DNA-dependent 
RNA polymerase (Yamada et al 1985),
Mechanisms of resistance to PAS, cycloserine and 
pyrazinamide have also been studied (David 1971, Hui et al 
1977, Konno et al 1967). Some appear to be due to chromosomal 
mutation resulting in modified targets which then becomes
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insensitive to the drugs. In others, permeability barriers 
appear to play an important part (McClatchy,1980).
Resistant strains of M. tuberculosis started to appear 
soon after antibiotics were used to treat patients. This is 
probably due to the early practice of monotherapy before the 
phenomenon of antibiotic resistance was fully realised. Multi­
drug treatment regimens have reduced this problem to some 
extent. However multi resistant strains have also begun to 
appear. Some strains have been isolated which are resistant 
to all five main antituberculous drugs. Other drugs have to 
be used to control these strains. More worryingly are reports 
of the isolation of strains which are totally resistant to 
all drugs that have been tested so far (John Stanford, 
personal communication). These strains are becoming a problem 
in certain parts of Iran.
The rise of the these resistant strains point to the 
urgent need for research into this phenomenon of antibiotic 
resistance in mycobacteria especially in M. tuberculosis. The 
understanding of the genetics of mycobacteria may enable the 
development of new drugs as well as more rational strategies 
to control mycobacterial diseases.
Section 3.1.4 The Origin of Drug Resistance
in Mycobacteria.
Even though the mechanisms of resistance to some 
antituberculous drugs have been investigated, definitive 
answers have still not been found for most of them. The
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genetic basis for these resistances still requires further 
investigation. Knowledge of the genetics and mechanisms of 
resistance will help in the development of new drugs or 
methods to combat the disease especially those caused by 
resistant strains.
The theory of origin of drug resistance in 
M. tuberculosis can be divided broadly into 2 categories: 
Chromosomal Mutation or Genetic Transfer.
Much in vitro and clinical evidence support the mutation 
theory of resistance in M. tuberculosis. The presence of 
plasmids in M. tuberculosis has not yet been reported in the 
literature. However plasmids have been found in many other 
species of mycobacteria including M. avium-Intracellulare 
which is the tubercle bacillus of birds and an opportunist 
pathogen in humans especially in AIDS patients.
Furthermore Jones and David (1972) and Mizuguchi et al 
(1981), have presented results which suggest, although not 
conclusively, the presence of plasmid-mediated antibiotic 
resistance in M, smegmatis and M. avium-intracellulare. Heavy 
metal resistance has also been suggested to be plasmid- 
mediated in various strains of M. scrofulaceum (Meissner and 
Falkinham, 1984; Meissner and Falkinham, 1986).
Mitchison (1968) in his review remarked that the 
Mutation Theory can explain most but not all the observed 
phenomenon of antibiotic resistance in M. tuberculosis and
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other possibilities cannot be disregarded. In conclusion, 
this particular field of study certainly has many avenues 
worth exploring and the emerging interest in the molecular 
biology of mycobacteria would help to answer some of these 
questions.
Section 3.1.5 BCG and Vaccination
BCG (Bacille Calmette-Guerin) is an attenuated strain of 
M. hovls produced by repeated passage over a period of 
thirteen years. During the four decades that followed its 
first use in 1921 for the prevention of human tuberculosis, 
the vaccine was prepared from the original Pasteur strain in 
various parts of the world. However, due to the differing 
growth conditions and methods of production a number of BCG 
vaccines with differing properties started to appear (Smith, 
1982). Lind (1960) showed that some strains contained an 
antigen called factor c which was absent others. Another 
antigen, antigen 15, was also missing in some BCG strains 
(Stavri et al, 1981). Minnikin et al (1984a) discovered that 
strains from Brazil and Sweden produced mycolic acids not 
found in others. There are also differences in the amount and 
types of secreted proteins (Abou-Zeid et al, 1986).
Some workers have even queried the true origin of BCG 
because of differences within BCG strains as well between BCG 
strains and M. bovis (Grange et al, 1983).
In 1966, a WHO Expert Committee on Biological 
Standardization gave several guidelines for the production
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of BCG. Among other aspects these guidelines stated that the 
vaccine should be freeze-dried and the strain should be 
maintained by the "seed lot system" whereby no vaccine is 
produced from a seed more than 12 passages removed from a 
primary freeze-dried seed lot.
Nevertheless, BCG remains as one of the most widely used 
vaccine in the world (Grange et al,1983) with a safety record 
as good or better than other live attenuated vaccines 
currently employed (Lotte et al, 1978, Smith, 1982).
A number of trials have been carried out in different 
parts of the world to determine the effectiveness of the BCG 
vaccine in protection against tuberculosis. Table 3D shows 
the results of these studies.
Table 3D Efficacy of BCG vaccination
Trial Percentageprotection Tuberculosis in control group per 1000 per year
1. N. American Indian (1935-38) 80 15.62. Chicago infants (1937-48)~ 75 2.23. Britishschoolchildren (1950-52)~ 78 1.34. South Indian rural (1950-55) 60 0.86population, Mandanapalle~ 5. Puerto Ricanschoolchildren (1949-51)~ 31 0.436. Alabama, Georgia,population (1950)~ 14 0.137. Georgianschoolchildren (1947)~ Nil 0.118. South Indian, Madras* (1968) Nil 38.3
Source: Sutherland, 1971 * Tuberculosis Prevention Trial,1979a, 1979b and 1980. The follow up study to this trial is still continuing.
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Table 3D shows that BCG can confer high degrees of 
protection against tuberculosis in some cases but in four 
different trials the protection was found to be low or none 
at all. The largest trial, involving 101106 vaccinated 
individuals in Madras, which is still continuing has so far 
revealed no protective effect of BCG. This unexpected finding 
has added fuel to the controversy of whether BCG vaccination 
affords protection against tuberculosis.
Several hypotheses have been proposed to explain the 
results where little or no protection was observed. Firstly, 
ten Dam et al (1976) suggested that the low protection rates 
were obtained when a low potency BCG strain was used. The 
Tice strain (produced by the Tice Laboratory, Chicago) was 
used in the trials in Puerto Rico and the two trials in 
Georgia, all of which showed low protection efficacy. The 
Tice vaccine of this period was tested and was shown to be 
weakly protective in animal models (ten Dam et al, 1976). 
However, this hypothesis cannot explain the result of the 
Madras trial because in this study the French (Pasteur) and 
Danish BCG vaccines were used instead, both of which have 
been tested and certified by a panel of international experts 
at the start of the trial (Tuberculosis Prevention Trial, 
Madras, 1979).
The protection rates in these trials were calculated by 
comparing the incidence of tuberculosis in the vaccinated and 
control (unvaccinated) groups. Sutherland (1971) suggested 
that as the incidence of tuberculosis in a population falls
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as a result of factors unrelated to vaccination, the 
contribution of a vaccination program in that area would be 
proportionately reduced. This suggestion was based on the 
observation that an almost direct relationship exist between 
the efficacy of BCG and the number of tuberculosis incidence 
in the control unvaccinated group (see Table 3D). Thus, the 
protection rate appear to be low simply because the incidence 
of tuberculosis infection itself is low in the trial area.
However, in the Madras trial the incidence rate in the 
control group was high. Similarly, in another trial reported 
by Bettag et al (1964), which was not included in the study 
by Sutherland and where no protection was found, the 
magnitude of infection in the control group was the same as 
in the British trial where a protection rate of 78% was found 
(Table 3D). Thus, in the Madras trial and in the trial 
reported by Bettag et al the BCG vaccine appear to have 
failed to work completely. Therefore, the hypothesis that 
low protective efficacy is simply due to a low infection rate 
cannot account for all observations.
Two questions that have to be answered therefore are:
( 1 ) The high natural resistance to tuberculosis in some areas 
as shown by the low infection rates in control groups in some 
trials.
(2) The apparent complete failure of the vaccination program 
in the Madras trial and that reported by Bettag et al (1964).
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Comstock and Palmer (1966) suggested that the poor 
showing of BCG in the Puerto Rico and Alabama/Georgia trials 
were due to the prevalence of "atypical" mycobacteria 
infection in the population, thus, sensitizing this 
population to further mycobacterial infection and affording a 
level of protection against M. tuberculosis.
This was supported by the results of the British trial 
which showed that in the control (unvaccinated) group, 
individuals who gave negative results to a 100 TU test dose 
of tuberculin (no sensitivity) developed tuberculosis more 
frequently than unvaccinated individuals who gave positive 
results to the same amount of test dose (low sensitivity); 
individuals giving positive results to 5-10 TU of tuberculin 
are considered to have come into contact with M. tuberculosis 
while those that only react to the higher dose have not come 
into contact with M. tuberculosis but have been in contact 
with other "atypical" mycobacteria.
This view was supported by experiments in guinea pigs 
which showed that prior infection with "atypical" 
mycobacteria afforded protection against M. tuberculosis 
infection ranging from 15% to 70% of that given by BCG 
vaccination (Palmer and Long, 1966).
This hypothesis was also supported by the results of a 
study by Shield (1983) on the Madras trial where it was found 
that a high proportion (> 90%) of the population were 
infected and sensitised to M. avium.
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However, the picture is not as simple as it seems 
because a further evaluation of the Puerto Rico trial by 
Comstock et al (1974) found that both tuberculin non-reactors 
and reactors to a 100 TU test dose in the control group, have 
virtually identical tuberculosis case rates. This is contrary 
to the British trial mentioned earlier where reactors were 
less likely to be infected. To complicate matters, it was 
found in the Madras trial that reactors were more likely to 
be infected than non-reactors in the control group.
To determine some of the factors involved in the trials 
resulting in the varied observations, Stanford et al (1981) 
evaluated the results of skin-test studies in areas where BCG 
is known to be effective as well as places where it failed. 
These authors proposed that the cell-mediated immune response 
to mycobacterial infections comes in two forms:
1. A Koch-type response which is non-protective. This 
response is able to stop the initial infection but d'o&^ not 
induce protection to future mycobacterial infection and is 
characterised by its appearance 4—6 weeks after infection 
and a skin-test time course which peaks at 40-48 hours and 
remains high for 90 hours (Rook and Stanford, 1979).
2. A Listeria-type response which is protective. This 
response is able to stop the initial infection and also 
induce mechanisms to protect the individual from future 
mycobacterial infections. This type of cell-mediated immunity 
is characterised by its appearance 10-20 days after infection
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and has a skin-test time course which peaks between 18-23 
hours, lasting for about 48 hours (Rook and Stanford, 1979).
The type of response is determined by the infecting 
mycobacteria. The fast-growers are only able to induce the 
Listeria-type response while the slow-growers can induce both 
types of responses (Stanford et al, 1980; Shield,1983). Thus, 
Stanford et al (1981) suggested that initial contact with a 
slow-growing species would induce the Listeria-type immunity 
response but excessive contact would induce the non- 
protective Koch-type response. Therefore, in a population 
where the predominant environmental mycobacteria is of the 
group that would induce the Listeria-type response, BCG 
vaccination would be effective. A population in excessive 
contact with a slow-growing environmental mycobacteria would 
be primed for the Koch-type response and thus, BCG 
vaccination would be ineffective and may even increase 
susceptibility to tuberculosis by reinforcing the non- 
protective response.
Shield (1983) reported that a very high proportion 
(>90%) of the population in the Madras trial were in fact 
sensitized to M,avium which may explain the failure of this 
vaccination program as well as the higher incidence rate 
among reactors than non-reactors in the control group.
Thus, a low protective efficacy of BCG in some of the 
trials may be due to a true failure of the vaccine or it may 
only be an apparent one. The results observed in the various
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trials and possible explanations are summarised below:
1. The tuberculosis infection rate in a population (both 
vaccinated and unvaccinated groups) is low, therefore, the 
protective effect of BCG is not readily apparent. No acquired 
immunity due to environmental mycobacteria.
2. Low infection rates in both vaccinated and control groups. 
The population has been primed with the Koch-type response by 
environmental mycobacteria but the naturally low infection 
rates would not reveal the true failure of the BCG vaccine.
3. Similar to (1) but this time the low infection rate is due 
to natural high resistance because of priming by 
environmental mycobacteria which induces the Listeria-type 
immunity response. BCG is effective but is not apparent due 
to the low infection rate in the unvaccinated control group.
4. High infection rates in both control and vaccinated 
individuals i.e. true failure of the BCG vaccine. This is 
due to contact with environmental mycobacteria which induces 
the Koch-type immune response.
Section 3.2 Other mycobacterial diseases
Other mycobacterial infections are uncommon when 
compared to leprosy or tuberculosis. Most are of the 
opportunistic type which often mimic the manifold forms of 
tuberculosis. Some examples of diseases caused by non­
tubercle mycobacteria are given below.
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Mycobacterium avium-intracellulare-scrofulaceum (MAIS)
are opportunist pathogens of man. They are associated with 
cervical adenitis but can also cause pulmonary infections. 
M. intracellulare are also pathogens of pigs while M. avium 
causes a tuberculosis-1ike infection in birds. During recent 
years, M. intracellulare have emerged as a frequent and 
serious pathogen of patients with acquired immune deficiency 
syndrome (AIDS) (Wayne et al, 1986).
M. chelonei is the tubercle bacillus of turtles (Grange 
1981 ). It is also an opportunist pathogen occurring in open 
wounds. It can be a problem as a hospital-acquired infection. 
M. fortuitum is another opportunist pathogen of superficial 
wound. It is also known to cause infections in transplant 
surgery and peritoneal dialysis.
M. "kansasii is associated with pulmonary infections but 
is occasionally found in skin lesions (Wayne, 1986). 
M. marinum is the causative agent of Swimming Pool Granuloma. 
The disease is usually self-limiting but serious infections 
may result if the tendons and joints are involved (Beckman et 
al, 1985).
A disease called the Buruli Ulcer is caused by 
M. ulcerans. The bacilli multiply ~ in the subcutaneous fat 
causing necrosis of the fat. The skin eventually breaks down 
and the necrotic fat is discharged. Specific immunological 
activity is suppressed, similar to that observed in 
lepromatous leprosy. For some unknown reasons, immune
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reactivity reappears, the bacilli disappear? and healing 
commences. However, fibrosis and contractures that occur 
during the healing process result in severe disability or 
disfigurement.
Section 3.2.1 Chemotherapy of non-tubercle mycobacteria
The therapy of infection caused by the non-tubercle 
mycobacteria causes much difficulty due to the innate 
resistance of most of these mycobacteria to antibiotics 
Collins et al, (1985).
Uncomplicated pulmonary infections due to M. kansasil, 
M. xenopl and M. avium-intracellulare are often resolved 
however by an extended standard anti-tuberculous regimen i.e. 
rifampicin, isoniazid and ethambutol despite results which 
show in vitro resistance.
Recently antibiotics not normally used in tuberculosis 
chemotherapy have been found to be useful against other 
mycobacteria. Cotrimoxazole, erythromycin, doxycycline and 
amikacin have been shown to be effective in some cases 
(Grange 1984). Other potentially useful drugs includes 
norfloxacin, ciprofloxacin (Gay et al, 1984), cefoxitin, 
cefotetan (Saito et al, 1984) and colistin (polymyxin E) 
(David and Rastogi, 1985).
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CHAPTER 4
The Genetics of Mycobacteria
Tuberculosis and leprosy are two diseases that have been 
known to Man for a very long time. They have also been 
studied for a long time but despite this questions concerning 
these two diseases are still unanswered due to complexity of 
the diseases as well as the causative agents themselves 
(Collins et al, 1985).
The World Health Organisation (1985) has outlined several 
objectives in the research program on tuberculosis and 
leprosy:
1. To develop vaccines.
2. To understand the best ways to use vaccines.
3. To develop improved sérodiagnostic techniques.
4. To improve the understanding of the pathology of the 
diseases.
5. To develop new drugs. .
6. To improve the use of existing drugs.
Molecular genetics have been used to unravel complex 
biological phenomena such as antibody production and 
morphogenetic processes with a high degree of success. 
Similar methods may be used to understand and eventually 
control tuberculosis and leprosy. Molecular biology may 
greatly aid research to answer some of those questions 
especially in the study of antigens and immunology for the
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development of vaccines. Research into biochemical pathways 
in the organisms may reveal novel targets for the development 
of new drugs.
The application of molecular biology to the 
understanding of mycobacteria and the pathology of the 
diseases that they produce have recently begun. There are 
several areas in which basic information have been obtained 
while interest have recently begun in others:
1. The DNA and RNA of mycobacteria
2. Mycobacteriophages
3. Genetic transfer in mycobacteria
4. Cloning and expression of mycobacterial genes in surrogate 
hosts.
5. Cloning and expression of genes in mycobacteria
Section 4.0 The DNA and RNA of Mycobacterium
M. tuberculosis has a genome size of about 2.0 x 10^  
megadaltons (Md) (Grange, 1975; Barksdale and Kim, 1977). 
Other mycobacterial species have similar sized genome 
although M. leprae appear to be slightly smaller at 1.3 to 
2.2 X 10^  Md (Imaeda et al, 1982).
Mycobacterial DNA has a high G+C content. 
M. tuberculosis for example has a G+C content of 
approximately 65% while that of M. leprae is about 56% 
(Jacobs et al, 1985, Imaeda et al, 1982). Rado et al (1976) 
and Srivastava et al (1981) have reported the evidence of
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DNA méthylation in strains of M. tuberculosis* They suggested 
that the fact that DNA méthylation was found in only some 
strains of M. tuberculosis indicated that this property may 
be plasmid-mediated. No direct evidence of extrachromosomal 
DNA however was found.
In one species of mycobacteria, plasmid-mediated 
restriction systems have been suggested (Crawford et al, 
1981). This suggestion was based on analyses of plasmid 
profiles of M. avium-intracellulare strains. Again no direct 
evidence has been presented. Mizuguchi et al (1981) found 
several plasmids in a strain of M. intracellulare* One of 
these plasmids was present in the parental, antibiotic 
resistant strain which also gave rise to translucent 
colonies, but was absent in antibiotic sensitive substrains 
which were obtained from the original stock by passaging 
through antibiotic free media. The sensitive strains were 
also different in giving rise to opaque colonies. The authors 
suggested that this plasmid, was responsible for changes in 
cell wall permeability barriers, which in turn leads to 
antibiotic resistance.
The lack of a system for genetic manipulation and 
analysis in mycobacteria has hampered studies on 
mycobacterial plasmids and so far no known genetic markers 
have been identified in them.
Franzblau at al (1986) have also suggested the 
relationship between antibiotic resistance and the presence
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of plasmids in M. avium-intracellulare • This suggestion was 
also based on plasmid profile analysis.
A large plasmid (about 50 kilobasepairs (kb) in size) 
was found in several strains of M. scrofulaceum which were 
all resistant to heavy metals (Meissner and Falkinham, 1986). 
The plasmid was absent in all strains that were sensitive 
although other different sized plasmids were present in both 
resistant and sensitive strains. The authors proposed that 
the resistance phenotype was encoded by the 50 kb plasmid. 
However, the presence of the resistance gene(s) on the 
plasmid have not yet been determined.
Although no plasmids have been isolated or shown to be 
present in M. tuberculosis, several reports have suggested 
the presence of antibiotic resistance plasmids in strains of 
M. tuberculosis by indirect evidence.
Alberghina et al (1973 ) suggested that resistance to 
kanamycin, neomycin and viomycin in some strains of 
M. tuberculosis could be due to extrachromosomal 
determinants. They made this suggestion based on the 
observation that the resistance to these antibiotics could be 
eliminated by treating the resistant strains with curing 
agents such as acriflavine. However, the loss of the 
resistance could be due to a mutation (or mutations) induced 
by the chemical agents used.
Similarly, Tsukamura (1977) showed that resistance to 
six aminoglycoside antibiotics in M, tuberculosis H37Rv could
54
be eliminated in a single step selection by incubating at 
45®C. They suggested that this, accompanied by other 
phenotypic changes such as a decrease in the uptake of 
isoniazid and attenuation of virulence, may be due to the 
loss of a plasmid. The antibiotics are all similar however, 
and the loss of resistance to all of them may be due to a 
single mutation.
The accompanying changes may also be connected to the 
loss of the antibiotic resistance. It may be possible that 
the various phenotypes are linked in some way to a common 
pathway or cell wall protein structure and a single mutation 
affecting this common link would affect all of them. 
Obviously more work is required to determine the genetic 
basis and other factors relating to the different phenotypes,
This result has many similarities to that reported by 
Mizuguchi et al (1981) concerning plasmid-mediated 
antibiotic resistance in M. Intracellulare, Cell wall 
variations have been suggested to be related to virulence in 
the MAIS complex (Collins et al, 1985; Wayne, 1985) and the 
possibility of a similar phenomenon in M. tuberculosis should 
be investigated.
Strains of M. fortuitum have yielded the greatest number 
of plasmids (Hull et al, 1984). Although many strains of this 
species produce aminoglycoside acetyltransferase no 
correlation was found between this phenotype and plasmids 
when the plasmid profiles of the strains were analysed.
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However, since none of these plasmids had been isolated 
and used to transform another strain which do not produce the 
enzymes simply due to the lack of a transformation system, it 
would be difficult to eliminate the possibility that the 
resistance determinants reside in different plasmids and 
hence no correlation would be found between any particular 
plasmid and the production of a particular enzyme.
None of the plasmids that have been found so far has 
been characterised fully. Recently however, Rauzier et al 
(1988) have sequenced a plasmid isolated from M. fortuitum 
called pALSOOO (Labidi et al, 1985a and 1985b). This 
development would certainly aid the molecular biology of 
mycobacteria with the possibility of the construction of 
cloning vehicles in mycobacteria. Another plasmid, from 
M. avium, has also been suggested as a possible cloning 
vehicle (Crawford and Bates, 1984).
Mycobacterial ribosomal RNA (rRNA) has also been 
studied. It was found that unlike other bacteria where 
multiple copies of rRNA genes exist (Kiss et al, 1977), in 
slow-growing mycobacteria such as M. tuberculosis, 
M. Intracellulare, M. lepraemurlum and BCG only one copy is 
present while some fast-growing ones such as M. phlel and 
M. smegmatis have two copies of the genes (Bercovier et al, 
1986, Suzuki et al, 1987).
Cox and Katoch (1986) showed evidence that there was 
genetic variability in the rRNA genes in mycobacteria which
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may be used for species and perhaps strain identification. 
Section 4.1 Mycobacteriophages
Mycobacteriophages have been known for a long time. The 
first reported isolation of a mycobacteriophage was probably 
by Gardner and Weiser in 1947 although earlier reports have 
mentioned the observation of lysis in tubercle cultures 
(reviewed by Redmond, 1963).
There was very little interest initially in the study of 
mycobacteriophages other than as tools for taxonomic studies 
(Baess, 1969). The use of mycobacteriophages in taxonomy 
however was found to be limited because many 
mycobacteriophages exhibit a very wide host range. Phage BK 
for example was found to lyse strains of M. fortuitum, 
M smegmatis, M. flavescens, M. chelonei and a strain of 
M. vaccae (Kubica et al, 1972). Kraiss et al (1973) also 
found similar results with phages B02a and B02h.
Studies by workers such as Sellers and Tokunaga (1966) 
showed that bacteriophage DNA can be used to transfect 
mycobacteria and that a state of competence similar to that 
observed in E. coll can be achieved with an increase in the 
uptake of phage DNA in the presence of calcium ions. Attempts 
to obtain transformation using chromosomal DNA however failed 
(Tarnok and Bonicke, 1970). Norgard and Imaeda (1978) in 
contrast have reported the successful transformation of M. 
smegmatis using chromosomal DNA. Unfortunately, no one
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appeared to have made any serious attempts to develop 
mycobacteriophages as cloning vehicles for mycobacteria.
Phage-mediated transduction has been reported. Juhasz 
(1960) found that M. phlel acquired streptomycin resistance 
when grown in a culture filtrate of streptomycin resistant 
BCG. Although positive proof was lacking, transduction was 
considered the most likely mechanism. 8arcja and Gopinathan 
(1973) showed that resistance to isoniazid and streptomycin 
as well as isoniazid sensitivity can be transduced by using 
the phage 13.
Reddy and Gopinathan (1987) recently made the first 
initial steps in characterizing the mycobacteriophage 13. 
Similar studies would greatly aid the understanding of 
mycobacteriophages and may lead to the development of cloning 
vehicles similar to those now available for B, coll.
LysogenSc' : phages have been found in several species of 
mycobacteria (Juhasz et al, 1969; Timme and Brennan, 1984). A 
phenomenon associated with lysogen&c mycobacteriophages is 
phage conversion. Colonial morphology, changes in enzymic 
activities, nutritional requirements and virulence are 
amongst some of various phenomena that have been linked to 
phage conversion (Juhasz and Bonicke, 1970; Bonicke and 
Saito, 1970; Juhasz et al, 1969; Mankiewicz et al, 1974; 
Nordstrom and Grange, 1974; Grange, 1975). Several examples 
of pathogenic bacteria owing their virulence to the lysogenic 
state are well documented and this raises the question
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whether a similar system exists in mycobacteria. Further 
elucidation is obviously required in this field.
Section 4.2 Other methods of genetic exchange
Genetic exchange by direct cellular contact has been 
found in mycobacteria (Tokunaga et al, 1973). Redmond (1970) 
described recombination between a smooth, auxotrophic and 
non-chromogenic mycobacterium with a rough, prototrophic, 
chromogenic strain resulting in the appearance of smooth 
chromogenic strains. This technique has also been used to 
determine the chromosomal loci of a number of biosynthetic 
and antibiotic resistance genes (Gelbart and Juhasz, 1970; 
Mizuguchi, 1972; Suga and Mizuguchi, 1974). No evidence of 
genetic transfer via plasmids have yet been reported.
Section 4.3 Cloning and expression of mycobacterial genes 
in surrogate hosts.
The lack of a reliable and reproducible transformation 
for mycobacteria have hampered research in the field of 
mycobacterial genetics. Work on cloning mycobacterial genes 
in surrogate hosts however, has achieved some early 
successes.
4.3.1 Cloning in Escherichia coll
DNA from various mycobacterial species such as 
M. tuberculosis, M, leprae and M. vaccae have been cloned 
into E. coll using standard cloning vectors ( Clark-Curtiss 
et al, 1985, Thole et al, 1985, Khandekar et al, 1986, Jacobs
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et al, 1986a). Expression of a BCG antigen was observed when 
a strong E. coll promoter was placed upstream of the BCG gene 
(Thole et al, 1985).
BCG DNA fragments were cloned into an E. coll promoter- 
probe plasmid, containing a promoterless chloramphenicol
resistance gene. The results showed that mycobacterial 
promoters were mostly poorly recognised by E. coll (Kieser et 
al, 1986).
Shinnick (1987) however showed that some mycobacterial 
promoters at least were recognised fairly efficiently 
resulting in expression of mycobacterial proteins by B. coll. 
Evidence that some mycobacterial promoters are well
recognised by B. coll was also shown by Moss (1988).
Lamb et al (1988) found that an M. leprae gene which 
codes for a 65 kilodalton (kD) protein could be expressed
using its own promoter in B. coll indicating that the
transcription and translational signals are efficiently 
recognised.
4.3.2 Cloning in Streptomyces
E, coll has been shown to be an excellent host for the 
primary cloning of mycobacterial genes. However, some 
important cell wall polysaccharides and lipids such as the 
cord factor in M. tuberculosis may require the product of 
several genes and it is unlikely that the complete set of 
genes could be made to express in B. coll especially in the
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light of the fact that most mycobacterial promoters are not 
well expressed in E. coll (Kieser et al, 1986). Furthermore, 
other gene products involved in pathogenicity and host immune 
response will probably include membrane or exported proteins 
which again are unlikely to be correctly expressed in a Gram- 
negative organism such as E. coll; exported proteins are much 
more prevalent in Gram-positive bacteria than in Gram- 
negatives (D.A, Hopwood, personal communication).
The next choice of host for mycobacterial genes would be 
the Streptomyces especially Streptomyces livldans where 
cloning techniques have been well developed (Hopwood et al, 
1985).
S. livldans has been shown to recognise promoters from 
other bacterial genera including Escherichia, Bacillus and 
Serratla (Bibb and Cohen, 1982). Furthermore, Streptomyces 
also contain several different forms of RNA polymerase with 
alternative sigma factors which is expected to facilitate the 
transcription of different classes of genes.
Kieser et al (1986) cloned BCG DNA fragments into an
S. livldans promoter-probe plasmid and were able to show that 
many promoters as well as translational signals from BCG were 
very well recognised by S. livldans. Lamb and Colston (1986) 
showed similar results using DNA from M, leprae and 
M. tuberculosis.
These initial results shows that Streptomyces may turn
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out to be a very good host for the cloning and expression of 
mycobacterial genes.
4.3.3 Cloning in Mycobacterium,
The best choice for cloning mycobacterial genes would of 
course be in Mycobacterium itself. Until recently, no 
transformation system was available for mycobacteria.
In 1987 Jacobs et al reported the transfection of 
M. smegmatls ATCC607 and BCG using a vector constructed from 
an E. coll plasmid fused with a mycobacteriophage. A 
sphaeroplast system was used. The vector was able to 
replicate as a plasmid in E. coll and in mycobacteria as a 
lytic phage (Jacobs et al, 1987).
However to develop a really useful expression vector, 
systems will have to be developed to introduce DNA into 
mycobacteria which can be stably replicated. A plasmid or a 
temperate phage based system would be required for progress 
to be made in this field.
Recent work, by Rauzier et al (1988) may initiate the 
development of genetic manipulation systems mycobacteria. The 
authors have sequenced a mycobacterial plasmid called 
pALSOOO, isolated from a strain of M. fortultum, and were 
able to identify several open reading frames. They have also 
constructed a shuttle vector by cloning an E. coll origin of 
replication and antibiotic resistance markers into pALSOOO 
and were able to introduce the vector into M. smegmatls by
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electroporation. However, the transformation frequency is 
still very low (10 transformants per )xg of DNA) and further 
development of the system would be required.
Another system for transforming mycobacteria was 
recently reported by Snapper et al ( 1988 ). The authors used a 
pool of recombinant plasmid vectors which was constructed by 
cloning an E. coll plasmid into different sites in the 
mycobacterial plasmid, pALSOOO. An electroporation system 
was used and they were able to obtain stable M. smegmatls 
transformants which expresses the kanamycin resistance gene 
present on the E. coll plasmid. The authors also indicated 
that the mycobacterial origin of replication was utilized in 
this system. The same authors also presented results which 
showed the transfection of M. smegmatls and BCG, by 
electroporation, with a temperate phage into which was 
cloned a kanamycin resistant gene. The marker was also 
expressed by the lysogenic mycobacterial transformants.
In this thesis (Chapter 10), a PEG (polyethylene glycol) 
based transformation system using M. smegmatls ATCC607 
sphaeroplasts is reported. The results suggest that an 
E. coll plasmid, pIJ666 was able to replicate independently 
in this mycobacterial species. The chloramphenicol resistance 
gene from Tn9, located on pIJ6 6 6, was found to be well 
expressed in M. smegmatls ATCC607.
Recently, Lugosi et al (1988) showed the tranformation 
of BCG with the same pool of recombinant plasmids described
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by Snapper et al (1988).
In conclusion, the recent interest and development in 
genetic manipulation systems for mycobacteria should aid the 
study of various aspects of the bacteria and the diseases 
that they produce.
PROJECT AIMS
There are two main aims in this projects:
1. To investigate the possibility of the presence of plasmids 
in M. tuberculosis • The reasons for this investigation are as 
follows:
a)No reports of a thorough investigation in this field have 
been communicated in the literature.
b)The genetics of Mycobacterium including M, tuberculosis is 
still poorly understood. A study of this aspect of 
mycobacterial genetics is justified on the grounds of 
furthering our knowledge on Mycobacterium as a whole bearing 
in mind the importance of plasmids in other genera not only 
in antibiotic resistance but in a range of other phenomena 
such as virulence.
2. To investigate the development of a transformation system 
in mycobacteria. The reasons for this are as follows:
a)The lack of established and efficient techniques for 
genetic manipulation in mycobacteria needs to be overcome. 
The development of vectors, including plasmid vectors, and an 
efficient mycobacterial transformation system would be of
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great importance in the study of aspects other than 
antibiotic resistance; the study of antigens for the 
production of vaccine against M. leprae, improvement of 
vaccines against M. tuberculosis and understanding the 
pathogenesis of mycobacterial diseases to name but a few. The 
last point is of increasing importance in diseases caused by 
the M. avium-Intracellulare~ scrofulaceum complex due to the 
high incidence rate in AIDS patients.
b) The availability of transformation systems for 
mycobacteria would also greatly aid the study and 
characterization of mycobacterial plasmids.
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MATERIZLLS AND METHODS
CHAPTER 5
Materials
Section 5,0 Bacterial strains
The bacterial strains used in this study are listed 
below:
Table 5A - Escherichia coli strains
Table 5B - Mycobacterium tuberculosis strains (frequently 
used strains only)
Table 5C - Other mycobacterial strains
Table 5A Escherichia coli strains
Strain Genotype Reference
HBlOl F-, proA2, recA, hsdR-, hsdM- Boyer and Roulland- Dusoix, 1969,
JM105 lacpro, thi, strA, endA, sbcBl5, hspR4, F-, traD36, lacIQZ Ml5 Messing et al, 1981
JM109 recAl, endAl, hsdR17, supE44, relAl,F-, traD36, lacIQZ Ml5 Pharmacia
LE392 F-, hsdR514, supE44, supF58, lacYl Maniatis et al, 1982
LM1035 F-, proA2, recA, hsdR-, hsdM- derivative of HBlOl from Celltech
P2392 F-,hsdR514, supE44, supF58, lacYl, P2 Frischauf et al,1983
(Only the relevant characteristics of each strain have been listed)
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Table 5B Mycobacterium tuberculosis strains*
Strain number Resistance patterns
40230 s. I, z.40654 s. I,50310 Classical (sensitive strain)50410 z.50495 s. I,60420 s. E, R,60921 I, Z, E, R,60925 I, E, R,61066 s. I, R,61104 1/ R,61125 I,61144 I, E, R,61158 s. I,61267 s.61377 I,61504 I,61513 s.61695 z.
E- Ethambutol, I- Isoniazid, R- Rifampicin, S- Streptomycin Z- Pyranizamide* Only frequently used strains are shown. All strains were kindly given by Malcolm Yates, Tuberculosis Reference Unit, Public Health Laboratory, Dulwich Hospital.
Table 5C Other mycobacterial species
Species Source
M,bovls BCG Glaxo (a)
M.bovls BCG Glaxo (b) M.bovis BCG NCTC 5692 M.fortultum 140 410 002 M.fortultum 140 410 003 M.fortultum-perlgrlnim 148 M. fortul turn-per Igrlmm 125 M. hitracellulare 103 M. phlelM.scrofulaceum W262
M. smegmatls ATCC 607 M. paratuberculosls
Central Veterinary Laboratory WeybridgeSt. George’s Hospital, Tooting Medical Research Council, Mill Hill A.Labidi, Pasteur Institute, Paris A.Labidi, Pasteur Institute, Paris A.Labidi, Pasteur Institute, Paris A.Labidi, Pasteur Institute, Paris Mizuguchi et al, 1981 Departmental culture collection J.O. Falkinham III, Virginia Polytechnic and State University J. Grange, Middlesex Hospital, London J.J. Mcfadden, this department
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Section 5.1 Plasmids
Table 5D shows the plasmids used in this study,
Table 5D Plasmids
Plasmid ResistanceMarker(s) Notes Source
PACYC184 Cm, Tc General purpose vector Depart. collectionPAL5000 Cryptic, from M.fortultum strain 140 410 002 A. LabidiPasteurInst.pBR322 Ap, Tc General purpose vector Depart. collectionPIJ666 Cm, Km Positive selection vector T. Kieser John Innes InstitutepSU300 Cryptic, from M. fortultum strain 140 410 003 A. LabidiPasteurInst.pSU301 Ap pUC8/pSU300 hybrid, EcoRI site. This thesispSU303 Ap pKK223-3/pSU300 hybrid EcoRI site This thesispSU309 Cm, Km pU666/pSU300 hybrid Bglll site This thesispSU312 Cm, Km pIJ666/pSU300 hybrid BaiaHI site This thesispSUSOO Cm, Km From M. smegmatls transformant This thesispSU501 Cm, Km From M.smegmatls transformant This thesisPSU502 Cm From M.smegmatls transformant This thesispTK Cm, Km A pool of hybrid plasmids, pIJ666 inserted into different Mbol sites of pALSOOO
Tobias Kieser John Innes InstitutepUC19 Ap Also carries the beta- galacto- sidase gene containing a multi­ple cloning site within it.
Pharmacia
PKK223-3 Ap, Tc Expression vector.Tac promoter Pharmacia
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Section 5.2 Recombinant phage EMBL4
Table 5E shows the lambda phage EMBL4 recombinants 
constructed and used in this study. The inserts consist of 
Sau3AI fragments of M. tuberculosis or M. fortultum 
chromosomal DNA (the strains used are indicated in Table 5E) 
ligated into the BamHI sites of phage EMBL4.
Table 5E Lambda phage EMBL4 recombinants
Recombinant Insert
EMBL4/A-3 DNA fragment from M. tuberculosis 50410
EMBL4/A-4 DNA fragment from M. tuberculosis 50410
EMBL4/B-6 DNA fragment from M. tuberculosis 50495
EMBL4/B-7 DNA fragment from M. tuberculosis 50495
EMBL4/C-8 DNA fragment from M. tuberculosis 60420
EMBL4/C-10 DNA fragment from M. tuberculosis 60420
EMBL4/D-12 DNA fragment from M. fortultum 140410003
EMBL4/D-13 DNA fragment from M. fortultum 140410003
Section 5.3 Antibiotics
Antibiotics were purchased from Sigma. All stock 
solutions were prepared with sterile distilled water and 
filter sterilized except chloramphenicol which was prepared 
with ethanol.
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Section 5.4 Media
L-broth
The following recipe was used for preparing L-broth:
15g Tryptone (Oxoid), 5g Yeast extract (Oxoid),
5g Sodium chloride AR (M and B), Distilled water to 1000ml
L-Agar
The same ingredients were used as for L-broth except with the 
addition of 1.5 % agar (Agar Technical No 3, Oxoid).
Lowenstein-Jensen medium
This medium with glycerol (LJG) or pyruvate (LJP) were 
purchased ready made from Difco.
Nutrient (N) agar
N-agar powder was purchased from Oxoid. The amount used was 
28g per litre of distilled water.
Nutrient (N) broth No.2
25g of N-broth No2 powder (Oxoid) were dissolved in one litre 
of distilled water.
Top (T) agar.
15g Tryptone, 5g Sodium chloride,
8g Agar Technical No.3, 2.46g Magnesium sulphate
The volume was made up to one litre and the agar was 
thoroughly dissolved by stirring on a magnetic hot plate. 
Aliquots of 3ml or 40 ml were dispensed into suitable 
containers and autoclaved.
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Top-agarose
The ingredients used in Top agarose were identical to Top 
agar except that the agar was replaced by agarose (BRL).
Tryptone Soya Agar plus Sucrose (TSAS)
Tryptone Soya Agar powder was purchased from Oxoid. 40g of 
the powder and 171.15g of sucrose (BDH) was dissolved in one 
litre of distilled water and autoclaved. This media was used 
to regenerate sphaeroplasts of Mycobacterium smegmatis.
Middlebrook 7H9 broth
The powder was purchased from Difco. 4.7g was dissolved in 
900 ml of distilled water. Either 0.5g of Tween 80 or 2ml of 
glycerol was added, 180ml aliquots were dispensed and then 
autoclaved. Immediately prior to use, 20 ml of sterile 
Middlebrook OADC enrichment supplement (Difco) was added to 
each 180ml aliquot.
Middlebrook 7H11 Agar
21g of 7H11 agar powder (Difco) was dissolved in one litre of 
distilled water containing 0.5% glycerol on a magnetic hot 
plate. 180ml aliquots were dispensed and autoclaved. OADC 
supplement was added as described for 7H9 broth.
General method for preparing broth and solid media 
The appropriate amounts of ingredients were placed in a one 
litre Duran bottle ( Schott ). The volume was made up to one 
litre, aliquots were dispensed and then autoclaved. 
Supplements e.g. antibiotics were added immediately prior to 
use after cooling to 50^C if required.
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Section 5.5 Buffers and Solutions
Aery1amide stock solution (30%)
300g Aery1amide (BDH), 8g bis-acrylamide
Deionised distilled water to one litre.
Alkaline SDS
2% SDS, 0.3M NaOH
Prepared in distilled water and autoclaved.
Brij/Doc solution
1% Brij 58, 0.4% sodium deoxycholate
Prepared in TE buffer pH8.0 and autoclaved.
<TE -  r e f e r  t o  pp 7 9 )
DEAE-Cellulose DE52 in L-broth for Phage DNA Extraction 
lOOg DEAE-cellulose DE52 (Whatman), 0.05N HCl 
NaOH (concentrated). Sodium azide
lOOg of DE52 was placed in a beaker and several volumes of 
0.05N HCl was slowly added until the pH was less than 4.5. 
Concentrated NaOH was then added slowly with gentle stirring 
until the pH reached 7.5. The cellulose was allowed to 
settle, the supernatant decanted and two volumes of sterile 
L-broth was added. The cellulose was gently resuspended and 
then allowed to settle. The supernatant was decanted and the 
resin was washed with L-broth in this manner several times 
until the pH of the decanted supernatant is identical to L- 
broth. The resin was finally resuspended in L-broth to give a 
final slurry of 75% resin, 25% L-broth. Sodium azide was 
added to give a final concentration of 0 .1% to prevent the 
growth of microorganisms. The slurry was stored at 4^ C.
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Denaturing solution for Southern blotting 
0.5M NaOH, 2.5M NaCl
This buffer was made up in deionised distilled water and 
autoclaved,
50X Denhardt's solution
0.5g Ficoll (MW 400,000), 0.5g Polyvinylpyrrolidone (MW 40,000)
0.5g Bovine serum albumin
The ingredients were dissolved in sterile deionised distilled 
water and dispensed into aliquots before storing at -20^ C.
Depurination solution for Southern blotting 
0.25M HCl
Made up in deionised distilled water and autoclaved.
Electroblotting buffer for Western transfers 
0.025M Tris base-HCl pH 8.3, 0.19M glycine
20% methanol
End labelling buffer lOX
lOOmM Tris-HCl pH7.5, lOOmM MgCl2
lOOmM mercaptoethanol, 500mM NaCl
Made up in deionised distilled water and autoclaved.
Freezing Mix 2X
12.60g K2HPO4, 0.9g Sodium citrate,
0.18g MgS0 4.7H20, 1.8g Ammonium sulphate,
3.6g KH2PO4, 88g Glycerol
Distilled water was added to a final volume of one litre,
dispensed into aliquots and autoclaved.
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Kushner Buffer; for preparing competent cells 
Solution A:
10 mM MOPS, lOmM RbCl, pH7.0
Solution B:
lOOmM MOPS, 50mM CaCl2, lOmM RbCl, pH 6.5
Both solutions were made up in deionised distilled water and
autoclaved.
Ligation buffer
T4 DNA Ligase was purchased from BRL which included prepared 
5X ligation buffer. The buffer was used as recommended by the 
manufacturers.
Loading buffer for agarose gels
10% Ficoll (molecular weight 400,000)
0.05% Bromophenol blue
Distilled water
Loading buffer for SDS polyacrylamide gels 
75mM Tris-HCl pH6.8, 5% Mercaptoethanol
2% SDS, 10% glycerol 
0.002% Bromophenol blue
Lysozyme solution
0.3M Sucrose, 25mM Tris-HCl pH 8.0 
25mM EDTA, 2mg Lysozyme (Sigma, Grade I)
The solution was usually made up fresh with sterile deionised 
distilled water. The concentration of the lysozyme can be 
varied from 2 to 10 mg/ml.
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Neutral SDS
2% SDS in deionised distilled water. Autoclaved.
Neutralising solution for Southern blotting 
3M Sodium acetate, pH 5.5
Made up in deionised distilled water and autoclaved.
Nick translation buffer IPX 
500mM Tris-HCl pH 7.2, lOOraM MgSO^
ImM Dithiothreitol (DTT), 500ug/ml bovine serum albumin (BSA) 
Made up in sterile deionised distilled water and filter 
sterilised.
PEG 6000 in SM buffer
200g Polyethylene glycol 6000 (PEG 6000, Sigma)
116.9g NaCl
SM buffer <;SM - refer to pp 77)
PEG 6000 and NaCl was dissolved in SM buffer. The volume was 
finally made up to 1000ml and autoclaved.
Phosphate Washing buffer for Southern Hybridization 
5mM NaH2P04, ImM EDTA 
0.2% SDS
The solution was prepared in distilled water and the pH 
adjusted to 7.0 before autoclaving.
Protein staining buffer: PAGE Blue 83 Stain 
2.0g PAGE Blue 83 (BDH), 1000ml 95% ethanol 
1000ml 20% Acetic acid
The dye was dissolved in 95% ethanol. Immediately prior to
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use an equal volume of 20% acetic acid was added.
Protein destaining buffer
1 volume Methanol, 1 volume Glacial acetic acid 
8 volume Distilled water
Protoplast buffer 
Basal solution:
103g Sucrose, 0.25g K2HPO4
2.02g MgCl2 *6H20, 2ml Trace element solution 
The buffer was prepared with deionised distilled water to 
800ml final volume and dispensed into 80ml aliquots before 
autoclaving. Prior to using the following sterile solutions 
were added per aliquot:
1ml 0.5% KH2PO4, 10ml 3.68% CaCl2 .2H20, 10ml 5.73% TES*pH7.2 
(*TES: N-Tris(hydroxymethyl)methyl-2-aminoethane sulphuric
acid.) (Trace element solution— refer to pp 78)
Restriction buffers
Enzymes were purchased from BRL. Appropriate restriction 
buffers were provided at lOX concentration and were used as 
recommended by the manufacturers. The composition of the four 
commonly used buffers are shown below:
REact 1 REact 2
Tris-HCl pH 7.4
Tris-HCl pH 8.0
MgCl2
NaCl
KCl
50raM
lOmM
50mM
lOmM
50mM
REact 3
50mM
lOmM
lOOmM
REact 4 
20mM
5mM
50mM
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4X Stacking buffer for SDS polyacrylamide gel.
0.4M Tris-HCl, pH 6.8; 0.4% SDS
Made up in deionised distilled water. Sterilised by 
autoclaving.
4X Separating buffer for polyacrylamide gels 
1.5M Tris-HCl pH 8.8, 0.4% SDS
Made up in deionised distilled water and sterilised by 
autoclaving.
5X SDS Acrylamide gel running buffer 
60,5g Tris base, 37.5g glycine 
5g SDS
Prepared in distilled water to a final volume of one litre. 
Autoclaved to sterilise.
SM buffer
200mM NaCl, ImM MgS0 4.7H20, 0.01% Gelatin
50mM Tris-HCl, pH 7.5
The volume was made up to one litre and then autoclaved.
20X SSPE buffer
3.6M NaCl, 20raM EDTA
0.2M NaH2P04/Na2HP04; pH 7.7
The ingredients were dissolved in 1 litre of deionised 
distilled water and autoclaved.
20X SSC
3M NaCl, 0.3M Sodium citrate
The ingredients were dissolved in distilled water to a final
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volume of one litre and the pH adjusted to 7.0 before 
autoclaving.
IX buffer
50mM Tris-HCl pH 7.5, 150mM NaCl
This buffer was usually made up lOX in deionised distilled 
water and sterilised by autoclaving.
^  TEST buffer
50mM Tris-HCl pH 7.5, 150mM NaCl
0.05% Tween 20
Made up in deionised distilled water and autoclaved.
Trace element solution 
40mg ZnCl2f 200mg FeClg.ôHgO 
lOmg CuCl2 .2H20, lOmg MnCl2 .4H20 
lOmg Na2B407, lOmg (NH4 )6Mo702.4H20
The solution was made up in deionised distilled water to one 
litre and dispensed into aliquots before autoclaving.
IX Tris Borate running buffer for agarose gels 
Ingredients per litre:
90mM Tris-HCl, 90mM Boric acid, 2.5mM EDTA 
pH 8.2
This buffer is usually made up lOX in distilled water.
IX Tris acetate running buffer for agarose gels 
Ingredients per litre;
40mM Tris-acetate, 20mM Sodium acetate, 2mM EDTA 
pH 8,3; Made up in distilled water.
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IX TE buffer
lOmM Tris-HCl; pH 8.0, ImM EDTA
Usually made up 10^ . deionised distilled water. The buffer 
was autoclaved.
IX TEN buffer
ImM EDTA, lOOmM NaCl
lOmM Tris-HCl pH 8.0
Usually made up lOX in deionised distilled water. Sterilised 
by autoclaving.
Tris CaCl9 competent cells buffer 
50mM CaCl2, 50mM Tris-HCl pH 8.0
The buffer was made up in deionised distilled water and 
autoclaved.
Western Blot colour development solution 
10 ml methanol,
30mg chloronaphthol
50ml TBS
lOpl hydrogen peroxide
The ingredients were added in order. Hydrogen peroxide was 
added just before using.
Section 5.6 Chemicals
BDH;
Acrylamide (Electran), Ammonium ferric citrate. Ammonium 
persulphate. Boric acid, Bromophenol blue. Calcium chloride 
(Analar), Dimethyl sulphoxide (Analar), D-Glucose, Disodium
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hydrogen phosphate. Glycine (Analar), Magnesium sulphate 
(Analar), Maltose (Analar), PAGE Blue 83 (Electran), Phenol 
(Analar), Polyoxyethylene sorbitan mono-oleate (Tween 80), 
Potassium dihydrogen orthophosphate. Sodium acetate. Sucrose 
(Analar), Tri sodium citrate (Analar)
BCL (Boehringer Mannheim)
Caesium chloride (Analar), EDTA (Ethylene diamine tetra- 
acetic acid, disodium salt) (Analar)
BRL (Bethesda Research Laboratories)
Ultrapure grade Agarose
Fisons
Glycerol
Difco
Middlebrook 7H9 broth, Middlebrook 7H11 agar, Middlebrook 
OADC enrichment, Lowenstein-Jensen medium
Hopkins and Williams Ltd.
Magnesium chloride (Analar), Potassium chloride (Analar)
May and Baker Ltd.
Chloroform (Pronalys AR), Dipotassium hydrogen phosphate. 
Ethanol (Pronalys AR), Glacial acetic acid (Pronalys AR), 
Hydrochloric acid (Pronalyas AR), Isopropanol (Pronalys AR), 
Methanol (Pronalys AR), Sodium chloride (Pronalys AR), Sodium 
hydroxide (Pronalys AR)
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Oxoid
Agar Technical No.3, Gelatin, Tryptone, Yeast extract. 
Nutrient agar and broth No.2, Tryptone soya agar and broth.
Schleicher and Schuell
NA 45 and BA 85 nitrocellulose membranes 
Sigma
Antibiotics, Arginine (freebase), L-asparagine (monohydrate), 
Brij 58, Bovine serum albumin, 4-Chloro-l-naphtol, DL- 
Dithiothreithol, Deoxyribonuclease I, ethidium bromide. 
Hydrogen peroxide, IPTG (Isopropyl-Beta-D-thio- 
galactopyranoside), Lysozyme Grade I, 2-Mercaptoethanol, 
N,N'-Methylene-bis-acrylamide, MOPS (3-[N-Morpholino] propane 
sulphonic acid, NBT (nitroblue terazolium), PEG 6000 
(polyethylene glycol MW 6000), Proteinase K, Ribonuclease A, 
SDS (Sodium dodecyl sulphate). Spermidine, Trizma base 
(reagent grade). Tween 20 (Polyoxyethylene sorbitan 
monolaurate), TEMED (N,N,N’,N,-Tetramethy1ethylene-diamine), 
X-Gal (5-bromo-4-chloro-3indolyl“beta-D-galactopyranoside)
Koch Light Laboratories 
Rubidium chloride
Whatman
3MM paper, DEAE-cellulose DE52
Section 5.7 Molecular biology and Immunological Reagents 
Amersham International
[alpha 32p] deoxyadenosine triphosphate (dATP), [alpha 32p]
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deoxycytosine triphosphate (dCTP), Hybond N filter membrane. 
Multiprime labelling kit, Streptavidin-biotinylated 
horseradish peroxidase complex
BCL
Calf intestinal alkaline phosphatase (CIAP), T4 DNA ligase 
BRL
All restriction enzymes, including buffers (unless otherwise 
stated), DNA polymerase I, DNA polymerase I Large fragment 
(Klenow).
Northumbria Biological Laboratories
Lambda vector EMBL4, Gigapack In Vitro Packaging Kit 
Sigma
Anti-rabbit IgG (whole molecule) biotin conjugate 
Stratech Scientific Ltd.
GENECLEAN kit
Tobias Kieser, John Innes Institute j_ Norwich.
Rabbit anti-NPTJJ IgG was kindly provided by Dr. Tobias 
Kieser.
Section 5.8 Films 
Fuji; X-Ray film RX
Polaroid: Land film Type 665 (Positive/Negative) and 667 
(Positive only).
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CHAPTER 6
Methods
Unless otherwise stated, buffers and solutions used are 
described in BUFFERS AND SOLUTIONS (Chapter 5).
Section 6.0 Maintenance of Strains
6.0.1 Escherichia coll strains
For long term storage of strains an equal volume of 2X 
Freezing mix was added to an overnight L-broth culture and 
stored at -70°C. Working stocks were streaked out on L-agar 
every four weeks.
6.0.2 Mycobacterium strains.
Working stocks were maintained on Lowenstein-Jensen 
slopes and kept at room temperature in the dark in the case 
of the slow growers, or at 4°C in the case of the fast 
growers. Broth cultures of Mycobacterium smegmatls were also 
kept frozen as described for the E. coll strains. Working 
stocks of M. smegmatls were also maintained on N- agar 
plates.
Section 6.1 DNA Extraction Methods
6.1.1 Extraction of "total" DNA from Mycobacteria
Reagents:
20% glycine 
TE buffer
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Lysozyme solution (lOmg/ml lysozyme)
10% Neutral SDS solution (in TE)
Phenol saturated with TE
Phenol; Chloroform (1:1, v/v) saturated with TE buffer
Chloroform saturated with TE
3M Sodium acetate, unbuffered
Absolute ethanol
80% ethanol
Isopropanol
RNAse A (lOmg/ml, heat treated)
Procedure 1: Broth culture
The cells were grown in the appropriate medium (N-broth 
No2 for M. smegmatis, 7H9 broth for the other species) until 
mid log phase; usually 48 hours for the fast growers and two 
to four weeks for the slow growers. Glycine was added to a 
final concentration of 2%. Incubation was continued for a 
further 16 or 48 hours for the fast and slow growers 
respectively.
Cells were harvested by centrifugation at 5000 RPM for 
10 minutes. The supernatant was discarded and the cells were 
resuspended in SOOul to 5m 1 of lysozyme solution (10ml 
cultures can be resuspended in the lesser volume ). This was 
then incubated at 37^C from 4 to 16 hours. A half volume of 
neutral SDS was added and the mixture was thoroughly mixed. 
After lysis has occurred, an equal volume of phenol was 
added and the mixture was vortexed thoroughly. The solution
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was centrifuged for 10 minutes at 5000 RPM (MSE Chilspin) or 
2 minutes if a microfuge was used. The aqueous phase was 
recovered while avoiding the white material collected at the 
interface of the two phases. The aqueous phase was then 
subjected to two further extractions; firstly with 
phenol : chloroform and then with chloroform. If the white 
material could still be seen at the interface, the phenol 
chloroform and chloroform extractions were repeated.
The final aqueous phase was recovered, a 1/lOth volume 
of 3M sodium acetate was added followed by an equal volume of 
isopropanol. This was incubated on ice for 30 minutes. The 
DNA was recovered by centrifugation for 15 to 30 minutes at 
4°C. The DNA was washed with 80% ethanol and then dried in a 
vacuum desii’Ccator. The DNA was resuspended in the appropriate 
volume of TE buffer. RNAse A was added to a final 
concentration of 50ug/ml and incubated at 37°C for 60 
minutes. A 1/lOth volume of 3M sodium acetate was added 
followed by 2.5 volumes absolute ethanol. After incubating on 
ice for 30 minutes, the DNA was recovered , washed, dried and 
resuspended in TE buffer as previously described. The DNA 
solution was stored at 4Pc.
Procedure 2: Solid medium culture
The bacteria were grown in 10 ml 7H9 broth for one week 
(M. tuberculosis) or overnight for fast-growers. The cells 
were centrifuged for 10 minutes at 5000 RPM (MSE Chilspin). 
The supernatant was removed and the cells were resuspended in
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the remaining fluid. The cell suspension was then plated out 
onto two or three petri dishes of 7H11 agar and incubated at 
37°C for two days to two weeks, depending on the species.
The cells were scraped off, pooled and resuspended in 50 
to 100 ml of 7H9 broth containing 2% glycine. The broth was 
incubated overnight or for 48 hours at 37°C. DNA extraction 
was then carried out as described in Procedure 1.
This method was developed especially for large scale DNA 
extraction of M. tuberculosis to efficiently utilise the 
limited space and equipment available in the Restricted 
Laboratory as well as to minimise the risks to other members 
of the Department. This method also yields up to twice the 
amount of cells available for DNA extraction compared to a 
200 ml broth culture.
6.1.2 Small Scale Extraction of Plasmid DNA
Two procedures were routinely used throughout this work. 
Procedures 1 and 2 were used for extracting plasmid DNA from 
E, coli strains. Slightly modified versions of the two 
procedures were used for extracting plasmid DNA from 
Mycobacterial species.
Reagents:
Lysozyme solution (2mg/ml)
Alkaline SDS (2%)
Alkaline SDS (1%)
3M Sodium acetate pH 4.8
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O.IM Ammonium acetate
Acid phenol : chloroform (5g phenol, 5 ml chloroform, 
distilled water)
Phenol:chloroform saturated with TE buffer
Absolute ethanol
Isopropanol
TE buffer
lOOmM Spermine-HCl
0.3M sodium acetate, lOmM MgCl2
Procedure 1: (Birnboim and Doly, 1979; Maniatis et al, 1982)
Cells were harvested from 1ml overnight broth culture 
of E. coli strains. Mycobacterial species however required 
about 2 to 3 ml of broth culture to obtain comparable amounts 
of DNA. The procedure was also modified slightly for 
mycobacteria by the glycine treatment as described previously 
for large scale chromosomal DNA extraction ( Section 6.1.1).
The cells were resuspended in lOOul of lysozyme solution 
and incubated on ice for 30 min or 2 to 4 hours at 37®C for 
mycobacteria. A 200ul volume of alkaline SDS was added and 
mixed by pipetting up and down. The suspension was kept on 
ice for 5 minutes after which ISOul of 3M sodium acetate 
added, mixed and kept at 0°C for one hour.
The mixture was centrifuged in a microfuge for 5 minutes 
at room temperature. A 400ul volume of the supernatant was 
recovered and transferred to a fresh microfuge tube. One ml 
of cold absolute ethanol was added and kept on ice for 30 to
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60 minutes. The DNA was recovered by centrifuging in the cold 
for 15 minutes. The pellet was resuspended in lOOul of O.IM 
sodium acetate to which was added 200ul of cold absolute 
ethanol. After keeping on ice for 30 minutes the DNA was 
again recovered by centrifuging for 15 minutes in the cold. 
The pellet was dried in a vacuum desiccator and then 
resuspended in lOOul of TE buffer.
The plasmid prepared in this way has limited stability 
but can be kept longer by extracting the final DNA solution 
with an equal volume of TE-saturated phenol chloroform and 
re-precipitating the DNA.
Procedure 2: Alkaline Lysis (Hopwood et ai, 1985)
The cultures were grown and the cells were harvested as 
described for Procedure 1.
The cell pellet was resuspended in lysozyme solution to 
give a final volume of 500ul and incubated at 0*^ C for 30 min 
or 37®C for 2 to 4 hours for B. coli and Mycobacteria 
respectively.
A 250ul volume of alkaline SDS was added and vortexed 
thoroughly. The mixture was then incubated at 70% for 15 
min, cooled in a water bath to room temperature after which 
80ul of acid phenol chloroform was added. The two phases were 
thoroughly mixed and then centrifuged for 2 minutes in a 
microfuge. A 700ul volume of the upper aqueous phase was 
placed in a fresh microfuge tube. At this stage samples can
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be taken and run on an agarose gel. Unbuffered 3M sodium 
acetate (70ul) was added followed by 700ul of isopropanol. 
This was kept at room temperature for 5 minutes and then 
centrifuged for 2 minutes. All the liquid was removed and the 
pellet resuspended in 500ul of TE buffer. A 25ul volume of 
lOOmM spermine-HCl was added and the mixture kept at room 
temperature for 5 minutes. This was followed by 
centrifugation for two minutes and the supernatant was 
removed completely. The pellet was dispersed in 300ul of 0.3M 
sodium acetate, lOmM MgCl2 after which was added 700ul 
ethanol and the mixture kept at room temperature for 60 
minutes. The DNA was recovered by centrifuging for 5 minutes 
and the supernatant was removed. The pellet was resupended in 
50ul TE and stored at 4 %  before using.
When this method was used to extract low copy number 
plasmids or in screening bacteria for the presence of 
plasmids, isopropanol or ethanol precipitation was carried 
out on ice for 30 minutes and centrifugation times were 
increased for up to 30 minutes for maximum recovery.
6,1.3 Large Scale Plasmid Extraction from Escherichia coli
(Maniatis et al, 1982)
Reagents:
L-broth
2mg/ml Lysozyme solution, freshly prepared 
Brij/Doc solution 
Chloramphenicol or Spectinomycin
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20mg/ml Ethidium bromide solution
Caesium chloride
Isopropanol
Isopropanol saturated with caesium chloride 
80% ethanol 
TE buffer
Procedure:
A single colony of the strain of interest was inoculated 
into 10ml L-broth, containing antibiotics where appropriate, 
and incubated at 37% with shaking overnight.
A 4ml volume of the overnight culture was then used to 
inoculate 150ml of pre-warmed L- broth ( again containing 
antibiotics if required) which was incubated with vigorous 
shaking at 37% for approximately 3 hours , until the optical 
density at 650nm was 0.9. Chloramphenicol was added to a 
final concentration of 170ug/ml (or spectinomycin to 200ug/ml 
if the cells are chloramphenicol resistant) and the culture 
reincubated for a further 4 to 18 hours.
The cells were harvested by centrifugation at 10,000 
RPM for 10 minutes in an MSE High Speed 18. The cells were 
resuspended in 6ml of freshly prepared lysozyme solution and 
kept on ice for 15 to 30 minutes. 4ml of Bri j/Doc solution 
was added and mixed by pipetting up and down a 10ml pipette. 
The solution was left on ice for 20 to 30 minutes to ensure 
complete lysis. Once this had been achieved cell debris and 
most of the chromosomal DNA was removed by centrifugation at
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17.000 RPM for 45 minutes (MSE High Speed 18).
The supernatant (cleared lysate) was recovered by 
decanting carefully into a fresh tube. The volume was 
determined and caesium chloride was added to a final 
concentration of 0.95g/ml. Ethidium bromide was then added to 
give a final concentration of 500ug/ml.
The cleared lysate was placed into a Beckman Quick Seal 
polyallomer ultracentrifuge tube, loaded onto a Beckman Ti
70.1 or Ti 75.1 rotor and spun for 48 hours at 40,000 RPM in 
a Beckman L5 or L8 ultracentrifuge.
The plasmid band was visualised using U.V. longwave 
(300nm) illumination and recovered by puncturing the side of 
the tube, just below the band, with a 19G disposable needle 
and drawing it into a 1ml syringe.
An equal volume of isopropanol saturated with caesium 
chloride was added and mixed thoroughly. This was allowed to 
stand for a few minutes until two phases were obtained. The 
top, isopropanol, phase was removed and this process was 
repeated until all the ethidium bromide had been removed.
To each 200ul of extract, 250ul of distilled deionised 
water was added followed by 50ul of 3M sodium acetate and 
500ul of isopropanol. This was kept on ice for 30 minutes and 
the DNA recovered by centrifuging for 15 minutes at 4^ C. The 
supernatant was removed and the pellet was washed with 400ul 
of cold 80% ethanol. The pellet was then dried in a vacuum
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desiccator before resuspending in TE buffer.
6.1.4 Large Scale Plasmid Extraction from Mycobacteria
Two methods were employed for large scale extraction of 
plasmid DNA from Mycobacteria. Both methods are essentially 
modified versions of procedures used for E. coli strains.
Reagents:
10% SDS in water 
2% alkaline SDS solution
lOmg/ml lysozyme solution, freshly prepared 
20% glycine
20mg/ml Ethidium bromide
Caesium chloride
Acid phenol chloroform
Neutral phenol chloroform
Phenol chloroform saturated with TE buffer
Isopropanol
Absolute ethanol 80% ethanol 
3M Sodium acetate
The initial stages for the two procedures were 
identical. The bacteria was first grown in 10ml of the 
appropriate broth (7H11 or N-broth No.2) containing 
antibiotics if required. A 4ml volume of this starter culture 
was then used to inoculate 200ml of broth, again containing 
antibiotics where appropriate. The culture was incubated at 
37°C for 48 hours or two weeks, with shaking, depending on 
the species. Glycine was then added to a final concentration
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of 2% and the culture was re-incubated for a further 16 or 48 
hours for fast and slow growers respectively. The cells were 
harvested by centrifuging at 10,000 RPM for 10 minutes. The 
pellet was then resuspended in lysozyme solution to a final 
volume of 5ml and incubated at 37% for 4 to 16 hours.
One of the procedures described below was then used to 
extract the plasmid:
Procedure 1: Alkaline Lysis (Scaled Up lOX)
This is essentially a modified lOX scaled up version of 
the method described in Procedure 2 of Section 6.1.2.
Briefly, 2.5ml of alkaline SDS was added to the cells 
suspended in lysozyme solution followed by incubation at 70% 
for 20 minutes. Acid phenol chloroform, 800ul, was added and 
then mixed and centrifuged. A 7ml volume of the top aqueous 
phase was recovered to which was added 700ul 3M sodium 
acetate. Isopropanol, 7ml, was added and kept on ice for 30 
minutes.
The mixture was centrifuged, 5,000 RPM for 15 to 30 
minutes at 4%. The resulting pellet was resuspended in 500ul 
TE buffer, 50ul 3M sodium acetate was added and then 250ul 
neutral phenol chloroform (acid phenol chloroform 
equilibrated with 0.5 volume IM Tris-HCl pH 8.8 and then with
0.5 volume 0. IM Tris-HCl pH 8.0). The solution was mixed 
thoroughly, centrifuged for 5 minutes and the upper aqueous 
phase was transferred to a fresh microfuge tube containing
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500ul isopropanol. This was kept on ice for 30 minutes, spun 
for 15 minutes at 4 %  and the pellet was washed with 500ul 
80% ethanol. The pellet was finally resuspended in TE buffer 
to which was added caesium chloride (0 .95g/ml) and ethidium 
bromide (250ug/ml). Ultracentrifugation and plasmid DNA 
recovery was as described in Section 6.1.3.
Procedure 2: Modified Cleared Lysate Method
This method was modified from the large scale plasmid 
extraction procedure for E. coll given in Section 6.1.3.
To 5ml of cells suspended in lysozyme solution was added 
2.5ml 10% SDS which was mixed by pipetting up and down 
several times. More SDS was sometimes needed to achieve 
lysis. The resultant lysate was centrifuged at 17,000 RPM for 
45 minutes at 4%. The cleared lysate was recovered and 0.5 
volume of phenol chloroform saturated with TE buffer was 
added. The two phases were mixed, centrifuged and the upper 
phase was recovered. A 1/lOth volume of 3M sodium acetate was 
added followed by an equal volume of isopropanol (or 2.5 
volume of absolute ethanol ). This was incubated on ice for 30 
minutes and then centrifuged at 5,000 RPM for 30 minutes. The 
supernatant was removed and the pellet was resuspended in TE 
buffer. This was then run on a caesium chloride-ethidium 
bromide gradient as previously described.
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6.1.5 DNA Extraction from Lambda Phage
Reagents;
L-broth; L-agar; Top agarose
chloroform
SM buffer
20% PEG 6000+2M NaCl in SM buffer
DEAE-cellulose DE52 in L-broth
O.lmg/ml Proteinase K
3M Potassium acetate
10% SDS
Isopropanol
1. Preparation of plating cells
The lambda phage from which the DNA was to be harvested 
can be prepared either from E, coli strains grown on agar or 
from liquid cultures.
A single colony of the required strain (LE392 or P2392) 
was inoculated into 10ml L-broth containing lOmM MgSO^, 0.2% 
maltose and incubated at 30^C overnight with shaking. The 
cells were pelleted at 2,000 RPM for 10 minutes at 4%. The 
cells were then resuspended in 4ml of lOmM MgSO^ and kept on 
ice. Before using, the cells were diluted to OD600nm of 0.5 
with SM buffer.
2. Preparation of lambda phage from solid media
To 200ul of the prepared plating cells was added 10 to 
lOOul of phage stock (in SM), suitably diluted with SM buffer
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to give approximately 10^ pfu (plaque forming unit). This was 
incubated at 37% for 20 minutes to adsorb the phage to the 
cells. The infected cells were inoculated into 3ml of molten 
top agarose, which had been cooled to 45%, and poured onto 
dried L-agar in 90mm petri dishes. The top agarose was 
allowed to set before incubating at 37% from 8 hours to 
overnight.
The plate was flooded with 5ml of SM buffer, sealed and 
shaken gently at 4 %  for 2 to 3 hours. The buffer was 
recovered and placed into a polypropylene tube. The plate was 
washed with 1 ml SM buffer and the wash was added to the rest 
of the plate lysate. 3 drops of chloroform was added and 
vortexed vigorously. This was then centrifuged for 10 
minutes, 4%, at 4,000 RPM. 4ml of the supernatant was 
recovered and used to harvest lambda phage DNA as described 
below.
3. Preparation lambda phage from liquid media
Lambda phage stock was diluted with SM buffer to give 
approximately 10^ pfu in a 10 to lOOul volume. Alternatively, 
a single plaque from a fresh plate was cored out using a 
sterile glass Pasteur pipette. The phage stock or the plaque 
was placed into 0.5ml freshly prepared plating cells and kept 
at room temperature for 15 minutes to allow the cells to 
adsorb the phage particles. 5 ml of L-broth containing 5mM 
CaCl2 was added and incubated with shaking for 3.5 to 4.5 
hours at 37% until the cells were just beginning to lyse.
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Three drops of chloroform was added and the lysate was shaken 
for 5 minutes. The lysate was then centrifuged at 3,000 RPM 
for 10 minutes. 4ml of supernatant was recovered and used for 
harvesting lambda phage DNA.
4. Extraction of DNA from lambda phage
To 4ml of phage lysate, prepared using either of the two 
methods above, was added 4ml of 20% PEG 6000, 2M NaCl in SM 
buffer. After mixing, this was incubated on ice for one hour. 
The mixture was centrifuged for 20 minutes at 3,000 RPM. The 
supernatant was decanted and the side of the tube was wiped 
with tissue to remove all traces of PEG. The pellet was 
resuspended in 750ul of L-broth. 750ul of DE52 suspension 
(prepared as described in BUFFERS AND SOLUTIONS) was added 
and mixed by inversion for 20 to 30 times.
The suspension was centrifuged for 5 minutes and the 
supernatant was transferred to a fresh microfuge tube. A 13ul 
volume of O.lmg/ml Proteinase K solution was added followed 
by 32ul of 10 % SDS. This was kept at room temperature for 5 
minutes. 3M potassium acetate, 130ul, was added and incubated 
at 88%  for 20 minutes. The tube was then transferred to ice 
and kept for 10 minutes. The solution was centrifuged for 10 
minutes on a microcentrifuge. 700ul of the supernatant was 
recovered to which was added 700ul isopropanol and kept on 
ice for 30 minutes. This was followed by centrifugation for 
15 minutes. The supernatant was removed and the pellet was 
washed with 80% ethanol. The pellet was dried briefly before
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resuspending in 20 to 50 ul of TE buffer.
Section 6.2 In vitro manipulation of DNA
6.2.1 Precipitation of DNA
DNA can be precipitated by ethanol or isopropanol 
precipitation.
Procedure:
To one volume of DNA solution was added the following in 
order: A 1/lOth volume 3M sodium acetate (unbuffered), 2.5 
volumes of absolute ethanol or one volume of isopropanol.
This was kept on ice for 30 minutes (or 
overnight at -20%) and centrifuged for 10 minutes or longer 
depending on the amount of DNA available and the type of 
centrifuge used.
The supernatant was removed and the resultant pellet was 
washed with cold (-20%) 80% ethanol. The pellet was dried 
briefly and then resuspended in TE buffer.
6.2.2 Quantitation of DNA
Procedure 1: Spectrophotometric method (Maniatis et al, 1982) 
This method measures the amount of UV irradiation 
absorbed by the bases. The DNA solution was diluted 10 to 20 
fold in deionised distilled water and placed in a quartz 
cuvette. The absorbance at 260nm and 280nm wavelengths were 
measured using a Pye Unicam model PU8820 UV/VIS 
spectrophotometer. The ratio of the readings, 260nm/280,
98
provides an estimate of the purity of the DNA preparation, A 
ratio of 1.7 or greater indicates DNA solution of high purity 
with little protein contamination. An absorbance of 1.0 at 
260nm is equivalent to a DNA concentration of 50ug/ml. 
Therefore the DNA concentration of the preparation can be 
calculated from the following formula:
DNA concentration- (OD260 X 50 X dilution) ug/ml
The presence of RNA, which would also absorb UV, can 
result in a value higher than the true DNA concentration. The 
measurement also includes the products of DNA degradation and 
again the true concentration of intact DNA may be less than 
the calculated value.
Procedure 2: Comparative Intensity Method
This method was used when not enough DNA sample was 
available for quantitation using Procedure 1 (total 
quantities of less than SOOng).
A known volume of the DNA sample of interest was 
electrophoresed on an agarose gel with a known amount of 
lambda DNA digested with Hindlll as size markers. The gel was 
stained with ethidium bromide and photographed under UV 
illumination (300nm). The intensity of fluorescence of DNA is 
directly proportional to the total mass of the DNA (Maniatis, 
et al, 1982). Therefore, by comparing the intensity of the 
DNA of interest to that of the lambda fragments, a marker 
fragment of similar intensity can be chosen and an
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estimation of the amount of DNA in the sample can be 
calculated as follows:
a) The ratio of the size of the marker fragment to total size 
of the marker DNA was first calculated :
Size of chosen fragment (kb)/Total size of marker DNA (kb)
= X
b) The amount of DNA in the sample volume can then be 
calculated:
X = see (a) above
Y = Total amount of marker DNA in nanogram (ng)
Therefore, the amount of DNA in the chosen marker fragment,
= X X Y ng
= Estimated amount of DNA in the sample volume (in ng).
6.2.3 Restriction Endonuclease Digestion of DNA 
Procedures:
Single restriction digests
Typical restriction digests, with one enzyme were set up 
as shown below:
lOul DNA (up to lug of DNA)
2ul lOX Restriction buffer 
7ul deionised distilled water 
lul enzyme (1 to 50 units)
The reaction mixture was then incubated at the required 
temperature for 60 minutes; usually 37^C. Digests were
100
stopped by heating to 65% for 10 minutes if the enzyme is 
heat labile. For heat stable enzymes, the reaction mix was 
extracted with 0.5 to 1 volume of phenol chloroform saturated 
with TE buffer followed by ethanol precipitation and 
resuspension in TE buffer.
Each restriction enzyme has a particular type of buffer 
composition which optimises the digest reaction. Enzymes were 
bought from BRL and lOX restriction buffers were provided 
with each purchase. The buffers were used as recommended by 
the manufacturers. The composition of some of the more 
frequently used buffers are shown in BUFFERS AND SOLUTION 
(Section 5.5). Table 6A shows a selection of some of the 
enzymes and buffers used in this work.
Table 6A Restriction enzymes and buffers
Enzyme lOX REact buffer
Alul 1BamHI 3Bglll 3Clal 1EcoRI 3EcoRV 2Haelll 2Hindlll 2PvuII 6Sail 3Sau3RI 4
Double Restriction Digests
The DNA was digested with both enzymes at the same time 
if the recommended buffers were identical for both. In some
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cases, the activity of one enzyme in a chosen buffer is less 
than 100%. The two digestions were still carried out at the 
same time if this activity is greater than 50%. The 
incubation time however was increased to 1.5 to 2 hours. If 
the activity is less than 50% or star activity of one enzyme 
occurred in the chosen buffer, digestion with one enzyme was 
done first, followed by enzyme inactivation. The salt 
concentration was re-adjusted or the DNA was precipitated and 
a new reaction mixture was set up using the other buffer.
Partial Restriction Digests
Partial digests were used to obtain suitably sized 
fragments (usually of chromosomal DNA) for cloning into phage 
or plasmid vectors.
Reaction mixtures were set up as described for single 
digests. The reaction mix was divided into aliquots which 
were then incubated. Aliquots were removed at various times 
and the enzyme inactivated. The degree of digestion was 
determined by electrophoresis. The required aliquots were 
pooled and the DNA was precipitated followed by resuspension 
in TE buffer.
6.2.4 Dephosphorylation of DNA
Following digestion with restriction enzymes, phosphate 
groups are exposed at the 5' terminus. These groups can be 
removed (dephosphorylated) by the action of two enzymes : 
bacterial alkaline phosphatase (BAP) and calf intestinal
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alkaline phosphatase (CIAP) (Maniatis et al, 1982). Vector 
DNA can be treated in this way to prevent self-religation and 
thus maximising the formation of recombinant molecule. If a 
positive selection vector was used (only recombinant 
molecules are viable in the host), then the insert can be 
dephosphorylated to prevent insert circularization and the 
production of recombinants with multiple inserts. CIAP was 
usually used as it can be inactivated by heating at 68*^0 .
Procedure:
Following restriction endonuclease digestion and enzyme 
inactivation, 0.1 unit of CIAP was added per microgram of 
DNA. Alternatively, the restriction enzyme was first removed 
by phenol chloroform extraction, the DNA was ethanol 
precipitated and resuspended in TE buffer before adding CIAP. 
The reaction mix was then incubated at 37% for 30 minutes. 
The reaction was terminated by heating to 70% for 30 minutes 
followed by phenol chloroform extraction. The DNA was then 
ethanol precipitated and centrifuged. The DNA pellet was 
resuspended in TE buffer.
6.2.5 End Filling of Recessed 3' Termini
Recessed 3'termini created by the digestion of DNA by 
some restriction enzymes can be filled in by using the Large 
Fragment of DNA Polymerase I enzyme ( Klenow fragment ), The 
Klenow fragment retains the 5'to 3' polymerase and 3' to 5' 
exonuclease activities of DNA Polymerase I but lacks the 5 ' 
to 3' exonuclease activity. The Klenow Fragment therefore has
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a variety of uses including the creation of blunt ends for 
blunt end ligations and end-labelling DNA with radiolabelled 
nucleotides by filling in recessed 3' termini.
Procedure:
The typical reaction was set up as follows:
Digested DNA (up to lug) lOul2mM dATP in water lul2mM dCTP in water lul2mM dGTP in water lul2mM dTTP in water lullOX End labelling buffer 2ulDeionised water 3ulKlenow fragment (1 u/ul) lul
The reaction mix was incubated at room temperature for 
30 minutes. The reaction was terminated by extraction with 
phenol chloroform and the DNA was recovered by ethanol 
precipitation and centrifugation. The DNA was resuspended in 
TE buffer and stored at 4%.
6.2.6 Agarose Gel Electrophoresis
Reagents:
Agarose (Ultrapure, BRL)
IX Tris borate buffer (TEE)
IX Tris acetate buffer (TAE)
30% Acrylamide stock prepared in TEE or TAE 
TEMED
10% ammonium persulphate 
20mg/ml Ethidium bromide
Agarose gels can be used to separate DNA molecules of 
different sizes and shapes. Agarose concentration, gel
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buffer, voltage, running time and the amount of DNA in the
sample determine the position of the DNA molecules on the
gel. The different types of DNA i.e. linear, closed circular, 
open circular etc. respond differently to the various 
conditions (Hopwood et al, 1985, Kieser, 1984, Maniatis et 
al, 1982).
In this study various types of gel electrophoresis kits 
were used:
Minigel Uniscience
Horizontal gels BRL Model H4 and H5
Vertical gels BRL Model VI6-2
The equipment was set up as recommended by the
manufacturers. Either Tris borate (TBE) or Tris acetate (TAE) 
was used, depending on the experimental requirements, in the 
preparation and the running of the buffer. Gel concentrations 
used ranged from 0.7 to 1.2% depending on requirements. Gels 
were prepared by boiling the agarose powder in the buffer 
until molten and cooled to 50% before pouring.
In addition, when vertical agarose gels were used, a 
small volume (c. 10ml) of 10% polyacrylamide gel was first 
prepared to support the agarose. This is due to the fact that 
agarose does not adhere very well to the glass plates used in 
preparing the gel and may slip down during electrophoresis. 
The polyacrylamide gel was prepared by diluting the stock 
solution with the appropriate buffer, 0.01 volume of 10% 
ammonium persulphate was added followed by 0.001 volume of
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TEMED, The gel was poured immediately and left to set for 20 
to 30 minutes before pouring the agarose.
Typical electrophoresis conditions are shown below (using 
Tris-borate running buffer:
Type of gel Voltage Running time
Minigel 80 40 minutesHorizontal (H5) 125 2.5 hoursHorizontal (H5) 25 15 hoursVertical (VI6 ) 50 15 hours
These conditions usually allow the marker dye to travel 
to about 2 to 3cm from the end of the gel.
The gel was stained with ethidium bromide (0.5 to 
lug/ml) for 10 minutes. The DNA bands were visualised using 
long wave UV illumination and photographed via orange filter 
(23A) using Polaroid 665 or 667 film.
6.2.7 Recovery of DNA From Agarose Gels
Several methods have been described for recovering DNA 
from agarose gels (Maniatis et al, 1982, Young et al, 1985a). 
Two methods were used which gave the best results.
Procedure 1: Recovery from NA 45 Nitrocellulose Membrane
(Young et al, 1985a)
Reagents:
Elution buffer (0.05M Arginine (free base), IM NaCl) 
TE buffer
Isoamyl alcohol (water saturated)
Isopropanol
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NA45 nitrocellulose membrane (Schleicher and Schuell)
DNA samples were electrophoresed through horizontal 
agarose gels under appropriate conditions. The gel was 
stained with ethidium bromide (0.5ug/ml) and the DNA 
fragments were visualised under UV illumination. The 
fragment(s) to be recovered was selected and slits were made 
in the gel just behind and in front of the fragment(s) of 
interest. A piece of NA45 membrane was then placed in each 
slit. Electrophoresis was continued until all the required 
fragment(s) had bound completely to the NA45 membrane.
The membrane was removed from the gel and placed into 
400ul of elution buffer which was then incubated at 70% for 
2 hours with intermittent shaking. The membrane was removed 
and the elute was cooled to room temperature. A 400 ul volume 
of isoamyl alcohol (water saturated) was mixed with the elute 
and left to stand for a few minutes. The top phase (alcohol) 
was removed. To the aqueous phase was added 400ul of 
isopropanol (or 1ml of absolute ethanol) and incubated for 30 
minutes. The DNA was recovered as previously described 
(Section 6.2.1).
Procedure 2: The GENECLEAN method
This method utilizes a commercial kit, called GENECLEAN, 
developed by BIO 101, which is based on the affinity of DNA 
molecules to a silica matrix. The affinity can be raised or 
lowered by varying the conditions and thus allows the 
recovery of DNA with very high efficiency.
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Reagents: All reagents were supplied with the kit.
Sodium iodide (Nal) stock solution
"Glassmilk" silica matrix suspension
NEW buffer (NaCl, Ethanol, Water; the exact
composition is not disclosed by the manufacturers)
TE buffer
The DNA sample was electrophoresed through agarose gels 
usually prepared and run in TAE running buffer (TBE was also 
used but TAE gave better DNA recoveries).
The gel slice containing the DNA fragment(s) required 
was excised from the gel and the weight was determined. 2 to 
3 volumes of Nal stock solution was added (calculated by 
multiplying the weight of the gel slice with the number of 
volume chosen) and then incubated at 55%  for 5 to 10 minutes 
until the gel slice was completely dissolved.
5ul (per 5ug of DNA) of "GLASSMILK" suspension was 
added, mixed thoroughly, and placed on ice for 5 minutes to 
allow binding of the DNA to the silica matrix. The silica 
matrix was pelleted by centrifuging for 5 seconds 
( mi cocentrifuge ). The Nal supernatant was discarded and 400ul 
of ice cold NEW buffer was added. The pellet was resuspended 
very thoroughly in this buffer by pipetting up and down 
several times. The resuspended silica matrix was then 
centrifuged for 5 seconds and the supernatant was discarded. 
The washing procedure with NEW buffer was repeated twice 
more. After the final spin, the supernatant was completely
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removed and 5 to 10 ul of TE buffer was added. The pellet was 
resuspended by vortexing followed by incubation at 55% for 3 
minutes and centrifugation for 30 seconds. The supernatant 
was recovered and the pellet was resuspended in another 
aliquot of TE buffer. The incubation and centrifugation was 
repeated and the supernatants were pooled and kept at 4°C.
This method enables the recovery of DNA with greater 
than 90% efficiency.
6.2.8 DNA Ligation
Reagents;
T4 DNA ligase 
5X Ligase buffer 
Distilled deionised water
The DNA molecules to be ligated were first digested with 
the appropriate restriction enzymes. Modifications such as 
blunt ending, linker attachment, dephosphorylation etc. were 
made if required. The DNA molecules to be ligated were then 
resuspended in buffer such that the concentrations of the DNA 
and the ratio of the different DNA molecules would result in 
maximum recombinant molecule production (see Maniatis et al 
1982, Hopwood et al, 1985 for optimal ligation conditions).
Typical reaction mixtures are set up as shown below:
DNA lOul5X Ligation buffer 4ulwater 5ulT4 DNA Ligase lul (lunit)
The mixture was incubated at room temperature for 4
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hours or 17°C overnight. For blunt end ligations, up to 3 
units of ligase was used. The T4 DNA ligase used was 
purchased from BRL which included the 5X Ligase buffer (250inM 
Tris-HCl, pH 7.6, 50mM MgCl2, 5mM ATP, 5mM dithiothreithol, 
25% w/v polyethylene glycol 8000).
110
Section 6.3 Construction of Mycobacterial Genomic Libraries
6.3.1 Preparation of Mycobacterial Genomic Libraries 
in Lambda Phage EMBL4 (Frischauf et al,1983)
EMBL4 (Figure 6A) is a lambda phage replacement vector
with a cloning capacity of 9 to 23 kilobases (kb). The number
of recombinant particles required to obtain a complete 
Mycobacterial genomic library, with 99% confidence limit was 
calculated from the formula:
N = log(1-P)/log(1-L/M) (Maniatis et al, 1982)
where
N = number of recombinants 
P = Probability = 0.99
L = length of insert = 9 kb (minimum length)
M = Genomic size = c. 10^ kb (Clark-Curtiss et al, 1985)
The calculated number was approximately 5,200 
recombinant phage molecules.
Reagents:
Gigapack Packaging Kit (NBL Ltd.), SM buffer. 
Chloroform, Top agar, L-agar, L-broth.
Dimethyl sulphoxide (DMSO), T4 DNA ligase,
5X Ligase buffer. Restriction enzymes and buffers.
The preparation of a library involves several stages:
1. Digestion of the vector with restriction enzymes and 
removal of the stuffer fragment.
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2. Partial digest of the genomic DNA to produce suitably 
sized insert fragments.
3. Dephosphorylation of insert fragments to prevent 
circularization or the production of recombinants with 
multiple inserts.
4. Ligation of inserts to vector. ^
5. In vitro packaging of recombinant DNA molecules.
6. Preparation of plating cells and transfection.
7. Titration of recombinant library.
8 . Amplification of library.
Figure 6A Lambda Phage EMBL4
0 3Kb J____ L 12 15 18 21 24 27 30 33 36 39 42_ ] _ _ _ _ _ !_ _ _ _ _ 1_ _ _ _ _ I -  I I t I I I I
Cos Site Cos Site
Sat I 8am HI Eco RIEco RI 8am HI saj |
Lett Arm 0-19289
Multiple Cloning Site Multiple Cloning Site
112
1. Preparation of vector
EMBL4 contains a staffer fragment flanked by two 
multiple cloning sites as shown in Figure 6A. Cloning is 
achieved by replacing the staffer fragment with the DNA 
fragment of interest. The staffer fragment can be removed by 
digesting the vector with BartiHI and Sail which would prevent 
the staffer fragment (with Sail complementary ends) from 
religating with the lambda arms containing the BamHI 
complementary ends. The removal of the short ends of the 
staffer fragment by selective precipitation further decreases 
the chances of non-recombinants being produced.
Two to five micrograms of EMBL4 DNA were digested with 
BawHI and Sail. The reaction was terminated by extraction 
with phenol chloroform. 0.15 volume of 0.35M sodium acetate 
was added followed by 0.6 volume of isopropanol. This was 
incubated on ice for 15 minutes and then spun on a microfuge 
for 10 minutes at 4^ 0. The supernatant was removed and the 
pellet was washed with 500ul of 0.35M sodium acetate:ethanol 
(1:2.5). This was centrifuged for 1 minute and the 
supernatant was removed. The wash was repeated. The DNA was 
pelleted by centrifugation in a microfuge for 10 minutes at 
4°C. The pellet was then washed with 400ul of 80% ethanol. 
After the final spin the DNA was dried briefly and 
resuspended in lOul TE buffer.
2, Preparation of insert.
The genomic DNA was prepared for insertion by partial 
digest with SauSRl^ which recognises a 4 base sequence, GATC.
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A test digestion was first set up to determine the best 
conditions to obtain the right sized fragments. Partial 
digests were prepared as described in Section 6.2.3. The 
trial digests showed that using 6 units of Sau3Rl and 
approximately 6ug of mycobacterial genomic DNA a good range 
of partially digested fragments could be obtained after 1, 2 
and 3 minutes of incubation at 37°C.
Six micrograms of mycobacterial DNA were digested with 6 
units of Sau3Rl with aliquots taken out at 1, 2 and 3
minutes. The reaction was stopped with phenol chloroform. The 
aliquots were pooled. The required fragments were enriched by 
using either of the two methods shown below:
One, the DNA was ethanol precipitated, resuspended in 
buffer and electrophoresed through a horizontal agarose gel. 
The required fragments were then collected on NA45 membrane as 
described in Section 6.2.7.
Alternatively, a modified selective precipitation 
method, similar to that used for preparing the vector was 
also employed. 0.15 volume of 0.3M sodium acetate, pH 6.0, 
was added followed by 0.3 volume of isopropanol. After 
incubating on ice for 15 minutes, the DNA was precipitated by 
centrifuging for 10 minutes. The pellet was then washed as 
described previously, dried and resuspended in TE buffer.
3. Dephosphorylation of insert
To prevent circularization of inserts and the production 
of multiple inserts, the digested DNA was dephosphorylated as
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described in Section 6.2,4. The DNA was finally resuspended 
in 20ul of TE buffer.
4. Ligation
The DNA solutions of vector and insert were pooled so as 
to give a molar ratio of 2:1 to 3:1 (vector: insert). The DNA 
was then precipitated and the resultant pellet was 
resuspended in 7ul deionised water (total DNA concentration 
c. 150 to 300 ug/ml). 2ul of 5X ligation buffer was added 
followed by lul(lunit) of T4 DNA ligase. This was incubated 
at room temperature for 4 hours. The DNA was precipitated and 
resuspended in 3ul deionised distilled water and was then 
used for in vitro packaging.
5. In vitro packaging
An in-vitro packaging kit, Gigapack (NBL), was used for 
packaging ligated DNA The recombinant phage molecules were 
packaged as recommended by the manufacturers. The final 
volume of the library was 500ul in SM buffer. A few drops of 
chloroform was added before storing at 4Pc.
6. Preparation of plating cells and transfection
The preparation of plating cells and infection procedure 
was described in Section 6.1.5. For the initial titration and 
amplification the E. coll strain used was P2 392 which is a 
P2 lysogenic strain which only allows recombinant EMBL4 phage 
to grow. In later stages of the work, a non- lysogenic 
strain, LE 392 was used.
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7. Titration of phage library.
lOul of the neat, 10“  ^and 10““^ dilutions of the library 
were used to infect the plating cells. After incubation at 
37°C, the numbers of plaques were counted and the total 
number of recombinant phage pqrticles was calculated.
8. Amplification of the library
A 400ul volume of the stock library was used to infect 
1.6 to 3 ml of plating cells (depending on the titre of the 
stock library). After allowing the phage to adsorb for 20 
minutes at 37*^ C, the cells were inoculated into 30 ml of top 
agar and spread onto dried L-agar (230mm X 230 mm plates). 
After overnight incubation at 37%, the plates were flooded 
with 15 ml of SM buffer. This was shaken gently at 4 %  for 6 
hours to overnight. The buffer was collected and the plates 
were rinsed with 5ml SM buffer. The wash was added to the 
phage lysate. One ml of chloroform was added and shaken for 
15 minutes at room temperature. Cell debris was pelleted by 
centrifugation at 4000 RPM (MSB Chilspin) for 10 minutes. 
Chloroform was added to 0.3 % final concentration (v/v). Half 
of the amplified library was stored at 4 %  while the other 
half was kept at -20% after the addition of DMSO to a final 
concentration of 7% ( v/v ).
Section 6.4 Hybridization Techniques
Hybridization techniques utilize the property of 
complementary single stranded DNA (or RNA) molecules to bind 
or re-associate with one another forming a hybrid. The 
stability of the hybrid is affected by several factors such
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as the temperature, G+C content of the DNA (or RNA) and the 
degree of homology between the two nucleic acid strands. The 
Tm (the temperature at which half of the hybrids are 
dissociated) have been derived:
For probes greater than 50 nucleotides in length:
Tm= 81.5% + 16.6logM + 0.41(%G+%C)- 500/n - 0.61(%formamide) 
where M = ionic strength of the hybridization solution 
(moles/litre)
n = the length of the shortest chain in the duplex.
(Maniatis et al, 1982)
For probes < 50 >20 nucleotides:
Tm(%)= 4(G+C) + 2(A+T)
where G, C, A and T are the numbers of the respective bases 
in the oligonucleotide.
(Maniatis et al, 1982)
The hybridization is usually carried out at temperatures 
25% or more below Tm (standard protocols often use 65% to 
68%  for hybridization without formamide) followed by washes 
of increasing stringency; either by increasing the 
temperature or lowering the ionic strength or sometimes both.
Hybridization techniques provide a very sensitive method 
for detecting related DNA sequences and thus are useful in 
many cloning experiments.
There are many practical variations to the technique and 
the method described below was the one commonly used 
throughout this thesis.
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5 stages are involved in this technique:
1. Immobilization of the DNA to be studied to a solid 
support; usually nitrocellulose or nylon membrane.
2. Preparation of the probe and labelling.
3. Hybridization.
4. Washing.
5. Autoradiography.
6.4.1 Immobilization of DNA to solid supports.
Nylon was usually the solid support of choice used 
throughout this project. Hybond-N (Amersham) is a supported 
Nylon 66 membrane filter with very high binding capacity.
Three methods of transferring DNA to the filter membrane 
were commonly used :
6.4.1.1. Southern blotting (Southern, 1975)
Reagents:
Agarose
Depurination buffer (0.25M HCl)
Denaturing buffer (2.5M NaCl, 0.5M NaOH)
Neutralising buffer (3M NaAcetate pH 5.5)
20X SSC
Procedure:
The DNA to be analysed was first digested with 
restriction enzymes, if necessary, loaded onto an agarose gel 
and electrophoresed as described earlier. The gel was then
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stained and photographed.
Next, the gel was placed in several volumes of 
depur ination buffer and shaken at room temperature for 30 
minutes with a change of buffer after 15 minutes. This step 
is optional and was only used if high molecular weight DNA, 
such as undigested genomic DNA, was to be transferred or to 
promote nicking in undigested closed covalent circle plasmid 
DNA.
The gel was rinsed with distilled water and was then 
placed in several volumes of denaturing buffer for 30 to 60 
minutes with gentle shaking. The gel was again rinsed with 
distilled water and was then placed in several volumes of 
neutralising solution. The gel was shaken gently for 30 to 60 
minutes.
The gel was given a final rinse and was then placed on a 
piece of 3MM paper (Whatman), supported by a glass plate, 
with both ends of the paper dipping into a reservoir of 20X 
SSC buffer. A piece of Hybond-N membrane filter, cut just 
bigger than the gel was then placed on the gel. Air bubbles 
were removed by rolling a 10ml glass pipette on the filter 
gently. 2 pieces of 3MM paper slightly larger than the gel 
were saturated with 20X SSC and were then placed on top of 
the membrane. This was followed by two dry pieces of 3MM 
paper and then by a stack of blotting paper or tissues cut to 
the right size. A glass plate was then placed on top of the 
assembly followed by a weight of at least 500g. This was left
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blotting for at least 12 hours but usually up to 24 or 48 
hours depending on the nature of the DNA being transferred 
(see Maniatis et al, 1982, for a schematic diagram of the 
Southern blotting apparatus ).
The blotting materials were removed and the position of 
the wells were marked on the filter membrane with a pencil or 
ball point pen. The filter was removed and washed briefly in 
6X SSC. It was air dried for 15 minutes and was then baked at 
80^C for 1 to 1.5 hours, usually with a vacuum to aid the 
drying process. Baked filters were kept at room temperature, 
in the dark, sandwiched between two pieces of 3MM paper.
5.4.1.2. Colony lift (E. coll)
Procedure:
Cells were grown on L-agar plates to give individual 
colonies. A piece of circular nylon membrane, 82mm in 
diameter, was placed on the agar surface. The filter was then 
marked with a sterile needle to ensure proper orientation. 
After 1 minute the filter was carefully removed and placed, 
colony side up, on a piece of 3MM paper saturated with 10% 
SDS for 7 minutes. The filter was next placed on paper 
saturated with denaturing solution followed by paper 
saturated with neutralising solution for 7 minutes each time. 
The filter was then air dried on a piece of 3MM paper and 
then baked at 80‘^C for 1 hour. The DNA could also be bound by 
UV cross-linking to the filter. In this method, the filter 
was wrapped with Saran Wrap and placed on a UV
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transilluminator for 4 minutes. The filter was kept in the 
dark before use.
6.4.1.3 Plaque Lift
Procedure:
Plaques were grown using methods described in Section 
6.1.5. The plates were kept at 4PC for 1 hour. The procedure 
used for lifting the plaque was identical to the colony lift 
except that the SDS step was ommitted.
6.4.2 Preparation of probe.
Reagents:
DNA Polymerase I
lOX Nick translation (NT) buffer stock 
Img/ml DNAase I stock (in O.IM NaCl, 50% glycerol) 
O.lmM each of cold dNTP in 50mM Tris pH 7.5 
alpha 32p labelled dCTP (or dATP) (lOuCi/ul) 
Multiprime Labelling Kit (random primer)
Two methods of labelling DNA probes were used; nick 
translation and random primer. The second method was used 
more frequently.
6.4.2.1 Nick translation
Procedure:
In this method, nicks were introduced at random along 
the unlabelled DNA chain by the endonuclease DNAase I which
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generates 3 * OH termini. The 5 ’ to 3' exonuclease activity of 
DNA Polymerase I was then used to remove existing nucleotides 
from the 5’ side of the nick. At the same time, the 5' to 3’ 
polymerase activity of the same enzyme was employed to fill 
in the resulting gap by the addition of nucleotides to the 
exposed 3’ OH groups. This results in the nick being 
translated along the DNA molecule. By providing labelled dNTP 
along with the other three cold dNTP's, labelled probes was 
thus manufactured.
Typical reactions were set up as follows:
DNA lug
0.2ug/ml DNAase I 1.5ul
IX NT buffer 43ul
NT (nick translation) buffer is identical to the End 
labelling buffer in Section 5.5.
The reaction was incubated at 37°C for 10 minutes. The 
reaction was terminated by heating to 70^C for 5 minutes and 
then cooled on ice. Then, the following reaction was set up:
Nicked DNA solution 44.5ul
O.lmM cold dNTP Is lul each 3ul
Labelled dNTP 10 uCi/ul 3ul
DNA Polymerase I (5 units/ul) 0.5 to 1 ul
The reaction was incubated at 14°C for 2 hours. Before 
using the probe was denatured by heating in a boiling water 
bath for 5 minutes and then cooled on ice.
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6.4.2.2 Labelling by Random Primer
In this method random hexanucleotide sequences, which 
hybridize to denatured DNA at numerous points along its 
length, were used to prime DNA synthesis along the length of 
the DNA.
The addition of a labelled dNTP with other cold dNTP's 
results in the production of radioactive DNA probes. The 
newly synthesized strand carrying the label was separated 
from the template by heating in a boiling water bath for 5 
minutes followed by cooling on ice.
The Multiprime labelling kit (Amersham) was used in this 
method according to recommended instructions by the 
manufacturers.
6.4.3 Hybridization
Reagents :
Hybridization buffer (5X Denhardt's solution, 5X SSPE,
0.2% SDS, lOOug/ml sonicated and denatured salmon sperm DNA) 
Labelled probe
Hybridization was performed in heat sealable plastic 
bags attached with luer ports through which buffers and 
solutions were introduced or removed. The bags were purchased 
from Hybaid Ltd.
The filter prepared from step 1. was placed in a bag, 
sandwiched between two pieces of gauze supports and the bag
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was sealed. Depending on the size of the bag used, 25 to 60 
ml of hybridization buffer, warmed to 68°C, was introduced 
into the bag. Air was removed using a vacuumi pump. A 20ml 
syringe was used to remove the air bubbles still remaining in 
the bag. The bag was then placed in a 68°C water bath for a 
minimum of 2 hours to overnight.
The buffer was removed and air was introduced into the 
bag. This pushes the remaining buffer to the bottom of the 
bag. The denatured probe was diluted with 1 ml of fresh 
hybridization buffer and this was introduced into the bag. 
8ml or 20 ml of fresh buffer was then added to the small and 
the big bag respectively. The ports were closed and the probe 
was thoroughly mixed with the buffer. The air was again 
removed as described previously and the bag was incubated at 
68°C overnight.
6.4.4 Filter Washing
Reagents:
2X SSC
2X SSC, 0.1% SDS
O.IX SSC, 0.1% SDS
Phosphate washing buffer (Section 5.5)
Procedure:
The hybridization buffer was removed, 50ml of 2X SSC 
pre-warmed to 68°C was then placed in the bag and the filter 
was rinsed briefly for 1 minute. The buffer was removed and
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replaced by 150 to 250ml of pre-warmed 2X SSC. The bag was 
incubated at 68°C for 15 minutes. The buffer was then 
replaced with the same volume of pre-warmed 2X SSC, 0.1% SDS. 
The bag was vigorously shaken for 15 minutes after which it 
was put back into the 68®C water bath for 15 minutes. 
Finally, the buffer was replaced with 100ml of O.IX SSC, 0.1% 
SDS and was incubated at 68°C for 10 minutes.
The filter was removed from the bag and placed on a 
glass plate. The filter was then covered with Saran Wrap and 
put into an autoradiograph cassette.
Alternatively, the filters were sometimes washed using a 
phosphate washing buffer (5raM NaH2P04, ImM EDTA, 0.2% SDS, pH 
7.0). The filter was washed as follows:
Ix 100ml wash buffer at room temperature 1 minute 
3x 250ml wash buffer at room temperature for 30 minutes each 
time with vigorous shaking. The filter was then prepared for 
autoradiography as described previously .
6.4.5 Autoradiography
A piece of RX X-Ray film (Fuji) was placed on the filter 
followed by an intensifying screen. The autoradiograph was 
allowed to proceed at room temperature or at -70°C and from 
two hours to a few days depending on the strength of the 
signal.
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6,4.6 Probe removal
The probe can be removed and the filter can be re-probed 
at a later date. The probe was removed in the following way:
a. The filter was incubated at 45^0 for 30 minutes in 0.4M 
NaOH.
b. The filter was then incubated in O.IX SSC, 0.1% SDS, 0.2M 
Tris-HCl pH 7.5 for 30 minutes at 45°C.
The filter was autoradiographed for 24 hours to check 
complete probe removal. The filter was then covered in Saran 
Wrap and stored at 4°C in the dark.
Section 6.5 Detection of Proteins
The detection of proteins involves several stages:
1. The preparation of crude protein extract.
2. The separation of the proteins by electrophoresis through 
an SDS polyacrylamide gel (SDS PAGE) (Laemmli, 1970).
3. Visualisation of protein bands by Coomassie staining or 
transfer of proteins to nitrocellulose filters (Western 
Blotting).
4. Detection of antigens by antibodies
6.5.1 Preparation of crude protein extract for SDS-PAGE 
Reagents:
SDS-PAGE Loading buffer ( see Section 5.5)
50mM Tris-HCl pH 8.0
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Procedure:
Cells (1ml, E. coll; 2ml, M. smegmatls) from a growing 
culture were harvested by centrifuging for 2 minutes in a 
microfuge tube. The supernatant was removed and the cells 
were resuspended in 50ul of 50mM Tris-HCl pH 8.0. 50ul of 
loading buffer was added and mixed thoroughly.
The cell suspension was then incubated in a boiling 
water bath for 5 minutes. 50ul of the lysate was then 
immediately loaded onto a prepared SDS-PAGE gel.
6.5.2 Preparation and running of SDS-PAGE gel
Reagents :
30 % Aery1amide stock, TEMED,
4X Stacking gel buffer, 4X Separating gel buffer,
10% Ammonium persulphate solution,
IX SDS-Page running buffer
Procedure:
SDS-PAGE gels were prepared using BRL Vertical Gel Kit 
Model V16-2. The gel was made up in two parts: a lower 
separating gel and an upper stacking gel. The concentration 
of the separating gel is determined by the size of the 
protein molecules to be separated; a concentration of 3-5% 
would be used to separate proteins larger than lOOKD, 5-12% 
would be used for proteins between 30KD to 150KD and 10-15% 
for proteins of lOKD to 80KD. Higher concentrations will 
maximise separation of proteins smaller than 15KD.
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Table 6B shows the formulae of SDS-PAGE separating gels 
at three different concentrations.
Table 6B Preparation of SDS-PAGE separating gel
Separating gel concentration (%)
7.5 10 12
30% Aery1amide stock 10.0ml 13.0ml 16.04X Separating gel buffer 10. 0ml 10.0ml 10.0mlDistilled water 19. 5ml 16.5 13.510% Ammonium persulphate 400ul 400ul 400ulTEMED 40ul 40ul 40ulFinal volume 40ml 40ml 40ml
The ingredients were added in the order given in Table 
6B ensuring that no air bubbles were introduced into the 
solution. The solution was briefly and gently mixed after the 
addition of the TEMED, and immediately poured between the two 
glass plates which forms the gel, to within 4cm of the top of 
the plates. The gel former consists of two glass plates 
(19.5cm X 16cm, 19.5cm x 19.5cm) placed back to back,
separated by 1.5mm thick plastic spacers on three sides, and 
held in place by bulldog clips. About 300ul of water 
saturated butan-l-ol was added gently via the side of the 
glass plates so as to overlay the top of the aery1amide gel. 
This allows the separating gel to form a sharp edge since the 
butanol separates the aery 1 amide from the air, which prevents 
aery 1 amide from setting. The gel was allowed to set for 15 
minutes before pouring the stacking gel.
128
30ml of 5% stacking gel was prepared as follows;
30% aery 1 amide stock 5.0ml
4X stacking buffer 7.5ml
distilled water 17.0ml
10% Ammonium persulphate 300ul
TEMED 30ul
The butanol layer was washed off. The prepared stacking 
gel was poured until overflowing. A 20-well comb was inserted 
into the stacking gel and the gel was allowed to set for 15 
minutes. The bottom spacer and the bulldog clips were removed 
and the whole assembly was placed into the vertical gel 
apparatus. SDS-PAGE running buffer (IX; see Section 5.5) was 
added to the upper and lower reservoir.
The protein lysates prepared as shown in Section 6.5.1 
were loaded into the wells, 50ul/well. The proteins were then 
electrophoresed through the gel at 60mA for 3 to 3.5 hours 
(or 15mA for 14 hours) until the tracking dye was within 1cm 
from the bottom edge of the separating gel. Rainbow Markers 
(Amersham) were included as weight standards.
6.5.3 Protein Staining and Transfer (Western blotting)
Reagents;
PAGE-Blue 83 Stain 
Destaining buffer 
IX Electroblotting buffer
The SDS-PAGE gel can either be stained with the PAGE
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Blue 83 dye (see Section 5.5 ) to visualize the protein 
bands or the proteins can be transferred to nitrocellulose 
filters (Western blotting) for immunological analysis.
Protein staining of SDS-PAGE gels:
Procedure:
The gel was removed from the electrophoresis apparatus, 
and placed in several volumes of PAGE Blue 83 staining 
buffer, prepared as described in Section 5.5. The gel was 
stained at room temperature for 30 minutes. It was then 
placed in several changes of the destaining buffer (Section 
5.5) until no more stain can be removed. The gel was then 
photographed and/or stored at room temperature wrapped with 
Saran Wrap.
Western Blotting:
Procedure:
Western blotting was done using Bio Rad Trans-Blot Cell 
Apparatus, consisting of a buffer tank and a gel holder. The 
gel was equilibrated in several volumes of Electroblotting 
buffer for 30 minutes. Two sheets of fibre pads (included in 
the apparatus), two pieces of 3MM Whatman paper and one piece 
of BA 85 Nitrocellulose membrane filter (Schleicher and 
Schuell), cut to the same dimensions as the gel, were also 
placed in the buffer.
They were then placed in an electroblot gel holder in 
the following order: Fibre pad; 3MM paper; SDS-PAGE gel;
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Nitrocellulose filter; 3MM paper; Fibre pad.
The gel holder was closed and then placed within the 
electroblotting tank, with the gel on the cathode (negative) 
side. Blotting was performed at 25V overnight at 4^ 0.
6.5.4 Immunological Detection of Antigens on Western Blots
Reagents;
lOX TBS buffer, IX TEST buffer,
10% Bovine Serum Albumin (BSA),
Primary antibodies - raised against the antigen. 
Secondary antibodies - raised against the primary 
antibodies and conjugated with biotin,
Streptavidin-biotiny 1 ated horseradish peroxidase 
complex.
Colour development solution 
Procedure:
The filter was removed from the Trans-Blot apparatus and 
placed in 100ml of TBST buffer for 10 minutes, with gentle 
shaking. Non-specific binding sites were blocked by 
incubating the filter, at room temperature, in 100ml of 3% 
BSA in TBST buffer for 60 minutes.
The filter was washed in TBST buffer for 10 minutes. The 
filter was then placed in 50ml TBST buffer containing 1% BSA 
and lOOul of primary antibodies (giving a final antibody 
dilution of 1:500). The filter was incubated in this solution 
for 60 minutes, with gentle shaking, at room temperature.
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Next, the unbound antibodies were removed with two 
washes of 100ml of TBST buffer, for 5 minutes each time. The 
filter was next incubated in 50ml of TBST containing 1% BSA 
and secondary antibodies to give a final dilution of 1:500 or 
1:1000. Incubation was carried out at room temperature for 60 
minutes, with shaking.
The filter was next placed in 50ml of TBST buffer 
containing Streptavidin-biotiny1ated horseradish peroxidase 
complex (final dilution 1:500). This was incubated at room 
temperature for 30 minutes.
The filter was then washed with three 100ml volumes of IX 
TBS for fifteen minutes. The final wash was removed and the 
replaced with the colour development solution, prepared as 
described in Section 5.5. The filter was left in this 
solution for up to 15 minutes.
Section 6.6 Transformation of Escherichia coll
Transformation in E. coll is a three step process. 
First, the cells have to be made "competent" to take up the 
plasmid DNA, Next, the plasmid DNA is introduced into the 
cell. Finally, the transformed cells are selected.
E. coll cells can be made to take up DNA by rendering 
them "competent", using a variety of techniques (Maniatis 
at ai, 1982, Pritchard and Holland, 1985). Two methods 
frequently used in this project are given below. Another 
method that was used in later experiments is also shown.
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6.6.1 Tris-CaCl2 Method (Maniatis et al, 1982)
Reagent:
50mM CaCl2, SOmM Tris-HCl pH 8.0 
Procedure:
An overnight culture of the host strain was grown at 
37 0^. A 0.6ml volume of this was used to inoculate 30 ml of 
pre-warmed L-broth in a 150ml flask. The culture was 
incubated at 37^0 for until the optical density at 650nm was
0.5. The culture was cooled on ice for 15 minutes. The cells 
were harvested by centrifugation at 5000 RPM (MSE Chilspin) 
for 10 minutes at 4°C. The cells were resuspended in 15ml of 
ice cold 50mM CaCl2, 50 mM Tris-HCl pH 8.0 and placed on ice 
for 30 minutes. The cells were re-harvested as previously 
described and the pellet was resuspended in 2ml of the same 
solution. The cells were kept on ice until required.
6.6.2 Kushner's Method (Maniatis et al, 1982)
Reagents:
Kushner's buffer 1 lOmM MOPS, lOmM RbCl, pH 7.0
Kushner's buffer 2 lOOmM MOPS, lOmM RbCl, 50mM CaCl2
pH 6.5
An overnight culture of the host strain was prepared in 
10ml L-broth. lOOul of the overnight culture was used to 
inoculate 20ml of pre-warmed L-broth in 100ml flask. The 
culture was incubated, at 37*^ C with shaking, until the OD650 
was about 0.15. The cells were harvested by centrifugation at
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5,000 RPM for 10 minutes at 4PC. The cells were resuspended 
in 6.7ml of ice cold Buffer 1. The cells were immediately 
recovered by centrifugation for 5 minutes at 4°c. The cells 
were resuspended in 6.7ml of ice cold Buffer 2 and kept on 
ice for 60 minutes. The cells were repelleted as before and 
then resuspended in 2.7ml of ice cold Buffer 2.
6.6.3 Transformation
Aliquots (0.2ml) of the competent cells, prepared as 
described above, were distributed into pre-cooled sterile 
microfuge tubes and were kept on ice. To each aliquot was 
added up to 2Oui of DNA solution containing no more than 40ng 
of DNA. The cells were kept on ice for 30 minutes. The cells 
were heat shocked at 45^C for 2 minutes and then kept on ice 
for another 15 minutes. 0,8ml of fresh pre-warmed L-broth was 
added and the cells were incubated at 37^C for 60 minutes. 
The neat culture or diluted samples were then plated out on 
selective agar plates.
6.6.4 PEG assisted transformation (Chung and Miller, 1988)
This rapid and effective method combines the preparation 
of competent cells, transformation and storage of the 
competent cells.
Bacterial cells were grown to early log phase (OD600nm 
of 0.3 for LM1035 and 0.6 for JM109) in L-broth. The cells 
were harvested by centrifugation at 3000 RPM for 10 minutes 
at 4°C (MSE Chilspin). The cells were resuspended in a 1/lOth
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volume of transformation and storage buffer (TSB) (L- broth 
pH 6.1, 10% PEG (MW 3, 350), 5% DMSG, lOmM MgCl.^ . and 10 mM 
MgSOf^ ) and incubated on ice for 10 minutes. The competent 
cells were then aliquoted into pre cooled microfuge tubes at 
lOOul each. The competent cells at this stage were either 
used for transformation or were immediately frozen using an 
ethanol dry ice waterbath.
For transformation, lOOpicogram (pg) of DNA was added to 
the cells and kept on ice for 5 to 30 minutes. The cells were 
then revived by adding 0.9ml TSB plus 20mM glucose. The cells 
were shaken for 60 minutes at 37®C before aliquots were 
plated out on selective media.
This method gave consistently good results of about 10^  
(with JM109) to 10^  (with LM1035) transformants per microgram 
of uncut vector,
6.6.5 Selection of transformants
Transformants were selected on L-agar plates containing 
the appropriate antibiotics and other supplements if 
required.
Table 6C shows the commonly used antibiotics and 
supplements.
Competent cells prepared using the Tris-CaClg method 
usually gave a transformation frequency rate of about 10  ^to 
10^ per microgram of intact plasmid. The Kushner method gave 
a frequency rate of up to 10^ for the same amount of DNA,
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Both these methods however usually gave transformation 
frequencies at the lower end of the range. The PEG assisted 
transformation method appeared to give higher transformation 
frequencies with more consistent results.
Table 60 Antibiotic concentration
Antibiotic/Chemical Concentration (ug/ml)
Ampicillin 20, 50Chloramphenicol 20, 40Kanamycin 20Tetracycline 20X-gal* 40
* 5-bromo-4-chloro-3-indoyl-beta-D-galactoside.
Section 6.7 Transformation of Mycobacterium smegmatls
This method was developed to overcome the limitations of 
cloning Mycobacterial genes in E. coll systems.
There are four steps involved in this method:
1. Preparation of M. smegmatls sphaeroplasts.
2. PEG-assisted transformation of the sphaeroplasts.
3. Regeneration of the transformed sphaeroplast
4. Selection of transformants.
6.7.1 Preparation of Mycobacterium smegmatls 
ATCC 607 sphaeroplasts
The method for producing protoplasts of Streptomyces 
(Hopwood et al 1985) was modified for use in Mycobacteria 
(Jacobs et al, 1987).
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Reagents:
Protoplast (P) buffer (see Section 5.5)
10.3% Sucrose solution, 20% Glycine solution, 
Lysozyme Grade 1 (Sigma), Tryptone Soya Broth (TSB)
Procedure:
M. smegmatls was grown on a 7H11 agar plate to give 
single colonies. A single colony was inoculated into 40ml of 
tryptone soy broth (Oxoid), containing 0.2% Tween 80, and 
incubated at 37^0 to an OD600nm of about 0.2 (usually 
overnight). Glycine was added to give a final concentration 
of about 1%. Incubation was continued for another 16 hours.
The cells were harvested by centrifugation and washed 
twice with 10.3% sucrose before resuspending in 5ml P 
(protoplast) Buffer (Hopwood et al, 1985) containing 2 to 4 
mg/ml lysozyme. The suspension was incubated at 37°C for 2 to 
4 hours. The protoplasts were pelleted by centrifugation at 
3000 RPM (MSB Chi11spin) for ten minutes and resuspended in 
10 ml P buffer. The protoplast suspension was divided into 
aliquots of 2.5ml and kept on ice. Each aliquot would be used 
for a single transformation experiment.
6.7.2 Transformation of M. smegmatls
Reagents:
25% PEG 1000 in P-buffer 
P-buffer
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Procedure;
To transform M. smegmatls sphaeroplast, lOOng to 500 ng 
of plasmid DNA was added to each aliquot of the sphaeroplast 
suspension. To each was added 500ul of 25% PEG 1000 
(Polyethylene glycol) in P buffer and then gently shaken at 
room temperature for 5 minutes, 5 ml of P buffer was added 
and mixed gently. The sphaeroplasts were recovered by 
centrifugation at 3000 RPM for 10 minutes at 4°C and 
resuspended in 500 ul P buffer.
6.7.3 Regeneration of transformed sphaeroplasts 
Reagents;
Tryptone Soya Agar plus 0.5M Sucrose (TSAS)
Nutrient (N) Broth No.2
To regenerate the sphaeroplasts, lOOul to 200ul of the 
resuspended, transformed sphaeroplasts were plated out on 
TSAS and incubated at 37^0 for 48 hours. The plates were 
flooded with 5ml of N-broth and the regenerated cells were 
resuspended in the broth with a plastic spreader. The 
resuspended cells were then recovered and placed in plastic 
universels. The cells were pelleted by centrifugation at 
5,OOORPM for 10 minutes. The pellets were resuspended in 1 ml 
of N-broth.
6.7.4 Selection of Transformants
Aliquots of the cell suspension, prepared as described 
in Section 6.7.3, were plated out onto Nutrient agar plates
138
containing the appropriate antibiotic. So far, only 
chloramphenicol at 40ug/ml has been successfully used to 
select for transformants. The plates were incubated at 37°C 
for up to 4 days.
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EXPERIMENTAL WORK
CHAPTER 7
Extraction of DNA from Mycobacteria
The genetic study and manipulation of the genus 
Mycobacterium in general, and the pathogenic slow growers in 
particular, is hampered by the lack of reproducible, 
efficient and relatively quick methods for extracting and 
manipulating DNA. Published methods ( Mizuguchi and Tokunaga, 
1970; Guerry et al, 1973; Crawford and Bates, 1979) were too 
cumbersome and time consuming for large scale DNA 
extractions, especially for the pathogenic slow growers such 
as Mycobacterium tuberculosis, where containment procedures 
usually results in limiting the available space, equipment 
and time.
One of the aims of this study is to develop techniques 
for the extraction of DNA; both chromosomal and plasmid; 
which are useable for both fast and slow growers and are 
reproducible, simple, efficient, relatively quick and can be 
used with limited resources.
The first project therefore, was to devise a simple 
technique for extracting "total" DNA from the various species 
of mycobacteria. By combining published methods for 
extracting mycobacterial DNA (Thacore and Willett,1963; 
Mizuguchi and Tokunaga, 1970; Yabu and Takahashi, 1977), and 
that of Streptomyces (Hopwood et al, 1985), a relatively 
quick and reliable method was produced.
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Secondly, another aim of this study was to look for and 
investigate the existence of plasmids in M. tuberculosis. 
Several workers ( Srivastava et al, 1981, Alberghina et al, 
1973) have reported results which seem to indicate the 
presence of plasmids in this species and possible 
relationship to antibiotic resistance. A relatively simple 
technique of plasmid screening large numbers of different 
M. tuberculosis strains was therefore required. Again, 
methods used for Streptomyces were successfully adapted for 
Mycobacteria.
Section 7.1 DNA extraction from Mycobacteria
7.1.1 Large scale total DNA extraction from Mycobacteria,
The large scale cultures for DNA extraction were 
prepared as follows:
1. Preparation of starter culture:
A loopful of cells from the stock culture (grown on 
Lowenstein-Jensen slopes) was inoculated into 10ml 
Middlebrook 7H9 broth containing 10% Middlebrook GADC 
enrichment and the appropriate antibiotics if necessary. The 
cultures were incubated at 37°C for the appropriate length of 
time; 1 to 2 weeks for slow growers, 2 to 3 days for fast 
growers.
Table 7A shows the various types of antibiotics used and 
the stock concentrations.
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Table 7A Antibiotics
Antibiotic Stock per 100ml concentration Volume added per of media
Amphotericin B lOOOug/ml 1mlTrimethoprim lOOOug/ml 1mlPolymixin B 20000 units/ml 1mlCarbenicillin* lOOOug/ml 0 .5ml
* Carbenicillin was only used for M. tuberculosis and BCG 
cultures.
The antibiotics were used to eliminate the problem of 
contamination which the slow growers were especially prone 
to, owing to the long period of incubation and the slow rate 
of growth. For non-pathogenic fast growers, antibiotics are 
not usually used.
The starter culture was then used for the preparation 
of large scale cultures for DNA extraction using either of 
the two methods. Procedure 1 or Procedure 2, described in 
Section 6.1.1).
2. When Procedure 1 was chosen, the starter culture was used 
to inoculate 250 ml of the same media, prepared in a 600ml 
plastic disposable tissue culture flask (Falcon). This type 
of flask was found to be ideal because it provides a shallow 
volume of fluid, with a large surface area, necessary for 
obligate aerobes such as M. tuberculosis, and circumvents the 
need to shake the cultures. The screw cap tops also provide a 
measure of safety. The cells were incubated for the 
appropriate length of time at 37°C.
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3. When Procedure 2 was used, the starter culture was first 
centrifuged and the supernatant removed. The cells were 
resuspended in the remaining fluid and this cell suspension 
was plated out onto 3 plates of Middlebrook 7H11 media 
containing the same supplements as described for the broth 
media above.
4. Alternatively, for M. smegmatls and M. phlel, the starter 
culture was used to inoculate 40 to 100ml of Nutrient broth 
No.2 without antibiotics.
The DNA was then extracted according to the method 
described in Section 6.1.1. Briefly, growing cells were 
treated with glycine for 16-48 hours. The cells were 
harvested and treated with lysozyme. The cells were lysed 
with SDS and the DNA purified by extractions with phenol, 
phenol: chloroform and chloroform. The DNA was recovered by 
precipitation with ethanol or isopropanol.
Table 7B shows the results of DNA extraction experiments 
using Procedure 2 (Section 6.1.1) which involves growing the 
organisms on solid media.
Extraction of DNA using Procedure 1 (Section 6.1.1), 
which involves growing the cultures in broth, gave similar 
results (results not shown).
However, Procedure 2 was the preferred method when 
working with slow-growing pathogenic mycobacteria because 
this method usually yields faster results, due to the higher
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rate of growth on solid media. Furthermore, this method uses 
less incubating space and less liquid media which is 
important when working space and facilities are limited.
Table 7B Extraction of total DNA from Mycobacteria spp.
using Procedure 2~ Solid medium culture
Species OD260/OD280 Total DNA Extracted (ug)
M.tuberculosis^ 2.1 33050410M. lntracellulare~ 1.9 158103M.scrofulaceumT 3.0 45W262M.fortultum~ 2.3 262140410003M.smegmatls* 2.29 240ATCC 607
Culture from three petri dishes (grown for 2 to 14 days 
depending on the species). See Section 6.1.1, Procedure 2.
* M. smegmatls DNA was extracted from 40ml of N-broth 
culture.
The amounts of DNA extracted can differ from one 
preparation to another by quite large margins (results not 
shown). The important factor in maximising the yield was 
found to be the glycine treatment. Without the glycine 
treatment the yield can drop by about 60% (Moss, 1987). 
Normally however, the yields tend to be in the range shown 
Table 7B.
The addition of glycine results in the production of 
wall-deficient cells, which then becomes more sensitive to
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the action of lysozyme and SDS, and results in a more 
efficient lysis (Rastogi et al, 1983a and 1983b).
The purity of the DNA extracted in this manner is 
indicated by the ratio of the absorbance 260nm/280nm (Table 
7A), all of which were greater than 1.7, and thus low protein 
contamination. DNA preparations which are significantly 
contaminated, can be purified further by re-extracting with 
equal volumes of phenol chloroform until the ratio rises 
above 1,7.
The purity of the DNA was also demonstrated by its 
availability to act as a substrate for restriction enzymes. 
Figure 7A shows the results of restriction digests, using 
BamHI, of DNA from various mycobacterial species (Tracks 1 
to 4; M. tuberculosis, M. Intracellulare, M. smegmatls and 
M. fortuitum respectively).
7.1.2 Small scale plasmid extraction from Mycobacteria
To test the suitability of the various published methods 
for extracting plasmids and adapt them for Mycobacteria, it 
was decided to try these methods on known plasmid-bearing 
Mycobacterial species. Table 7C shows the various species 
used in this study.
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F i gu r e 7 A BamHI digest of mycobacterial DNA 
Track No. Source of DNA
1 M . tuberculosis 50410
2 M . intracellulare 103
3 M . smegmatis ATCC607
4 M . fortuitum 140 410 002
0.56-
Figure 7B Plasmid extraction from mycobacteria 
Track n o . Species/Strain
1 M . intracellulare 103
2 M . fortuitum-perigrinum 125
3 M . fortuitum 140 410 002
4 M . fortuitum 140 410 003
5 M . scrofulaceum W262
6 M . fortuitum-perigrinum 148
6.6—
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Table 7C Mycobacterial species
Species Strain Plasmid(s) size(s) kilobases
M.fortuitum* CIPT 140410002 5.0, 32
M.fortuitum* CIPT 140410003 5.0, 32
M.fortultum- perlgrlnum* 148 5.0, 18.9, 24,
M.fortultum-perlgrlnum* 125 15, 18.9, 24, 32, 112
M.scrofulaceum+ W262 9.5, 100, 115, 185
M.Intracellulare~ 103 6.5, 76.9
* From A.Labidi, Pasteur Institute, Paris (Labidi et al.1984)
+ From J.O. Falkinham III, Virginia State University, (Meissner and Falkinham, 1984)
From Y. Mizuguchi, University of Occupational and Environmental Health, Japan (Mizuguchi et al, 1981)
Various methods (Wheatcroft and Williams, 1981; Crawford 
and Bates, 1979) were tested with various adaptations 
(glycine treatment, increased lysozyme concentrations etc. ) 
on these strains including established procedures for E, coll 
(Maniatis et al, 1982). These methods were mostly found to be 
ineffective, probably mostly due to the relatively poor lysis 
in mycobacteria.
The method that was finally adopted was a modified 
version of the alkaline lysis procedure used for E. coll and 
Streptomyces (Hopwood et al, 1985). The full details of this 
method are given in Section 6.1.2.
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Usually samples were taken out and electrophoresed after 
the first phenol chloroform treatment as well as after DNA 
precipitation and resuspension. Figure 7B shows the results 
of some of the plasmid screening experiments: Tracks 1 to 6; 
M. Intracellulare 103, M. fortultum-perlgrlnum 125, 
M. fortuitum 140 410 002, M. fortuitum 140 410 003,
M. scrof ulaceum W262 and M. fortultum-perlgrlnum 148 
respectively.
Not all the expected plasmids were found, as shown in 
Figure 7B; the M. Intracellulare strain 103 did not appear to 
contain the 76.9kb plasmid although there is some evidence 
for the presence of low molecular weight bands (Figure 7B, 
track 1). However, this strain did not have the expected 
antibiotic resistance profile (Mizuguchi et al, 1981) and 
therefore may not be the correct strain.
In the other strains, (Figure 7B, Tracks 2 to 6 ) the 
apparent sizes of some of the plasmid bands do not appear to 
correspond to those expected from the given plasmid profiles 
(Table 7C). However, the samples have not been cut and some 
of the bands may be supercoiled plasmid DNA and thus, the 
position of some of the plasmid bands, relative to the linear 
DNA marker fragments (lambda DNA digested with Hlndlll), may 
not reflect their true sizes; supercoiled, open circular and 
linear forms of a plasmid DNA have different mobilities 
during electrophoresis through agarose gels (Maniatis et al, 
1982; Hopwood et al, 1985). Varying amounts of chromosomal 
DNA were also present in the samples.
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The results however, show that this method can be used 
to screen mycobacteria for the presence of plasmids.
7.1.3 Large scale plasmid extraction from Mycobacteria.
Plasmids from two strains of M. fortuitum (140 410 002 
and 140 410 003) were extracted.
A loopful of cells from the stock culture, on LJ slopes, 
was inoculated into 10ml 7H9 broth containing 10% GADC 
enrichment and antibiotics as described previously. The 
culture was incubated at 37^c with shaking, overnight or up 
to 2 days. The whole 10ml of starter culture was then used to 
inoculate 200ml of the same broth in a disposable tissue 
culture flask or in two aliquots of 100ml in two 250ml glass 
conical flasks. The cells were incubated at 37®C with shaking 
for 48 hours. Glycine, to 2% was added and incubation was 
continued for another 16 hours.
The cells were harvested by centrifugation and the 
plasmids were extracted as described in Procedure 1, Section
6.1.4 (scaled-up alkaline lysis procedure). The DNA was then 
run on a caesium chloride-ethidium bromide gradient. The 
plasmid band, if visible, was recovered. When the plasmid 
band was not visible, fractions below the chromosomal band 
were removed. The DNA was then purified by dialysis against 
TE buffer.
Figure 7C shows the plasmids extracted from the two 
M. fortuitum strains. Tracks 1 to 4 shows the plasmid called
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pALSOOO (Labidi et al, 1985; see Figure 7D for the 
restriction map of pAL5000), isolated from strain 140 410 
0002 (undigested, BamHI, EcoRI and Hlndlll digested 
respectively). Tracks 5 to 8 shows a plasmid, isolated from 
strain 140 410 003, digested in an identical manner. This 
plasmid was designated pSU300.
The digests showed that the two plasmids appear to be 
similar but differences may not be revealed by this limited 
range of digests. The linearised plasmids (BamHI and EcoRI 
digests, tracks 2, 3, 6 and 7) are approximately 5kb in size.
Only one plasmid was isolated from each strain although 
the plasmid profile indicated the presence of another plasmid 
(Table 7C) in both strains. One possible reason may account 
for this: the 32kb plasmid (reported by Labidi et al, 1984 ) 
may be a multimeric form of the 5kb plasmid. A later paper by 
Labidi and David ( 1985a>^describing the isolation and 
restriction mapping of pAL5000 in fact indicated that only 
one plasmid was present in M. fortuitum 140 410 002.
An estimated 20 to 50ug of pSU300 and pALSOOO was 
extracted from each 250 ml culture. The yield is 
comparatively low and this is probably due to incomplete 
lysis of the cells and or to the low copy number of the 
plasmids. However, the results suggest that the method can be 
successfully used to extract plasmids from mycobacteria. This 
method was also used to extract plasmids from other 
mycobacterial strains (results not shown).
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Figure 7C Restriction Digests of mycobacterial plasmids 
Track No. Plasmid Digest
pALSOOOpALSOOOpALSOOOpALSOOO
PSU300pSU300pSU300pSU300
UncutBamHIEcoRIHlndlll
UncutBamHIEcoRIHlndlll
Figure 7D Restriction map of pALSOOO
,A15000
ISl
The plasmid pSU300 was cloned into a variety of E. coll 
vectors to increase the amount of available DNA for further 
studies.
Section 7.2 Cloning of pSU300
The plasmid pSU300 was cloned into the E. coll vectors 
pUC8 , pKK223-3 and pIJ6 6 6. Table 7D shows the restriction 
sites that were chosen for the cloning experiments.
Table 7D Cloning of pSU300
Vector Restriction site used (vector)
Insert Restriction site used (insert)
Recombinantplasmid Host strain
pUC19 EcoRI pSU300 EcoRI pSU301 JM105
PKK223-3 EcoRI pSU300 EcoRI PSU303 JM105
pIJ666 BamHI pSU300 Bglll pSU309 HBlOl
PIJ666 BamHI pSU300 BamHI PSU312 HBlOl
Figures 7E, F and G show the restriction maps of pUC19, 
pKK223-3 and pIJ666 respectively.
The plasmids were digested with the appropriate 
restriction enzymes (see Table 7D) and dephosphory1ated where 
necessary. The ligation was performed as previously 
described. The preparation of competent cells are as shown in 
Section 6 .6 . The ligated DNA was then used to transform the 
prepared competent cells.
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Figure TE Simplified restriction map of pUC19
Clonmg
pUC19
2«S6 bp«00
Bgll
Figure 7F Simplified restriction map of pKK223-3
p«i"'I
rmB position 
«BR322 posWon
Fuakm:pBR322 positk» 
to 375
pKK223
Pvü II
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Figure 7G Simplified restriction map of pIJ666
CAT
0RI
p IJ 666
671 6 b p Puu 11,1628 Puu II ; 1721-LAG
'Puu 11,1989 HitrS III, 20871ER4584, P s t  4478, Puu NEC! TER X Bam HI .2429 \  \Hit-û III .2439 \ Bco RV.2595 Bam HI,2785
3716. m /  II 3661, Pst I 3127Puu
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Table 7E Cloning of pSUSOO and transformation
Recombinant vector (ug) pSU300(ug) Transformants Recombinant
pSU301 0.7 (pUC19) 1.5 480 414*pSU303 0.4 (PKK223-3) 0.8 59 (a)pSU309 1.3 (pIJ66 6) 1.9 150 (b)pSU312 2.0 (pIJ66 6) 
Controls
1.0 201 (c)
pUC19 0.02 undigested
- >1000 0~
pUC19 digested 0.02 dephosphory1ated and religated
2 0
pUC19 EcoRI 0.02 digest;ligated. - >1000 0
PKK223-3 0.05 undigested - >1000 0
PKK223-3 0.05 digested,EcoRT dephosphory1ated and religated
5 0
pIJ566 0.03 undigested — >1000 0
pIJ666 0.03 digested,BamHI dephosphory1ated and religated
2 0
* The transformed cells were plated out on L-agar containing ampicillin (50ug/ml) and X-gal (40ug/ml). Recombinants were white colonies (86%). Non-recombinants were blue.
(a) Transformants selected on L-agar with ampicillin (50ug/ml
(b) and (c) Transformants selected on L-agar containing
chloramphenicol (40ug/ml). (Selection of recombinants from
(a), (b) and (c) is described in the text below).
~ All colonies obtained from the control experiments are assumed to be non-recombinants since no insert DNA was added.
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Table 7E shows the results of the cloning and
transformation experiments.
The control experiments showed that the alkaline 
phosphatase treatment have worked well (although less plasmid 
DNA was used than in the experimental ligations). The control 
experiment using digested pUC K) which were ligated without 
dephosphory1ation, indicated that the ligation reactions also 
worked very well. Untransformed competent cells did not give 
any colonies on antibiotic containing media.
When pSU300 was cloned into pUC19, the transformants 
were selected on L-agar containing ampicillin (50ug/ml) and 
X-gal (40ug/ml). The multiple cloning site in the vector is 
located downstream of the promoter region of the beta- 
galactosidase gene (see Figure 7E). The presence of an insert 
in the multiple cloning site would inactivate this gene so 
that the substrate X-gal would not be hydrolysed. Thus, a 
white colony indicates that the transformant contains a 
recombinant plasmid. In this experiment, 414 out of 480 (86%) 
colonies were white. Plasmids from 12 randomly selected 
clones were isolated and digested with EcoRI followed by 
electrophoresis through an agarose gel. The results showed 
that each plasmid contained the full-sized insert (results 
not shown). One of these plasmids was chosen and designated 
as pSU301.
In the experiment where pKK223-3 was used as the cloning 
vector, the transformants were selected on L-agar containing
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ampicillin (50ug/ml). Small scale plasmid preparation 
(Procedure 1, Section 6.1.2) were made on 26 randomly 
selected colonies to ascertain the presence of plasmids. 
Eleven transformants (41%) contained a plasmid with an insert 
of 5kb (shown by digestion with EcoRI and agarose
electrophoresis) which suggests that the full-sized insert 
had been obtained (results not shown). One transformant 
containing a recombinant plasmid was chosen and designated as 
pSU303.
When pXJ666 was used as the cloning vector, the
transformants were selected on L-agar containing 40ug/ml of 
chloramphenicol. 36 colonies from experiment (b) (Table 7E) 
and 29 colonies from experiment (c) (Table 7E) were 
toothpicked and transferred to a fresh chloramphenicol plate. 
The colonies were then transferred to a nylon membrane and 
probed with ^^P labelled pSUSOO as described in Section 6.4.
Figure 7H shows the result of this colony hybridization
experiment. 28 from 36 colonies of (b) (80.6%) and 24 out of
29 colonies of (c) (79.3%), were positive (indicated by the 
dark spots). One transformant from each of (b) and (c) were 
chosen and designated pSU309 and pSU312 respectively. The 
plasmid from each clone was isolated, and the presence of the 
full insert was confirmed by digestion with the appropriate 
enzyme followed by electrophoresis through an agarose gel 
(results not shown).
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The plasmids pSU301, pSU303 and pSU312 (pSU309 was not 
included) were digested with the appropriate enzymes and 
electrophoresed through an agarose gel. The gel was stained 
with ethidium bromide and photographed. The results showed 
that all the plasmids contained the full-sized insert (Figure 
71); track 2, pSU301 (EcoRI digest); track 4, pSU303 (EcoRI 
digest); track 6, pSU312 (BamHI digest). pSU301 was used as 
a probe in subsequent experiments.
Figure 7H Colony Hybridization
(b) pIJ666/pSU300 (BamHI/Bglll sites) recombinant.(c) pIJ666/pSU300 (BamHI site) recombinant.
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Figure 71 Restriction digests of recombinant plasmids 
Track No. DNA Digest
Lambda Hindlll (marker)pSU301 EcoRIpSU301 uncutpSU303 EcoRIpSU303 UncutpSU312 BamHIpSU312 uncutLambda Hindlll (marker)
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CHAPTER 8
Plasmid Screening of Mycobacterium tuberculosis
Various reports in the literature (Alberghina et al, 
1973; Srivastava et al, 1981) have cited evidence which 
suggests the presence of extrachromosomal DNA and its 
association with various phenomena such as DNA méthylation 
and antibiotic resistance, in M. tuberculosis. A large-scale 
plasmid screening of antibiotic resistant strains of this 
species was undertaken to investigate the presence of 
plasmids in clinical isolates of M. tuberculosis.
Section 8.1 Plasmid screening
DNA was prepared using, the alkaline lysis plasmid 
extraction method described in Section 6.1.2 (Procedure 2), 
from 20ml cultures of each strain grown in 7H9 broth. "Total" 
DNA was also prepared from a similar amount of culture 
(Procedure 1, Section 6.1.1). DNA samples were analysed by 
vertical agarose gel elptrophoresis.
A total of 197 strains of M. tuberculosis, resistant to 
one or more antituberculous drugs were screened in this way. 
In addition, six M. bovis BCG strains were also tested. All 
the M. tuberculosis strains came from patients in the South­
east of England (Tuberculosis Reference Laboratory, PHLS, 
Dulwich Hospital).
The results were mostly negative. No evidence of low 
molecular weight plasmids were detected from any of the
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samples. However, in a few of the samples, a band running 
above the chromosomal DNA was detected: Figure 8A; tracks 9, 
11, 12, 15, 16 and 18 and Figure B; tracks 6, 11, 18 and 20.
The bands could possibly be due to an artefact from the
running of the gel. However, this band was not evident in all
the tracks as would be expected, if this is the case. The
strains showing this band were re-grown, and the DNA 
extracted, several times. Analysis of the different DNA 
samples from strain 40654, which previously showed the 
presence of the band (Figure 8A, track 15), showed that the 
band was present in some preparations but not in others 
(results not shown). Similar results were obtained from the 
strains chosen for re-testing.
No correlation between the presence of the band and 
resistance to any particular antibiotic was detected.
Attempts were made to extract the DNA from the gel, 
using the NA45 membrane method (Section 6.2.7, Procedure 1), 
but these were unsuccessful. This may be due to the fact that 
the DNA was too large to be successfully removed in this 
manner.
The fact that the band could sometimes be seen in one 
preparation but not in another suggests that if the band is a 
plasmid, then it may be able to exist independently and in an 
episomal state. Growth conditions could perhaps influence the 
nature of the plasmid; whether as an independent entity or 
integrated with the chromosome.
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The next step was to try and isolate the presumptive 
plasmids by running large scale plasmid preparations of the 
selected strains on caesium chloride-ethidium bromide 
gradients.
Figure 8A Agarose electrophoresis of M. tuberculosis plasmid
DNA preparations.
Track Strain Resistance
1 2 3 4 5 6 7 812345678910 11 12131415161718 19
5010350151501675018550197502035022750233400504019740230412874153341605406545041050411 50495 50514
9 10 n  12 1 3 14 15 16 1 7 18 19
S,I,Z
50ul of each DNA preparation was electrophoresed through a 1% vertical agarose gel (Section 6.2.6). Tris acetate buffer was used as the running buffer. The gels were usually run at 50 V for 15 to 16 hours. Duplicate gels were also run for a shorter length of time ( 8 hours ) to ensure the detection of low molecular weight plasmid if present.S - Streptomycin, I - Isoniazid, E - Ethambutol,R - Rifampicin, Z - Pyrazinamide
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Figure 8B Agarose gel electrophoresis of "total" DNA of
M. tuberculosis.
Track Strain Resistance
1 50271 S,I2 50272 S,I,R,Z3 50298 Z4 50301"" Sensitive5 50303"" Sensitive6 50305 Sensitive7 50306 S,I8 50318 S,I9 50341 S10 50365 I,R11 50377 Z12 Lambda Hindlll marker13 50380 I14 50383 S15 50384 S,I16 50407 I17 50530 I18 50410 z19 50411 I20 50437 s
1 2 3 4 5 6- 7 8 9 10 11 12 13 14 15 16 I 7 18 19 20
50ul of each DNA preparation was electrophoresed through a 1% vertical agarose gel (Section 6.2.6). Tris acetate buffer was used as the running buffer. The gels were usually run at 50 V for 15 to 16 hours. Duplicate gels were also run for a shorter length of time ( 8 hours ) to ensure the detection of low molecular weight plasmid if present.
S - Streptomycin, I - Isoniazid, E - Ethambutol,R - Rifampicin, Z - Pyrazinamide
Asian variant
The low molecular weight bands can be eliminated by RNAd*e A 
(heat treated) treatment.163
Section 8.2 Large scale plasmid preparation of
Mycobacterium tuberculosis
"Plasmid" preparations from four M. tuberculosis strains 
were made using the two methods previously described in 
Section 6.1.4.
Table 8A shows the four strains used in this experiment. 
Table 8A M. tuberculosis strains
Strain Antibiotic* resistance
40230 S, I, Z40654 S, I50410 Z50495 S, I
* Antibiotic symbols 8 - Streptomycin, I - Isoniazid, Z - Pyrazinamide
No plasmid band were observed any of the samples. 
Fractions were removed from below the chromosomal band, and 
dialysed against several volumes of TE buffer. Samples were 
analysed by electrophoresis through agarose gels. No plasmid 
DNA however was observed in any of the fractions. The result 
suggests that the band observed in some strains during the 
previous screenings is probably an artefact. However, the 
possibility remains that the band may be an unstable plasmid 
(Duggleby et al, 1978; Wheatcroft and Williams, 1981) or a 
linear one (Hirochika and Sakaguchi, 1982; Stark et al, 1984) 
which may not be possible to isolate using the methods 
described above.
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Section 8.3 Probing of Mycobacterium tuberculosis total DNA
The negative and ambiguous results from the previous 
experiments prompted a look at the question of the existence 
of plasmids in M. tuberculosis from another angle.
It was decided to probe "total" DNA from M. tuberculosis 
strains with the plasmid pSU300, isolated from 
Mycobacterium fortuitum. The reasoning behind this strategy 
was that plasmids from different species within the same 
genus may have regions of homology. Certain regions, such as 
the origin of replication, insertion sequences or 
transposable elements may be present and be highly conserved. 
By using a mycobacterial plasmid as a probe, low copy number 
plasmids, or plasmids in the episomal states, if they exist 
in M. tuberculosis, could perhaps be detected by using 
hybridization techniques.
The plasmids pSU300 and pALSOOO were used mainly because 
they were available in reasonable quantities at the time this 
study was started.
Several stages were involved in this experiment:
(1) Extraction of total DNA from M, tuberculosis.
(2) Restriction digest and electrophoresis of the DNA.
(3) Transfer of the DNA to nylon filter membrane by Southern 
blotting.
(4) Labelling of pSU300 with 32p.
(5) Hybridization and washing of the filters.
(6) Autoradiography.
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8.3.1 Extraction of total DNA from Mycobacterium
The method for extracting total DNA from M, tuberculosis 
has been described in Section 6.1.1. Twenty two strains of 
M. tuberculosis, one strain of M. intracellulare and one 
strain of M. scrofulaceum were chosen for this study. Table 
8B shows the strains used, the antibiotic resistance and the 
amount of DNA extracted from each strain.
8.3.2 Restriction digests and electrophoresis
One to two micrograms of DNA from each strain were 
digested with PvuII or BamHI and then electrophoresed through
0.8% agarose gels at 25V for 16 hours or 125V for 2.5 hours. 
The gels were stained with ethidium bromide and photographed 
before transferring the DNA to Hybond-N nylon membrane 
filters.
8.3.3 Southern blotting
The gels were treated with depurinating, denaturing and 
neutralising solutions and then blotted as described 
previously. After the transfer, the filters were baked at 
8QOc for one hour. The filters were kept at room temperature 
in the dark before using.
8.3.4 Labelling of pSU300
The methods for labelling the probe are described in 
Section 6.4.2. In earlier experiments, the probes were 
labelled by the nick translation method and the probe used
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Table 8B Mycobacterial strains
Strains Antibiotic1 resistance Total DNA extracted (ug)
M. tuberculosis
40230 s. I, Z 5540654 s. I 6550310 Sensitive 8050410 Z 22050495 s. I 10060420 s. E, R 15060469 18060660 51060680 3060921 I, E, R, Z 6060925 I, E, R 10061066 s. I, R 6061104 I, R 6061116 7061125 I 15561144 1/ E, R 1561158 S, I 15061267 S 8561377 I 18061504 I 21061513 s 10561695 z 85
Other strains
M.scrofulaceum W262 90M.Intracellulare 103 100
Antibiotic symbols
I- Isoniazid, S- Streptomycin, E- Ethambutol, R- Rifampicin Z- Pyranizamide
was pSUSOO from the mycobacterial host strain, purified 
twice on caesium chloride-ethidium bromide gradients.
Later experiments used the random primer labelling 
technique while the probes were either pSU301 (pUC19/pSU300 
recombinant) or the pSUSOO fragment excised from pSU301, and
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recovered from the agarose gel using the GENECLEAN procedure 
(Section 6.2.7). Probes prepared from the recombinant E. coll 
plasmid are not only more convenient to produce but may also 
avoid spurious results due to probe contamination with 
M. fortuitum chromosomal DNA.
8.3.5 Hybridization Experiments
Initially, only three M. tuberculosis strains were 
probed with pSU300. These strains (40230, 40654, 50410
showed the possible presence of an extrachromosomal band in 
the initial plasmid screening experiment.
The hybridization experiments were performed according 
to the methods previously described. Figure 8C shows the 
result of the hybridization experiment. Undigested and Pvull 
digested DNA samples from each strain were used.
Figure 8C shows that the genomic DNA from the three 
strains contained fragments that were able to hybridize with 
pSU300 (tracks 2, 4, 6, and 8; strains 40654, 40230a, 40230b 
and 50410 respectively). 40230a and b are two different 
preparations of the same strain. The fact that the uncut DNA 
also gave a positive signal in all the samples suggest that 
the hybridizing fragments are located within the genomic DNA. 
The probe used was pSU300 (from M. fortuitum) and the DNA 
wojS labelled with 32p ^y nick translation.
Another experiment was conducted, using DNA digested 
with BamHI. Figure 8D shows the result of the hybridization
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experiment and again bands were observed in the tracks 
containing the digested DNA (tracks 1, 5, and 7; strains 
40654, 40230b and 50410 respectively) but the banding
patterns were different from the results obtained when PvuII 
digested DNA was used. The DNA in track 3 (strain 40230a)
f
however was not cut by the restriction enzyme but also gave a 
positive signal.
Figure 8C Probing of uncut and PvuII digested M. tuberculosis DNA
Track Strain
1 40654 (uncut)2 406543 40230a (uncut)4 40230a5 ■ 40230b (uncut)6 40230b7 50410 (uncut)8 50410
2 3—
9.4—
6.6—
4.4-
2#3—2.0—
1 2  3w
I
5 6 7 8
The probe was pSU300. Autoradiography was for 24 hours at -70°C
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Figure 8D Probing of uncut and BamHI digested M tuberculosis DNA.
Track Strain 2 3 4
1 406542 40654 (uncut)3 40230a4 40230a (uncut)5 40230b 2 3— f6 40230b (uncut) 9.4-7 - 50410 6.6-8 50410 (uncut) '^4-
2*3—2.0-
I •*
The probe was pSU300. Autoradiography was for 24 hours at -70°C
The results from the two experiments are summarised in 
Table 8C.
Table 8C Probing of M. tuberculosis DNA with pSU300
Fragment Sizes"" kilobasebairs (kb)
Digests 40230a 40230b 40654 50410
PvuII 5.0 5.0 17.0 20,9.4
BamHI uncut 20,6.8 6.6,2.3,1.0- 3.0
Fragment sizes were determined by using the Beckman Microgenie Program linked with a Sonic digitizer.
Other bands appear to be present but were dificult to determine due to a high background smearing (Fig D, track 1).
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Most of the tracks showed background "smearing" which 
suggest that the probe may be contaminated with M. fortuitum 
chromosomal DNA which would be expected to contain sequences 
homologous with M. tuberculosis DNA. This suggests that the 
strongly hybridising fragments may be due in fact to 
contaminating M. fortuitum chromosomal DNA. To determine 
this possibility further experiments were conducted using 
probes prepared from the E. coll recombinant plasmid (pSU301) 
which should eliminate the problem of contaminating 
M. fortuitum chromosomal DNA.
In one experiment, chromosomal DNA from various 
M. tuberculosis strains, M. Intracellulare 103 and 
M. scrofulaceum W262 was digested with BamHI. The DNA was 
then probed with pSU301, labelled by the random primer 
method.
Banding patterns were discernible in all the 
M. tuberculosis strains (see Figure 8E for the results of 
some strains) but not in the other two mycobacterial species 
(results not shown). Numerous bands can be seen in each 
strain. Furthermore, the banding pattern appear to differ 
from one strain to another. Some of the weaker hybridising 
bands may be due to partial digestion of the DNA which may 
also explain the fairly high background signal in each track. 
Indeed, analysis of the agarose gel under UV illumination, 
after staining and before Southern blotting, showed that most 
of the DNA samples were only partially digested (results not
s h o w n ) . pijr:19 alone as the probe did not give any bands.
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The results from this initial study suggests that 
plasmid-related DNA sequences may be present in 
M. tuberculosis. No bands were seen below or above the 
chromosomal band in the undigested material. This and the 
fact that the probe also hybridizes with the undigested
fchromosomal DNA suggest that the plasmid-related regions 
are located within the chromosomal DNA rather than on a self- 
replicating plasmid.
The observed banding patterns that appear to be strain 
variable clearly suggest that this phenomenon should be 
investigated further. Chapter 9 describes the results of 
further investigation into plasmid-related DNA sequences in 
M. tuberculosis.
Figure 8E Probing of BamHI digested M. tuberculosis DNA 
Track Strain 9 101 611582 612673 609254 615045 61377 2 3-6 60420 9.4-7 50310 6.6—8 61695 4.4-9 6151310 61695
2.3 —20-
I
The probe was pSUSOl. Autoradiography was for 48 hours at room temperature.
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CHAPTER 9
Cloning of Mycobacterium tuberculosis DNA in Lambda EMBL4:
Construction of Genomic Libraries
The results from Chapter 8 suggest that plasmid-related 
sequences may be present in M. tuberculosis genomic DNA. 
Furthermore, the banding patterns that were observed suggest 
that some sequences may be present in multiple copies.
The results also poses three important questions:
1. What are these sequences that are hybridizing with the 
plasmid DNA?.
2. What phenotype or phenotypes are associated with these 
sequences?
3. Could these fragments be used to look for the presence of 
restriction fragment length polymorphism in M. tuberculosis?
To study the region or regions of interest 
M. tuberculosis DNA fragments were cloned in E. coll.
Firstly, M. tuberculosis DNA fragments were cloned using 
two plasmid vectors, pIJ666 and pUC19. However, subsequent 
work revealed that the mycobacterial plasmid, pSU300, which 
was used as the initial probe to pick out homologous 
M. tuberculosis DNA fragments, also contained regions which 
cross-hybridizes with the E. coll vectors. Cloning using 
plasmid vectors was therefore not pursued. A different 
strategy was employed, involving the use of the lambda phage 
EMBL4 vector, to construct genomic libraries of
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M, tuberculosis. Lambda had been found not to cross hybridize 
with the probe, pSUSOO in previous experiments.
In this experiment, the stages involved are as follows:
1. Restriction digest of the vector, EMBL4, and removal of 
the short ends of the stuffer fragment.
2. Restriction digest of the total DNA of M. tuberculosis, 
fragment enrichment and dephosphorylation to prevent multiple 
inserts.
3. Ligation of the inserts and vector.
4. In vitro packaging.
5. Selection of recombinants and amplification of the 
library.
6. Screening of recombinants.
7. Plaque purification.
8. DNA extraction from lambda phage.
9. Screening of inserts.
10. Recovery of positive insert(s) from agarose gels.
11. Labelling of inserts with 32p^
12. Probing of M, tuberculosis genomic DNA with positive 
inserts.
Section 9.1 Preparation of Mycobacterial genomic library
Lambda EMBL4 is a phage vector with a cloning capacity 
of 9-23 kilobases. The vector contains a multiple cloning 
site (Figure 9A) between each lambda arm and the stuff er 
fragment.
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Figure 9A Lambda Phage EMBL4
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42
Kti I I I I I I I I I »______1______I----------!--------- 1----------L.
Cos Sit*
Sal I Bam HI Eco RIEco Al 8am HI Saj |
Sluftor Fragment 
19399-33106
Lett Arm 
0-19289
Multiole Cloning Site Muitioi* Cloning Sil*
Each cloning site contains single restriction sites for 
EcoRI, BamHI and Sail. Production of non-recombinants were 
minimised by performing double digests; in this case BamHI 
and Sail. The production of recombinants was further 
increased by removing the short ends of the stuffer fragment 
using selective precipitation. The stuffer fragment with Sail 
complementary ends would not be able to ligate to the lambda 
arms which contain the BamHI complementary ends.
The stuffer fragment contains two genes, red and gam, 
which gives the non-recombinants the Spi+ phenotype, making 
the phage susceptible to P2 inhibition and thus unable to 
grow in bacterial strains lysogenic for the phage P2. When
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the stuffer fragment is removed and replaced with insert DNA, 
the phage becomes Spi- and will be able to grow in a P2 
lysogen. EMBL4 can thus be used as a positive selection 
vector. The P2 lysogen used in this experiment is the E. coll 
strain P2 392. Table 9A shows the details of mycobacterial 
strains used in this section.
Table 9A Mycobacterial strains
Species Strain Resistance/Notes
M. tuberculosis 50410 ZM. tuberculosis 50495 S, IM. tuberculosis 60420 S, E, RM. fortuitum 140 410 003 Original host of PSU300
Z- Pyrazinamide, I- Isoniazid, S- Streptomycin, E- Ethambutol R- Rifampicin
The M. fortuitum strain is the original host of pSUSOO. 
The library constructed from this strain should contain 
clones carrying fragments of this plasmid. Therefore, this 
library can be used as a positive control during the 
screening process.
Total DNA was extracted from each strain using methods 
previously described (Section 6.1.1). The full details for 
the preparation of the library, selection of recombinants and 
library amplification (Steps 1 to 5) are described in Section 
6.3. A brief summary of the methods involved in the library 
construction is given below.
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Three to four micrograms of total DNA from each strain 
were partially digested with the restriction enzyme Sau3Rl. 
Each sample was divided into two aliquots. One aliquot was 
electrophoresed through an agarose gel. Fragments of the size 
range 9 to 23kb were recovered from the gel using the NA45 
membrane method (Section 6.2.7).
Similar fragments were enriched from the second aliquot 
by selective precipitation (see Section 6.3.1). Two methods 
were used to ensure a good yield of the required fragments 
and because the membrane method sometimes results in low 
yields of large sized (greater than 15kb) DNA fragments. 
Large fragments are difficult to elute from the NA45 
membrane, probably due to greater binding of the DNA to the 
membrane.
Samples from the two methods were analysed by agarose 
gel electrophoresis (Figure 9B; DNA from strain 50410; track 
2, selective precipitation method; track 3, NA45 membrane 
method). Figure 9B shows that the selective precipitation 
method gave a greater recovery of the required fragments as 
judged by the greater amount of fluorescence at the size 
range 9 to 23 kb in track 2 compared to that of track 3.
The fragments recovered using the selective 
precipitation method were dephosphory1ated and then ligated 
to the prepared EMBL4 lambda arms.
177
Figure 9B Fragment Enrichment of DNA from Strain 50410 
Track. Enrichment Method
1 Lambda Hindlll marker
2 Selective precipitation
3 NA45 membrane
1 2 3
Electrophoresis was for 40 minutes at 60V on a minigel.
The vector was prepared by restriction digest of the DNA 
with BamHI and Sail (both at the same time). The short ends 
of the stuffer fragment was removed by selective 
precipitation (Section 6.3.1).
The ligation of the inserts and lambda arms was 
performed as previously described (Section 6.2.8). The 
ligation conditions used in this section are summarised in 
Table 9B.
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Table 9B Ligation conditions
InsertStrain Amount of insert used (ug)* EMBL4Amount(ug)
Total DNA concentration (ug/ml)
M. tuberculosis
50410 1 2 30050495 2 5 35060420 2 5 350
M. fortuitum
140 410 003 1 2 300
Control 0 1 300
* Approximate amount of DNA.
The amount of insert DNA shown in Table 9B is an 
approximate amount of fragments 9 to 23 kb in size, obtained 
after enrichment procedures.
After ligation of the inserts to the lambda arms, the 
library was produced by packaging the recombinant DNA 
molecules using a Gigapack Packaging Kit (NBL), performed 
according to the manufacturer’s instructions. The number of 
recombinants were determined by titering each library using 
the E. coll strain P2 392 (P2 lysogen) which only allows 
recombinant phage molecules to grow (see Section 6.3).
The number of recombinants required to obtain a complete 
genomic library with 99% confidence, was calculated to be 
about 5,200 (Section 6.3). Table 9C shows the number of 
recombinants obtained in each library preparation determined 
by titration of each library after packaging.
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Table 9C Mycobacterial genomic libraries
Species and Strain Number of recombinants in SOOul library stock
M. tuberculosis 50410 5,100M. tuberculosis 50495 8,500M. tuberculosis 60420 9,000M. fortuitum 140 410 003 5,500Control* 0
* BamHI and Sail digested Lambda DNA selectively precipitated to remove the short ends of the stuffer fragment.
The control experiment shows that, non-recombinants are 
not expected in the libraries. The results also shows that 
three of the libraries contained more than the minimum 
number of recombinants required to achieve 99% confidence of 
a complete library. The EMBL4/50410 library however, had 
slightly fewer recombinants than required but is probably 
sufficient for these purposes.
Each library was amplified (in strain P2 392) as 
described in Section 6.3. The amplified libraries were kept 
at -70®C. Working stocks were kept at 4°C. Table 9D shows the 
number of phage por+ eg in each amplified library working 
stock as determined by titration.
Table 9D Titre of Amplified EMBL4 Libraries
Library Total Volume (ml) Concentration (pfu/ml)
EMBL4/50410 42 4.1 x 10^EMBL4/50495 18 1.0 x 10^EMBL4/60420 20 6.6 x 10?EMBL4/140410003 40 3.3 x 10^
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Section 9.2 Screening of phage libraries for pSUSOO
related sequences.
For the first round of screening, about 13,000 to 30,000 
plaques were screened from each library. Plating cells were 
prepared as described in Section 5.1.5. E. coll strain LE392 
was used for the screening and subsequent procedures. The 
phage suspension (neat or diluted) was each added to 3ml of 
plating cells followed by incubation at 37^C for 20 minutes 
to adsorb the phages. The cells were then inoculated into 
30ml of molten top agar, cooled to 45^C, which was then 
plated out onto L-agar (230mm x 230 mm). The plates were 
incubated at 37°C for 8 to 12 hours. Table 9E shows the 
results of the infection procedure.
Table 9E Plaque production for library screening
Library Dilution Volume used (ul) Number of plaques*
EMBL4/50410 Neat 700 28, 000EMBL4/50495 10"3 30 28, 000EMBL4/60420 10-2 20 13, 500EMBL4/140410003 Neat 100 20, 000
* Approximate number. See text below.
The number of plaques were estimated by dividing the 
assay plate (230mm x 230mm) into 8 equal sectors, counting 
the number of plaques in one sector and multiplying that by 
eight.
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The plaques were transferred to Hybond-N nylon membrane 
and prepared for hybridization as described in Section 6,4. 
The recombinant plasmid, pSU301 (pUOT/pSU300), was labelled 
with 22p by using the Multiprime Labelling Kit (Amersham) and 
used to probe the phage libraries (Section 6.5). The filters 
were washed with 5mM NaH2P0 4, ImM EDTA, 0.2% SDS as follows:
1 X 100ml for 1 minute at room temperature
3 X 250 for 30 minutes at room temperature with vigorous 
shaking.
1 X 300 ml for 1 to 2 hours at 68^C.
The filters were then autoradiographed at -70°C (24
hours). Several possible positive plaques were detected in 
each library as indicated by the darker spots on the X-ray 
film after developing. The result for EMBL4/60420 is shown in 
Figure 9C as an example. A total of 29 presumptive positive 
plaques were detected from the four libraries. Table 9F shows 
the number of presumptive plaques that were identified from 
each library. Each presumptive positive was plaque purified.
Table 9F Number of positive plaques
Library Number of presumptive positives
EMBL4/50410 3
EMBL4/50495 6
EMBL4/60420 16
EMBL4/140410003 4
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Figure 9C Plaque hybridization of EMBL4/60420 library
s .
The probe was pSU301. Autoradiography was at -70°C for 24 
hours. Only 12 out of 16 positive plaques are shown in this 
figure.
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Section 9.3 Plaque purification
The density of the plaques was too high to accurately 
determine the correct positive plaque therefore, an area 
surrounding each presumptive positive plaque was removed 
(containing about 5 to 8 plaques) and placed into 1 ml of SM 
buffer in a microfuge tube , containing 1 drop of chloroform. 
The tube was vortexed and left to stand at room temperature 
for 2 hours. The suspension was centrifuged for 10 seconds 
(microfuge) and the supernatant was recovered to which was 
added one drop of chloroform. The phage suspension was kept 
at 4°C until use.
For the first round of plaque purification, 10~1 and 
10"2 dilutions were made from each phage suspension. lOOul of 
each dilutions were used to infect 200ul of LE392 plating 
cells. After incubating at 37°C for 20 minutes, the cells 
were inoculated into 3ml of top agarose and overlaid on a L- 
agar plate (standard petri dish). The plates were incubated 
for 8 hours at 37®C. Plates containing 100 to 200 well 
separated plaques were chosen. Only one plate per phage 
suspension was used for the hybridization experiment.
Plaque lifts were then performed and the filters were 
probed with pSU301, The filters were washed with the same 
buffer as previously described. The filters were 
autoradiographed for 2 and 12 hours at -70°C.
In this round of plaque purification, the percentage of 
positive plaques was low. For example, one of the three
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presumptive positives from EMBL4/50410, yielded four positive 
plaques out of a total of approximately 200 plaques on the 
plate. Similar results were obtained from some presumptive 
positives. Others however did not yield any positive plaque 
in this round of screening and were not included for further 
purification.
The plaques produced for this round of purification were 
well separated so that it was possible to align the X-ray 
film with the plate and determine the position of each 
positive plaque. Single plaques can thus be isolated. One 
plaque was recovered from each plate containing positive 
plaques. Each plaque was removed from the agar using a 
sterile glass Pasteur pipette. The plug of agar containing 
the plaque was then placed into 500ul of SM buffer containing 
one drop of chloroform. This was then left at room 
temperature for 4 hours. The suspension was centrifuged for 
10 seconds in a microfuge. The supernatant was recovered and 
a drop of chloroform was added. The phage suspension was kept 
at 4°C before using.
Table 9G shows the number of presumed independent 
positive clones recovered from each library.
For the second round of plaque purification dilutions of 
each phage suspension were made and used to produce 
approximately 50 to 100 plaques per plate. The plaques were 
probed with labelled pSU301 as previously described.
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Table 9G Number of independant positive clones
Library Number of independant positive clones
EMBL4/50410 2
EMBL4/50495 3
EMBL4/60420 10
EMBKL4/140410003 4
All plaques produced from the two EMBL4/50410 clones 
hybridized with pSUSOl. Two EMBL4/50495 clones also produced 
plaques which were all positive. The other clone from this 
library gave no positive plaques. Similarly of the ten 
EMBL4/60420 clones, five gave rise to plaques, all of which 
hybridised with the probe while all four EMBL4/140410003 
clones gave positive plaques.
Figure 9D shows the results of some of the 
hybridization experiment. Positive (numbers 1 to 4) and 
negative (numbers 5 and 6) results are shown for comparison.
One plaque from each positive plate was isolated and the 
phage molecules were recovered. The phage suspensions were 
kept at 4^C before using.
Section 9.4 DNA extraction from lambda clones.
Two positive clones (independent clones arising from 
different plaques on initial screening) from each library 
were chosen for further study. Table 91 shows the designation
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Figure 9D Plaque Purification and Hybridization 
No. Clone Library
1 EMBL4/D-132 EMBL4/A-33 EMBL4/A-44 EMBL4/B-75 EMBL4/B-86 EMBL4/C-11
140 410 0035041050410504955049560420
ft V ^ I
The probe was pSU301. Autoradiograpy was at -70°C for 24 
hours.
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of the clones for future reference. Only M. tuberculosis 
clones are shown in Table 91. Further work in this chapter 
will relate to these clones only.
Table 91 Positive M. tuberculosis clones
Library Clone
EMBL4/50410 EMBL4/A-3
EMBL4/50410 EMBL4/A-4
EMBL4/50495 EMBL4/B-6
EMBL4/50495 EMBL4/B-7
EMBL4/6042G EMBL4/C-8
EMBL4/60420 EMBL4/C-10
The positive clones were first amplified before their 
DNA was extracted. lOOul of lO'^and lO^^dilutions of the 
previously prepared phage suspensions, were used to infect 
200ul of LE392 plating cells. The cells were inoculated into 
3ml of top agarose which was then overlayed onto L-agar. The 
plates were incubated at 37°C for 12 hours.
Phage suspensions for DNA extraction were prepared by 
flooding the plates with 5ml of SM buffer, gently shaken for 
3 hours at 4°C, and the buffer was recovered.
Alternatively, a single plaque was cored out using a 
sterile glass Pasteur pipette, placed into 0.5ml freshly 
prepared plating cells and allowed to adsorb for 15 minutes 
at room temperature. 5ml of L-broth containing 5mM CaCl2 was 
added and this was incubated with shaking until the cells
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had just lysed. 3 drops of chloroform was added and the 
lysate was centrifuged for 10 minutes to remove cell debris 
and the supernatant was recovered.
A 4ml volume of the phage suspension, prepared using 
either of the two methods were used for DNA extraction 
described in Section 6.1.5.
9.5 Screening of presumptive positive clones.
The DNA prepared from the chosen clones was digested 
with EcoRI or EcoRI + BamHI and then electrophoresed through 
0.8% agarose gels. The DNA from the gel was transferred to 
Hybond-N nylon membranes using methods described previously, 
and was then probed with pSU300 (isolated from the 
M. fortuitum host and purified twice on caesium chloride 
gradient). pSU300 and not pSU301 was used for this screening 
to avoid possible contamination by E, coll chromosomal DNA 
which would hybridise with E. coll chromosomal DNA which is 
present in the phage DNA preparation. The pSU300 DNA had been 
purified twice through caesium chloride/ethidium bromide 
gradient to remove contaminating mycobacterial chromosomal 
DNA. However, small amounts of chromosomal DNA may still be 
present in the probe.
Figure 9E shows the results of some of the digests and 
electrophoresis through an 0.8% agarose gel. The EcoRI digest 
of the DNA from EMBL4/A-3 (a clone from the EMBL4/50410 
libarary) shows the presence of several bands (Figure 9E, 
track 2 ). Two of those bands must be the two arms of the
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EMBL4 vector (Right arm, 9.26kb; Left arm; 19.3kb). The rest 
of the fragments therefore must have come from the insert, 
indicating that the insert contains several internal EcoRI 
sites. The EcoRI + BamHI digest of the same clone (track 3) 
generated a greater number of fragments indicating that the 
insert also contains several internal BamHI sites. The sum of 
the sizes of the observable fragments (smaller fragments may 
not be discernable) suggests that the insert in EMBL4/A-3 is 
approximately 17kb in size which is well within the size 
limits of the vector.
Another clone from the same library, EMBL4/A-4 (track 4; 
EcoRI digest, track 5; EcoRI+BamHI digest) gave different 
banding patterns compared to the corresponding EMBL4/A-3 
digests. This confirms that the two clones arose from two 
different plaques on initial screening. E, coll chromosomal 
DNA contamination can also be seen in all the tracks. Similar 
results were observed with clones from other M. tuberculosis 
libraries (results not shown).
Figure 9F shows the results of the hybridization 
experiment of the gel shown in Figure 9E, Figure 9F shows 
that all the clones contain fragments which hybridize with 
the probe. However, the strength of the signal from the 
different fragments were found to vary indicating different 
levels of homology between the fragments and the plasmid DNA. 
Figure 9F (track 2) shows that clone EMBL4/A-3 contains three 
fragments which hybridize with the probe {EcoRI digest). The 
signal from the largest fragment (15 kb) was weak. The 9kb
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Figure 9E Electrophoresis of DNA from mycobacterial clones
Track Clone Digest
1 Lambda Hlndlll marker2 A-3 EcoRI3 A-3 EcoRI+BamHI4 A-4 EcoRI5 A-4 EcoRI+BamHI
Electrophoresis was at 25V for 16 hours.
Figure 9F Hybridization of EMBL4 clones (I) 
Track Clone Digest
2 A-3 EcoRI3 A-3 EcoRI+BamHI4 A-4 EcoRI5 A-4 EcoRI+BamHI
The probe was pSU300. Autoradiography was at hours. -70°C for 20
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fragment gave a stronger signal while the 5kb fragment gave 
the strongest signal.
In track 3 {EcoRI + BamHI digest of EMBL4/A-3) the two 
strongest signals came from two fragments of about 4kb and 
3kb in size. These two bands must have originated from the 
5kb fragment observed in the EcoRI digest (track 2) as judged 
by the similarity in the strength of the signal of the three 
fragments. This suggests that the 4kb fragment in track 3 may 
be a partial digest of the 5kb EcoRI fragment observed in 
track 2.
The other clone from the same library, EMBL4/A-4 (Figure 
9F, tracks 4 and 5) did not appear to contain fragments with 
the same homology to the probe as EMBL4/A-3. Other clones 
contain insert fragments which hybridize to the probe. Figure 
9G shows the result of the hybridization experiment for these 
clones. Clone EMBL4/B-7 (from the library of strain 50495) 
also contains a fragment, 3.4kb in size, which hybridize 
strongly with the probe (Figure 9G, track 1). Fragments which 
hybridize less strongly to the probe are also present in this 
clone (track 1). Clones from other M. tuberculosis 
libraries appear to contain insert fragments with less 
homology to the probe (Figure 9G, tracks 3 to 5).
The results for the clones from the three 
M. tuberculosis libraries are summarised in Table 9J (which 
includes results not shown in Figures 9F and 9G).
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I
Figure 9G Hybridization of EMBL4 clones II
Track Clone Digest
1 B-7 EcoRI+BamHI2 C-8 EcoRI3 B-6 EcoRI4 C-10 EcoRI5 C-10 EcoRI+BamHI
The probe was pSU300. Auradiography was at -70®C for 20 
hours.
Table 9J Sizes of positive fragments
Clone Digest Sizes of positive bands (kilobases)
EMBL4/A-3 EcoRI 15, 9", 5~EMBL4/A-3 EcoRI+BamHI 15, 8, 4~, 3-EMBL4/A-4 EcoRI 15, 7,EMBL4/A-4 EcoRI+BamHI 15EMBL4/B-6 EcoRI 15 8, 4EMBL4/B-7 EcoRI 15,11-EMBL4/B-7 EcoRI+BamHI 15, 8-, 3.5~EMBL4/C-8 EcoRI 15-, 4K  4EMBL4/C-10 EcoRI 15-, 4EMBL4/C-10 EcoRI+BamHI 15-, 8, 4
Medium signal ~Strong signal Other fragments hybridize weakly with the probe
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The results shows that all the selected clones contain;; 
DNA fragments which were related to the plasmid pSU300. The 
strength of the signal from the different fragments within 
the same clone was found to vary indicating different copy 
number or levels of homology. Furthermore, similar sized 
fragments from different clones may have different levels of 
homology to the probe as indicated by the strength of the 
signal. However, different sized fragments from different 
clones may have the same homology to the probe (Figure 9F, 
track 3, and Figure 9G, track 1). These variations suggest 
that the inserts in the clones from the different libraries 
may have come from different parts of the M. tuberculosis 
genome but all contain pSU300-related sequences to a greater 
or lesser extent.
The hybridization that was observed may also be due to 
contaminating M. fortuitum chromosomal DNA. However, the fact 
that the clones were isolated by initial screenings with the 
recombinant E. coll plasmid tend to suggest that the observed 
bands are hybridized by the plasmid DNA rather than 
M. fortuitum chromosomal DNA. Furthermore, the plasmid DNA 
has been purified twice on caesium chloride/ethidium bromide 
gradient which should minimise the presence of chromosomal 
DNA in the probe.
Later results (see Table 9L and N) indicated that the 9 
and 5kb fragments in clone EMBL4/A-3 did not hybridize to 
chromosomal DNA of different strains of M. fortuitum*
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9.6 Recovery of positive fragments
The next step was to isolate some of the positive 
fragments and use them to probe M. tuberculosis chromosomal 
DNA to determine whether they can be used to detect 
restriction fragment length polymorphism in this species. The 
positive fragments from the various clones were recovered 
from the agarose gel using the GENECLEAN protocol. Figure 9H 
(and Table 9K) shows some of the recovered fragments after 
electrophoresis through a 0.8% agarose gel which indicate 
that the recovery of the 9 and 5kb EcoRI fragment from 
EMBL4/A-3 (track 2 and 3) was good. These two fragments will 
be used for further work in this chapter.
Figure 9H Recovery of inserts from EMBL4 clones
(Electrophoresis- 40V for 30 min; minigel)
Table 9K Sizes of recovered EMBL4 insert fragments
Track Source DNA
1 Lambda2 EMBL4/A-33 EMBL4/A-34 EMBL4/B-75 EMBL4/B-76 EMBL4/B-7
Digest
HindlllEcoRIEcoRIEcoRIEcoRI+BamHIEcoRI+BamHI
Fragment size ( kb )
95116.03.5
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Section 9.7 Probing of Mycobacterial total DNA with the
9kb EcoRI fragment from EMBL4/A-3
Total M. tuberculosis DNA was digested with PvuII and 
was then electrophoresed through 0.8% agarose at 25V for 16 
hours. DNA from other mycobacterial species were similarly 
treated for comparison.
The results of the digest are shown in Figures 91 
(M. tuberculosis and related species) and 9J (other 
mycobacterial species). Figure 91 shows that the PvuII digest 
banding pattern of all the M. tuberculosis strains are 
; indicating the close relationship between the 
strains. Furthermore, the wild type M. bovis strain also 
gave the same banding pattern. The BCG samples (Glaxo 
substrain, DNA prepared in this laboratory), tracks 12 and 
13, however gave very different banding patterns compared to 
the other species. This may indicate that the BCG strain kept 
in this department may not be BCG at all or it may have been 
contaminated with another mycobacterial species.
To determine this possibility, DNA samples were obtained 
from the Medical Research Council laboratory at Mill Hill 
(substrain NCTC 5692) and St.George’s Hospital in London 
(substrain Glaxo). However, the banding pattern from these 
digests were not detailed enough to enable a thorough 
comparison (results not shown). The various BCG strains will 
be included in the hybridization experiment.
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Figure 91 PvuII digest of M. tuberculosis complex
Track Species Strain
1 Lambda Hindlll marker2 M. tuberculosis 503103 M. tuberculosis 504104 M. tuberculosis 609255 M. tuberculosis 610666 M. tuberculosis 611047 M. tuberculosis 611258 M. tuberculosis 612679 M. tuberculosis 6137710 M. tuberculosis 6151311 M. bovis12 BCG (a)13 BCG (b)14 As (1)
Electrophoresis was for 18 hours at 20V.
BCG (a) and (b) are DNA samples of the departmental BCG 
strain extracted at different times.
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Figure 9J PvuII digest of non-tubercle mycobacteria
Track Species Strain
1 Lambda Hindlll marker2 M. parairuberculosis3 M. intracellulare 1034 M. scrofulaceum W2625 M. phlei6 M. fortuitum 60660
Electrophoresis was for 18 hours at 20V
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The DNA from these digests was transferred to Hybond-N 
nylon membrane and fixed by baking at 80°C for 1 hour. The 
filters were then probed with one of the positive fragments 
from EMBL4/A-3. DNA from other M. tuberculosis strains not 
shown in the previous figures was also probed in a similar 
manner.
The DNA fragment chosen as the probe was the 9kb EcoRI 
fragment isolated from the clone EMBL4/A-3, The fragment was 
labelled by using the Multiprime Random Primer method as 
previously described. The filters containing the tubercle DNA 
were pre-hybridized and probed with the labelled DNA 
fragment.
After hybridization, the filters were autoradiographed 
from 16 to 24 hours at room temperature or -70*^ 0. Figures 9K, 
9L and 9M shows the results of the hybridization experiment 
(Figure 9K corresponds to Figure 9%). The result of the 
hybridization experiment are summarised in Table 9L. Table 9L 
also includes results from strains of M. tuberculosis and 
other mycobacterial species not shown in the previous 
figures.
The results indicate that the probe, a 9kb EcoRI 
fragment from EMBL4/A-3 (from the library of strain 50410), 
is able to show the presence of restriction fragment 
polymorphism (RFLP) in M. tuberculosis (see Figures 9K, L, 
and M). In this species 5 different banding patterns were 
observed designated A to E, (Table 9L).
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Figure 9K Probing of M. tuberculosis
EcoRI fragment from
Track Species Strain
1 M. tuberculosis 503102 M. tuberculosis 504103 M. tuberculosis 60925 r4 M. tuberculosis 610665 M. tuberculosis 611046 M. tuberculosis 611257 M. tuberculosis 612678 M. tuberculosis 613779 M. tuberculosis 6151310 M. bovis11 BCG (,a)12 BCG (b)
0.56-
The probe was the 9kb EcoRI fragment of EMBL4/A-3
Autoradiography was for 16 hours at room temperature.
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Figure 9L Probing of M. tuberculosis complex DNA with the
9kb EcoRI fragment from EMBL4/A-3.
Track
12345678910 11 12
Species Strain
M. tuberculosis 50410M. tuberculosis 60925M. tuberculosis 61066 'M. tuberculosis 61104M. tuberculosis 61125M. tuberculosis 61267M. tuberculosis 61377M. tuberculosis 61513M. bovisBCG (Mill Hill) NCTC 5692 BCG C'CVL,Weybridge) Glaxo BCG (St.George's) Glaxo
0.5 6-
The probe was the 9kb EcoRI fragment of EMBL4/A-3
Autoradiography was for at -70°C for 16 hours.
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Figure 9M Probing of M. tuberculosis strain 40230
Track
1
2
Strain
40230
40230
Digest
EcoRI
PvuII
The probe was the 9kb EcoRI fragment of EMBL4/A-3
Autoradiography was for at -70°C for 16 hours.
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Table 9L Sizes of positive fragments in PvuII digest.
Species Strain Sizes of positive fragments (kb)(PvuII) Type
M.tuberculosis{sens*) 50310 6.7,5.0,3.5,3.0,0.7 0.4 A
M. tuberculosis (Z) 50410 5.0,3.5,3.0,0.7 0.4 B
M. tuberculosis (I,E,R) 60925 6.7,5.0,3.5,3.0,0.7 0.4 A
M. tuberculosis (S,I,R) 61066 14, 5.0,3.5,3.0,0.7 0.4 C
M. tuberculosis (I,R) 61104 6.7,5.0,3.5,3.0,0.7 0.4 A
M. tuberculosis (I) 61125 6.7,5.0,3.5,3.0,0.7 0.4 A
M. tuberculosis (S) 61267 5.0,3.5,3.0,0.7 0.4 B
M. tuberculosis (I) 61377 6.7,5.0,3.5,3.0,0.7 0.4 A
M. tuberculosis (S) 61513 17, 5.0,3.5,3.0,0.7 0.4 D
M. tuberculosis (S,I,Z) 40230 6.7, 2.3, 1.9, 1.0 * E
M. tuberculosis (S,I) 40654 5.0,3.5,3.0,0.7 0.4 B
M. tuberculosis (S,I) 50495 5.0,3.5,3.0,0.7 0.4 B
M. tuberculosis (S,E,R) 60420 5.0,3.5,3.0,0.7 0.4 B
M .tuberculosis (S,I) 61158 6.7,5.0,3.5,3.0,0.7 0.4 A
M .tuberculosis (I) 61504 6.7,5.0,3.5,3.0,0.7 0.4 A
M.. bovis wild type 19, 5.0,3.5,3.0,0.7 0.4 F
BCG(1) Glaxo 6.0, 2.0 +
BCG(2) Glaxo 6.0, 2.0 +
BCG(3) NCTC" 19, 5.0,3.5,3.0,0.7,0.4 F
BCG(4) Glaxo 19, 5.0,3.5,3.0,0.7,0.4 F
continued ....
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Table 9L (continued)
Species Strain Sizes of positivefragments(kb) 
(PvuII) Type
M.paratuberculosis None-
M. intracellulare 103 None
M.scrofulaceum W262 None
M.phlei None
U.fortuitum 60660 None
M.fortuitum 125 None
M.fortuitum 148 None
M.chelonei 60680 None
M.chelonei 60469 None
* Weaker signal in comparison to M.tuberculosis of a similar DNA loading.
+ Very weak signal
The signal from mycobacterial species not related to M.tuberculosis were either completely negative or so extremely weak in comparison to M*tuberculosis of a similar loading that the results were considered as negative.
(1),(2) - BCG DNA prepared at this laboratory. The stock was originally obtained from the Central Veterinary Laboratory, Weybridge.(3) - BCG DNA prepared at MRC, Mill Hill,(4) - BCG DNA prepared at St. George's Hospital, London.
S- Resistance E- Resistance R- Resistance Z- Resistance I- Resistance NCTC 5692
to streptomycin to ethambutol rifampicin to pyrazinamide to isoniazid
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Fragments sizes 5.0, 3.5, 3.0, 0.7 and 0.4 kb appeared 
in all the strains except in strain 40230 which has a 
completely different pattern. The different types of banding 
patterns are shown below:
19kb
A B C D E
17kb
14kb
6.7kb 6.7kb5.Okb 5.Okb 5.Okb 5.Okb 5.Okb3.5kb 3.5kb 3.5kb 3.5kb 3.5kb3.Okb 3.Okb 3.Okb 3.Okb 3.Okb2.3kb1.9kbl.Okb0.8kb0.7kb 0.7kb 0.7kb 0.7kb 0.7kb0.4kb 0.4kb 0.4kb 0.4kb 0.4kb
An analysis of the banding patterns and resistance 
phenotype did not reveal any relationship between the two 
factors. For example, strain 50310 (Figure 9K, track 1) which 
is sensitive to all the antituberculous drugs share the same 
banding pattern with strains which are resistant to one or 
more antibiotics. Strains 51267 and 61513 are both 
streptomycin resistant but do not have the same banding 
pattern (types B and D for 61267 and 61513 respectively, see 
Figure 9L; Tracks 6 and 8).
An analysis of the patients from which the strains were 
initially isolated was made to detect any possible 
relationship between the observed banding pattern and racial 
and/or geographical factors. Table 9M shows the available
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information on the strains and patients from which they were 
isolated.
All the M. tuberculosis strains shown in Table 9L were 
determined to be of the Classical variant on the basis of 
resistance to thiopen-2-carboxylic acid hydrazide, TCH, 
(Grange et al, 1985). The Asian variant is sensitive to TCH. 
Most of the strains isolated in London and the South-East of 
England were of the Classical type (91% from European 
patients and 82.8% from Asian patients) as reported by Grange 
et al (1985). Two strains of the Asian variants were included 
in this study but the results have not been good enough for 
inclusion in Table 9L.
However, one of these Asian strains, 61695 (resistant to 
pyrazinamide) appear to have a banding pattern similar to 
that of Type A but with an extra band of about 14kb. More 
strains of the Asian variant would have to be tested to 
obtain a clearer picture.
Although termed the Asian variant, it cannot be assumed 
that all strains of this type originated in Asia. 
Furthermore, the Asian variants isolated from European 
patients need not originally come from Asian patients. The 
Asian variants isolated from European patients may in fact be 
present in this country for many years brought over by 
members of the British colonial power in India and represent 
a bactériologie population different from that found in Asian 
communities.
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Table 9M M. tuberculosis strains and Patients
Strain Resistance Pattern Patient’s Race Place of Specimenisolation
40230 s. I, Z E Caucasian Saudi Arabia Sputum40654 s. I B Asian~ Margate Sputum50310 sensitive A Caucasian Tunbridge Wells Sputum50410 Z B Caucasian Portsmouth Sputum50495 s. B Asian London Bronchialwashing60420 s. E, R B Caucasian Switzerland Sputum60925 I, E, R A Asian London Sputum61066 s. I. R C Caucasian Australia Abdominaltissue61104 I, R A Caucasian London Sputum61125 I A Asian London Uterinetissue61158 s. I A Asian London Sputum61267 S B Caucasian London NeckAbcess61377 I A Asian London Sputum61504 I A Caucasian London Sputum61513 s D Asian London Cervicaltissue
s- Resistance to streptomycin, E- Resistance to ethambutol R- Resistance rifampicin, Z- Resistance to pyrazinamide I- Resistance to isoniazid
Patients of Asian origin are usually from the Indian subcontinent or surrounding geographical regions.
Another possibility is that the Asian variants in this 
country could have evolved from the Classical type already 
present here.
Types A and B are the most common banding patterns 
observed in M. tuberculosis. Six out of fifteen strains 
tested have the A type pattern while 5 of the strains show 
the B type pattern. Of the six A type strains, 4 of the 
patients from which the strains were isolated are of Asian 
origins while the two Caucasians were English (see Table 9M),
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Three of the patients with strains of type B were 
Caucasians. One of these strains, 60420, was isolated in 
Switzerland, The other two patients with type B strains were 
of Asian origins.
The number of strains tested so far are too small for a 
firm conclusion of any kind. It might be possible, however 
to make a few speculations from the available data.
The human strain of M. tuberculosis as mentioned earlier 
could be divided into the predominant Classical or Asian 
variants on the basis of TCH resistance. The banding patterns 
observed within each variants, or the Classical type at 
least, may represent geographical variations. Strains with 
type A banding pattern could originate from the east (India 
and adjacent regions) while strains with type B banding 
pattern were of European origin.
The link between geographical regions and the banding 
patterns are further suggested by the less common pattern 
types:
Firstly, the only type C banding pattern was exhibited 
by strain 61066. This strain was isolated in Australia.
Another strain with a unique pattern type, designated as 
D, was isolated from an Asian patient in London (strain 
61513). Although this patient also came from the same region 
as that of other patients carrying the A and B type strains.
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the different pattern may reflect a local variant. The Indian 
subcontinent and surrounding regions constitute an extensive 
area in which variants may develop locally especially in 
remote areas where populations tend to remain relatively 
static.
The type E pattern which was found in only one of the 
strains of M. tuberculosis tested so far (strain 40230, 
Figure M; track 2) is so completely different from other 
strains of this species (and M. hovis) that it suggest that 
this strain is not actually a member of this species at all 
and is probably a contaminant. However, all the non­
tuberculosis strains tested so far do not hybridize at all 
with the probe. It is therefore possible that this strain 
does belong to the species M. tuberculosis but represent an 
extremely divergent variant of the species. This strain was 
isolated from a patient in Saudi Arabia. More strains would 
have to be tested and more information concerning the 
patients must be collected to obtain a more complete picture 
of the relationship between observed banding patterns and 
factors such as that speculated above.
Correlation between banding patterns and unusual 
infection sites is suggested by comparing type C (abdominal 
tissue) and D (cervical tissue) with the rest of the strains 
which are usually isolated from the sputum. However, a type A 
strain (61125) was also isolated from an unusual site 
(uterine tissue) while the unique type E strain was recovered 
from a sputum sample. Hence, the evidence at this stage do&a
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not appear to point to any correlation between the banding 
type and the site of infection.
The patterns designated types D (M. tuberculosis^ strain 
61513) and F (M, bovis, wild type) looked very similar in 
Figure 9L (track 8 and 9 respectively). However, the same 
samples electrophoresed at a lower voltage and for a longer 
time (25V, 16 hours compared to lOOV, 3.5 hours) improved the 
separation of the larger fragments to show that the two top 
bands (Figure 9K, tracks 9 and 10 respectively) were slightly 
different in sizes with the top band in type F (19kb) being 
the larger of the two (17kb for type D). However, to be 
completely certain the electrophoresis should be run for a 
longer length of time or at a lower gel concentration to 
obtain a better separation of these large fragments. The 
similarity of the two patterns however indicates the close 
relationship of M. tuberculosis and wild type M. bovis»
The pattern of the bands in M. bovis and two of the BCG 
samples, the Glaxo strain from St. George’s and NCTC 5692 
from Mill Hill, were identical (Figure 9L, tracks 9, 10 and 
12). This result indicates the close relationship between the 
wild type M. bovis and BCG. The fragments which are present 
in all the M. tuberculosis strains are also found in M. bovis 
and BCG , reflecting the closeness of the three species. The 
BCG sample from this department (Figure 9K; track 11 and 12, 
Figure 9L track 11) however was totally different. Some bands 
are seen but are so weak comparative to the other strains 
that the result can be considered as negative. There are
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three possible reasons for these observations:
Firstly, the BCG stock in this department may have been 
contaminated with another mycobacterial species right from 
the beginning or the contamination may have occurred during 
the growth of the culture for DNA extraction.
The second possibility could be that this strain is 
actually a different and hitherto unknown mycobacterial 
species which is closely related to BCG biochemically and is 
thus not differentiated by the usual cultural and biochemical 
test.
The third possibility is that this strain may actually 
be another variant of BCG. The source of this strain (Central 
Veterinary Laboratory, Weybridge) indicated that this BCG 
strain was different to other strains as determined by 
protein secretion profiles.
To determine the various possibilities the strain was 
sent to the Mycobacteria Reference Laboratory (Dulwich 
Hospital) for species confirmation. The results of the tests 
showed that this strain is actually a member of the M. avium- 
intracellulare complex. This surprising result (in view of 
the original source) underlines the usefulness of this probe 
in differentiating the tubercle- related species from 
atypical mycobacteria.
The 9 kb EcoRI fragment from EMBL4/A-3 may prove to be 
a useful tool for epidemiological studies of tuberculosis.
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More isolates from different parts of the world must be 
tested with this probe to determine the hypothesis of 
regional variations represented by the banding patterns that 
have been observed. The banding patterns may also be related 
to other factors as yet to be identified.f
This fragment was also used to probe total DNA of 
M. tuberculosis digested with EcoRI. However, the banding 
pattern that was observed showed less variations. Only two 
different types of banding patterns can be seen as shown in 
Figure 9N. This digest is therefore not as useful as the 
PvuII digest when the 9kb fragment was used as the probe.
Figure 9N Probing of EcoRI digested mycobacterial DNA with
the 9kb EcoRI fragment of EMBL4/A-3
1 2 3  4 5  6 7 8  9 1 0 11Track1 M .
Species
tuberculosis
Strain
50310
2 M . tuberculosis 50410 ' 23-3 M . tuberculosis 60925 9.4-4 M . tuberculosis 61066 6j6-5 M , tuberculosis 61104
6 M . tuberculosis 61125 • 44-
7 M . tuberculosis 612678 M . tuberculosis 61377 23_.9 M . tuberculosis 61513 2.0-10 N . bovis
11 BCG (C V L ,W e y b r i d g e ) Glaxo
The probe was the 9kb EcoRI fragment from EMBL4/A-3Autoradiography was at -70^C for 16 hours.
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Section 9.8 Probing of total DNA of M. tuberculosis with
the 5kb EcoRI fragment from EMBL4/A-3
The second positive fragment from clone EMBL4/A-3 was 
next used to probe DNA from M. tuberculosis and other 
mycobacterial species.
A second aliquot of PvuII digested DNA identical to that 
used in the previous experiment (Figure 9L), was 
electrophoresed and transferred to Hybond-N nylon membrane as 
previously described. The 5kb EcoRI fragment was labelled 
with and then used to probe the DNA. After washing at
high stringency (O.IX BSC, ôB^c, 30 minutes), the filter was 
autoradiographed for 6.5 hours at room temperature.
The result, as shown in Figure 90, was very surprising. 
Numerous bands were observed in each M. tuberculosis strain. 
Furthermore, the banding patterns appear to be unique to each 
strain.
The two strains of BCG (Glaxo, St. George's and NCTC 
5692, Mill Hill) have identical patterns (Figure 90, track 11 
and 13) but this pattern is very different from that of 
M. bovis wild type (track 10). Although a band can be seen in 
the strain previously identified as BCG (track 12) but is now 
known to be M. avium-Intracellulare, the signal is so weak 
that it can be considered as negative. Other mycobacterial 
strains did not hybridize with the probe (results not shown). 
Table 9N gives the summary of the results.
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Figure 90 Probing of PvuII digested mycobacterial
the 5kb EcoRI fragment of EMBL4/A-
Track Species Strain
1 M. tuberculosis 503102 M. tuberculosis 504103 M. tuberculosis 609254 M. tuberculosis 61066 ■5 M. tuberculosis 611046 M. tuberculosis 611257 M. tuberculosis 612678 M. tuberculosis 613779 M. tuberculosis 6151310 M. bovis11 BCG Mill Hill NCTC 569212 M.avium-Intracellulare13 BCG St. George's Glaxo
066-
The probe was the 5kb EcoRI fragment from EMBL4/A-3.
Autoradiography was for 6.5 hours at room temperature
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Table 9N Positive fragments in M. tuberculosis DNA
Species and Strainresistance phenotype Sizes of positive fragments Patterntype
M.tuberculosis (sens*) 50310
M.tuberculosis (Z) 50410
M.tuberculosis (I,E,R) 60925 
M.tuberculosis (S,I,R) 61066 
M.tuberculosis (I,R) 61104
M.tuberculosis (I) 61125
M.tuberculosis (S) 61267
M.tuberculosis (I) 61377
M.tuberculosis (S) 61513
M. bovis wild type
M. avium-Intracellulare
BCG(1) NCTC~
BCG(2) Glaxo
M.paratuberculosls 
M.Intracellulare 103
M.scrofulaceum W262
M.phlel
Numerous 
Numerous 
Numerous 
Numerous 
Numerous 
Numerous 
Numerous 
Numerous 
Numerous 
4.4, 3.5, 2.5,
None^
3.8, 2.8, 2.35, 0.7
3.8, 2.8, 2.35, 0.7 
None
None
None
None
2,3
1
2
3
4
5
6
7
8
9
10
11
11
continued....
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Table 9N (continued)
Species and resistance phenotype Strain Sizes of positive fragments Patterntype
M.fortultum 60660 None
M.fortultum 125 None
M.fortultum 148 None
M.chelonel 60680 None
M.chelonel 60469 None
* Weaker signal in comparison to M. tuberculosis of a similar 
DNA loading.
+ Very weak signal
The signal from mycobacterial species not related to 
M. tuberculosis were either completely negative or so 
extremely weak in comparison to M. tuberculosis of a similar 
loading that the results were considered as negative.
(1) - BCG DNA prepared at MRC, Mill Hill.
(2) - BCG DNA prepared at St. George’s Hospital, London.
S- Resistance to streptomycin E- Resistance to ethambutol R- Resistance rifampicin Z- Resistance to pyrazinamide I- Resistance to isoniazid
NCTC 5692
The banding patterns observed were totally different 
from that obtained with the previous probe. Although 
initially some bands appear to occur in both experiments, 
closer analysis reveal that they are not the same. For 
example, the smallest fragment that hybridizes with the 5kb
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probe is approximately 0,7kb in size, similar to that found 
when the 9 kb fragment was used as the probe. However, 
although this fragment appeared in the track containing the 
M. bovis DNA in Figure 9L, track 9 (when the 9 kb fragment 
was used as the probe), no band of this size can be seen in 
the same sample when tested with the 5kb probe ( see Figure 
90, track 10). This appears to rule out contamination of the 
5kb probe with the 9kb fragment. Thus, the 0.7kb fragment 
seen in this experiment would appear to be diffferent to that 
found previously. Furthermore, the stronger signal obtained 
with the 5kb probe supports the suggestion that the bands are 
not identical in the two experiments.
These observations suggest that the original DNA 
fragment from M. tuberculosis strain 50410 that was cloned in 
EMBL4/A-3 contains two regions that are homologous to two 
different regions in pSU300 but the two regions in 
M. tuberculosis are very close to each other in the genome. 
Alternatively, it is possible that two fragments from 
different parts of the genome have been fortuitously cloned 
together.
The two probes used in this study are large DNA 
fragments. Therefore, some of the bands observed in the 
hybridization experiments may be due to regions other than 
the pSU300-related sequences present on the probes. However, 
the original hybridization experiment, described in 
Chapter 8, also showed the presence of numerous bands in the 
M. tuberculosis strains when pSU300 was used as the probe.
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In the experiments with the 5kb probe, the numerous 
bands seen in M. tuberculosis suggests that the 5kb fragment
contains at least one sequence which are repeated in many
different parts of the genome.
The most interesting aspect of the result with the 5kb 
probe is the diversity of the banding pattern that can be 
seen in the various M. tuberculosis strains. Although some 
bands appear in more than one strain, the overall banding 
pattern of each strain is unique to each one. The similarity 
to the reported DNA fingerprinting technique (Jefferys, 1987) 
is interesting. This offers the prospect of using this 
fragment as a highly specific probe for epidemiological 
studies. More work is required to determine if the banding
patterns are stable in each strain.
Another interesting prospect offered by this probe is in 
its ability to differentiate between M. tuberculosis, 
M. bovis and BCG. In situations where normal methods of 
identification are not available or where the time factor is 
important (normal identification procedures takes between 6 
to 8 weeks; Collins et al, 1985) the use of this probe may 
prove to be useful.
The two probes have not been able to differentiate 
between the two strains of BCG used in this study, Glaxo and 
NCTC 5692, where the banding pattern appeared to be 
conserved. BCG substrains are known to differ significantly 
from each other. The differences occur in areas such protein
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secretion, mycolic acids components and antigenic factors 
(Abou-Zeid et al, 1986; Stavri et al, 1981; Grange et al,
1983). The protective efficacy of some BCG strains in animal 
models are also known to be significantly lower than others 
(Grange et al, 1983). These differences may be crucial 
factors in determining the success or failure of a 
vaccination program.
It may be possible to detect strain variations using the 
DNA probes found in this study. Other substrains should be 
tested with the probes to determine whether other banding 
patterns can be observed. Furthermore, similar DNA probes 
could be developed for differentiating BCG strains using the 
same method described in this chapter.
No significant bands were detected in other 
mycobacterial species tested so far. The specificity of the 
probes therefore, suggests that they can be used to develop 
rapid systems to identify M, tuberculosis and other related 
species. It may be also be possible to develop techniques to 
identify the tubercle bacterium in clinical samples.
The cloned DNA fragment in EMBL4/A-3 has yielded two 
probes which are proving to be very interesting. The two 
probes may be useful as tools for the further studies of the 
genetics of M. tuberculosis and closely related species. 
Furthermore, their application in the study of the 
epidemiology of the disease is indicated by the results. 
Other clones produced in this study may also prove to be
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equally useful. Further work on the other clones would be 
required.
The most immediate step would be to identify and 
sequence the homologous regions on the two probes to 
determine its nature. Furthermore, the relationship of the 
sequence to other aspects of M. tuberculosis such as 
virulence, immunological response, geographical distribution 
and many other factors must be investigated. The results 
obtained in this thesis is hopefully another step towards the 
greater understanding of this important disease.
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Chapter 10
Transformation in Mycobacteria
The study of the genetics of Mycobacteria has been 
particularly hampered by the lack of reliable and 
reproducible transformation systems for the genus. Several 
reports of transformation of Mycobacteria have been published 
(reviewed by Tarnok and Bonicke, 1970), but these involved 
the use of chromosomal markers and have not found general 
applicability.
A system reported by Norgard and Imaeda (1978) for 
producing "competent" mycobacterial cells was tried using 
pIJ666, pACYC184 and pUC19 to transform the cells. However, 
the results were negative.
Recently Jacobs et al (1987) reported the transfection 
of Mycobacterium smegmatis sphaeroplasts with a phasmid, 
constructed by fusing an Escherichia coli plasmid with a 
mycobacteriophage.
It was decided to employ a similar system using a pool 
of hybrid plasmids, referred to as pTK, which were 
constructed by Tobias Kieser at the John Innes Institute, 
Norwich. A plasmid from M. fortuitum of about 5kb in size 
called pALSOOO was linearised by partial digestion with Mbol. 
The 5kb fragments were recovered and then inserted into the 
BamHi cloning site of an B. coli plasmid called pIJ666 (see 
Figure lOF). It was hoped that by using this strategy, a
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mycobacterial origin of replication might be cloned, 
therefore allowing the plasmid to be replicated in 
M. smegmatis. The chloramphenicol and kanamycin resistance 
genes contained in pIJ666 were used as the markers.
10.1.1 Transformation and selection of transformants
The methods used for preparing M. smegmatis 
sphaeroplasts and the transformation procedure are described 
in Section 6.7. Table lOA shows the details of the 
transformation experiment.
Table lOA Transformation of M. smegmatis
Plasmid DNA Amount used (ug) Sphaeroplast
1. pTK pool 0.45 Yes2. pIJ666 0.50 Yes3. None - Yes4. None Non-sphaeroplasted cells
The experiments numbered as (2), (3) and (4) were used 
as negative controls. The sphaeroplasts were regenerated on 
TSAS media for 48 hours at 37°C. The cells were then 
resuspended in N-broth and aliquots were plated out on N-agar 
containing chloramphenicol (40ug/ml) or kanamycin (40ug/ml) 
and media with no antibiotics as control. The plates were 
incubated at 37°C for 2 to 4 days.
No colonies were found on selective plates from the 
untransformed sphaeroplasts or the non-sphaeroplasted cells. 
The regenerated sphaeroplasts transformed with the pTK pool
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gave approximately 500 colonies on the chloramphenicol 
plates. No colonies were found on the kanamycin plates. The 
absence of colonies on the control plates suggest that the 
transformants are not chloramphenicol resistant mutants.
Unexpectedly however, a similar number of colonies were 
obtained from the control transformation using pIJ666 alone, 
on chloramphenicol. Again none were seen on the kanamycin 
plates. To confirm that the observed colonies were true 
transformants, 67 and 46 colonies from the pIJ666 and pTK 
transformed colonies respectively, were toothpicked and 
transferred to chloramphenicol (40ug/ml) plates and incubated 
at 37°C for 48 hours. Twenty seven of the pIJ666 transformed 
cells grew well as did 31 of the pTK transformants. Cells 
growing on chloramphenicol were then transferred to plates 
containing 5, 10 and 15ug/ml kanamycin. Again, none of the 
cells grew at any of these concentrations of kanamycin.
10.1.2 Plasmid Stability
The stability of the plasmid in M. smegmatis was 
determined for two of the transformants. Single colonies from 
ZZlOO and ZZ103 (both pIJ666 transformants) were each 
inoculated into 10ml of antibiotic-free N-broth containing 
0.2% Tween 80 and incubated at 37°C to obtain dispersed 
growth. Serial dilutions to lO"^ were made and lOOul aliquots 
of the final dilution were plated out to obtain single 
colonies on ant «biotic-free N-agar plates.
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After 3 days of incubation at 37^ C, 50 to 100 colonies 
were obtained. Selected colonies were toothpicked and 
transferred to chloramphenicol plates. 15 out of 51 (31%) 
colonies of ZZ103 were still resistant after two .passages 
through antibiotic free medium, 33 of 41 colonies (76%) from 
strain ZZlOO were still resistant.
This result suggests that the chloramphenicol resistance 
is mediated by a self-replicating plasmid. Resistance due to 
chromosomal mutation should be more stable than that obtained 
for the two transformants (Mitchison, 1968, Gangadhar am,
1984). Although the degree of stability is low in one 
transformant (ZZ103), the fact that a significant number was 
still resistant after two passages through antibiotic-free 
media is encouraging. The transformants were further analysed 
by Southern hybridization to confirm that transformation had 
been obtained and to show the presence of extrachromosomal 
DNA.
10.1.3 Analysis of the Mycobacterial Transformants by
Southern Hybridization
Gel electrophoresis of small scale plasmid DNA 
preparation of the transformants did not reveal the 
presence of extrachromosomal DNA. This suggests that the 
plasmid may be present in low copy numbers, as a self 
replicating plasmid, or it may be in an episomal state. To 
resolve this, total DNA from the transformants was analysed 
by Southern hybridization.
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Three pIJ666 and four pTK transformants from the 
chloramphenicol plates (Section 10.1.1) were streaked out 
onto chloramphenicol plates to give single colonies. A single 
colony was then inoculated into 40ml of N-broth containing 
chloramphenicol (40ug/ml). Untransformed M. smegmatis was 
grown in both antibiotic-containing and antibiotic-free broth 
as control. After 2 days of incubation at 37%, no growth was 
found in the culture of untransformed M. smegmatis inoculated 
into the antibiotic-containing broth. All the transformants 
grew well but their rates of growth appeared to be less than 
that of the parental strain grown in N-broth alone (by 
comparing the turbidity of the cultures).
Total DNA was extracted from each of the cultures. Three 
to five micrograms of purified DNA from the transformants 
were each digested with a variety of enzymes and samples were 
electrophoresed through agarose gels. DNA from the 
untransformed parental strain, was included in each 
experiment as the control. The DNA was transferred to nylon 
filter membranes and probed with labelled pIJ666.
One pIJ666 transformant, referred to as ZZlOO, showed 
the presence of two bands in the undigested DNA (Figure lOA, 
track 5 ). Single bands were seen in the digested samples 
(track 1 to 3) except in the SstI digest (track 4) which 
showed identical bands to the undigested material. No bands 
were seen in the parental strain even after extended exposure 
(Figure lOA, tracks 6 to 10).
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Figure lOA Southern hybridization of ZZlOO
Track Strain Digest1 ZZlOO BamHI2 ZZlOO EcoRV3 ZZlOO EcoRI4 ZZlOO SstI5 ZZlOO Uncut6 ATCC607 BamHi7 ATCC607 EcoRV8 ATCC607 EcoRI9 ATCC607 SstI10 ATCC607 Uncut11 (Lambda Hindlll m,12 pIJ666 Uncut
The marker sizes indicated are that of Lambda DNA digested with Hindu I.
Tracks 6-10, ATCC607, is the parental M. smegmatis strain.
The probe was pIJ666 labelled with the Multiprime Kit(Amersham). Autoradiography was at -70% for 2 days.
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other pIJ666 transformants showed identical results but 
only after a longer exposure (results not shown). The pTK 
transformants also showed the presence of bands including in 
the undigested material (results not shown).
The presence of the bands in the undigested DNA sample, 
is consistent with an independently replicating plasmid. 
Furthermore, the comparative weakness of the bands and the 
absence of the plasmid bands in the stained gel suggest that 
the plasmids are present in very low copy number in 
M. smegmatis.
The pattern of the restriction digests of the pIJ566 
transformants, are very similar to that expected for pIJ666. 
However, the fragment sizes appeared to be smaller than 
expected. Two possible reasons may explain this result: 
Firstly, the difference may be an artefact due to the high 
loading of the sample DNA (up to 1.5ug), This may affect the 
electrophoresis of the DNA resulting in an anomalous result.
Another possibility is a deletion in the plasmid. The 
fact that the transformants did not grow on kanamycin 
supports this hypothesis and suggests that the deletion may 
have occurred in the kanamycin resistance gene. Later results 
however, did not support this hypothesis (see Section 
10.1.6). An alternative explanation for the lack of kanamycin 
resistance would be that the expression of the gene (Rphll in 
pIJ666) may be at a level too low to confer resistance.
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To test the last hypothesis, the transformants were 
analysed by Western blotting using polyclonal rabbit 
antiserum raised against the kanamycin phosphotransferase 
enzyme; this antiserum was donated by Tobias Kieser,
10.1.4 SDS-PAGE electrophoresis and Western blotting
The transformants were grown in 10ml N-broth at 37®C 
with shaking for 48 hours. Cells from 1.5ml aliquots of each 
strain were harvested, lysed and electrophoresed through a 
12% (separating gel) SDS-PAGE gel as described in Section 
6.6. The proteins were then transferred to a nitrocellulose 
filter membrane by electrophoretic transfer (Section 6.6.4).
The filter was probed with polyclonal rabbit antiserum 
raised against the kanamycin phosphotransferase enzyme. Goat 
antirabbit IgG (biotin conjugated) was used as the secondary 
antibody. Streptavidin-biotinylated horseradish peroxidase 
complex was employed as the detection system.
The enzyme was not detected in any of the transformants 
tested (results not shown). This result supported the 
deletion hypothesis but could not be taken as a confirmation. 
The kanamycin resistance gene may not be expressed in 
M. smegmatis even though the gene may still be intact.
A single positive band of about 69kD was observed in all 
the samples including the control parental strain (results 
not shown). This band is probably due to a biotinylated 
protein present in M. smegmatis. Biotinylated proteins have
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been observed in other mycobacteria (Collins et al, 1986). 
Furthermore, the presence of this band in all the samples 
confirms that the transformants are M. smegmatis ATCC607 and 
are not contaminating bacteria. The presence of this band 
also confirms that the cells were successfully lysed and that 
the negative result is not due to failure of the lysis 
process. However, the questions concerning the size of the 
plasmid and the expression of the kanamycin resistance gene 
still remains.
To resolve these questions, it would be necessary to 
isolate the plasmid and re-transform E. coll.
10.1.5 Large scale preparation of plasmid DNA from a
Mycobacterium smegmatis transformant.
The strain ZZlOO (pIJ666 transformant) gave the 
strongest signal in the Southern hybridization experiment. 
This strain was passaged repeatedly through 10ml N-broth 
containing chloramphenicol (40ug/ml), to eliminate the 
possibility of passively adsorbed plasmid or non-replicating 
plasmid DNA from the original transformation.
1ml aliquots of the culture from the sixth, eighth and 
eleventh passages were inoculated into each of 200ml N-broth 
containing chloramphenicol. The modified cleared lysate 
method (Section 6.1.4, Procedure 2) was used to extract 
plasmid DNA from the first two large scale cultures while the
scaled up alkaline lysis method was used for the last
(Section 6.1.4, Procedure 1).
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No extrachromosomal DNA band was discernible in the 
caesium chloride gradient in any of the preparations. 
Fractions were therefore recovered from below the chromosomal 
band from each gradients. The fractions were subjected to the 
plasmid DNA recovery procedure as described earlier. The 
pellets recovered after this procedure were resuspended in 
lOOul of TE buffer.
Fractions recovered from the 6th and 8th passages were 
analyzed by electrophoresis on the same agarose gel (0,8%) 
and stained with ethidium bromide. The results (Figure lOB) 
showed the presence of low molecular weight bands in some of 
the fractions (track 2; 6th passage, tracks 3 and 4; 8th 
passage). The fractions were also contaminated with varying 
amounts of chromosomal DNA. Fractions from the 11th passage, 
which was prepared at a different time, was not included in 
the electrophoresis.
The uncut DNA bands that were seen in the two samples 
appeared to be different. The sample prepared from the sixth 
passage (Figure lOB, track 2) contained only one 
extrachromosomal band, at the 6.6 kb marker position although 
this would not necessarily indicate the true size of the 
plasmid because it is presumably in the closed covalent 
circle form.
The sample prepared from the eighth passage gave two 
bands; at the 7 and 3kb marker positions (Figure lOB, track 
3 and 4). The two bands may be different forms of the same
230
plasmid (see Kieser, 1984) However, the important question is 
the relationship between the plasmid obtained from the 6th 
passage and the plasmid (or plasmids) from the 8th passage; 
are they the same or different plasmids ? To answer this 
question the plasmids were analysed further as described 
below.
Figure lOB Electrophoresis of plasmid DNA preparations from
strain ZZlOO.Track Passage
1 Lambda Hindlll marker2 6th3 8th4 8th5 Lambda Hindlll marker
Electrophoresis was for lOOV for 2 hours on a ERL H5 horizontal electrophoresis apparatus with IX Tris-borate running buffer.
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10.1.6 Plasmid DNA recovery from agarose gel
To further characterise the plasmids, the DNA bands were 
recovered by using the GENECLEAN protocol. The DNA was 
digested with restriction enzymes, electrophoresed through a 
0.8% agarose gel (lOOV, 2 hours) and the DNA was transferred 
to a nylon filter membrane by Southern blotting. pIJ666 was 
included for comparison. The filter was then probed with ^^P 
labelled pIJ666. The results showed that the plasmid isolated 
from the 6th passage (Figure IOC, tracks 1 to 3 ) gave an 
identical restriction pattern to that of pIJ666 (Figure 100, 
tracks 4 to 6).
The DNA bands isolated from the second preparation (8th 
passage) also hybridized with the pIJ666 probe. The result 
was not clear due to a high background but it suggested that 
the restriction digest patterns were not identical to that of 
pIJ666 (results not shown). Table lOB shows the sizes of the 
restriction fragments shown in Figure IOC.
Table lOB Restriction fragment sizes of the plasmid from
M. smegmatis transformant ZZlOO
Plasmid DNA EcoRI source
M.smegmatis 6.7 6th passage
Restriction enzyme
Hindlll EcoRI+PstI
Fragment size (kb)
5.7,0.7,0.3 3.7,2.0,0.9
Parental plasmid* from E.coli
6.7 5.7,0.7,0.3 3.7,2.0,0.9
*Original plasmid used to transform M. smegmatis sphaeroplasts.
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Figure lOC Hybridization of the plasmid from
the 6th passage.
Track Plasmid Source
1 ZZlOO 6th passage2 ZZlOO 6th passage3 ZZlOO 6th passage4 Parental pIJ6665 Parental pIJ6666 Parental pIJ666
Digest
EcoRIHindlllEcoRI+PstIEcoRIHindlllEcoRI+PstI
2' 314 5 6
— 6.6
0.56
Electrophoresis was for 2 hours at lOOV (H5 gel apparatus). Autoradiography was for 17 hours (tracks 1-3) or 3 hours (4- 6) at -70%.
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10.1.7 Re-transformation of Escherichia coll
The plasmids isolated from the three different passages 
of ZZlOO were next used to transform E. coll. Competent cells 
of E. coll strain LM 1035 were prepared and transformed with 
plasmid DNA preparations (CsCl gradient purified and ethanol 
precipitated) from the 6th and 8th passages without further 
purification by gel electrophoresis.
The CsCl gradient fractions from the 11th passage was 
not analyzed by electrophoresis. Each CsCl gradient fraction 
from this passage was ethanol precipitated to recover the 
DNA. The pellet in each fraction was resuspended in TE 
buffer and then used to transform different aliquots (200ul) 
of the prepared competent cells. The results of this 
transformation experiment are shown in Table IOC.
Table IOC Re-transformation of E. coll
Plasmid DNAsource(cfu)
Amount used (ug) Total number of colonies iT ran s f orman t s per o‘f DNA
ZZlOO
1.6th passage 0.012 63 5 X 1032.8th passage 0.008 4 5 X 1023.11th passage NA 40* NA
Controls
4.None5.Untransformed 0 0 0cells 0 0 0
* Total number of colonies from five CsCl purified fractions NA- Not available.
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The amount of plasmid DNA extracted from the 11th
passage (Table IOC) was not determined, hence the
transformation frequency cannot be calculated.
Transformants were selected on L-agar plates containing 
chloramphenicol (10, 20 and 40 ug/ml ) . The plates were
incubated at 37^C overnight, A number of colonies were 
obtained from each preparation (see Table IOC for details). 
No colonies were observed from the two controls indicating 
that the observed colonies have been transformed with plasmid 
preparations from the M. smegmatis transformant.
A selection of colonies (27, 4 and 20 from the 6th, 8th 
and 11th passage respectively) were toothpicked and 
transferred to L-agar containing kanamycin (10 and 20ug/ml). 
All colonies transformed with plasmids from the earlier two 
preparations grew on kanamycin plates. None of the colonies 
transformed with the plasmid preparation from the 11th 
passage grew on kanamycin, even at the lower concentration. 
The control (untransformed LM1035) did not grow on kanamycin.
The host strain, transformed with pIJ666 was able to grow on
kanamycin (20ug/ml).
The results suggest that the pIJ666 plasmid used in the 
original M. smegmatis transformation, has undergone 
modifications whilst in the mycobacterial host. This is 
indicated by the fact that the plasmid from the 11th passage 
did not confer resistance to kanamycin in E. coli although 
the chloramphenicol resistance phenotype was still observed
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in the E, coll transformants. Large scale plasmid 
preparations from the three different types of E. coll 
transformants were performed for further analysis of the 
plasmids.
10.1.8 Large scale plasmid extractions of re-transformed
Escherichia coll strains
Four E. coll clones, designated A to D, from Experiment 
No.l, 2 clones, called E and F, from Experiment No.2, and 2 
clones, G and H, from Experiment No.3 (see Table IOC) were 
chosen for small scale plasmW preparation.
Small scale plasmid extraction from each clone and 
agarose electrophoresis revealed the presence of 
extrachromosomal DNA. Plasmids were then extracted from two 
clones of transformation Experiments No. 1 (A and B), one 
from Experiment No.2 (E) and two from Experiment No.3 (G and 
H) using the large scale method described earlier. Table lOD 
shows the designated names of the various plasmids isolated 
from the E. coll clones.
Table lOD Plasmids from E. coll clones
Plasmid Isolated from E. coll clone
pIJ666 (a)* A- (6th passage)pIJ666 (b)* B- (6th passage)pSUSOO E- (8th passage)pSUSOl G- (11th passage)PSU502 H- (11th passage)
* ( ) indicates that the plasmid has been shuttled betweenthe M. smegmatis transformant, ZZlOO, and E. coll and is not the original plasmid used in the initial M. smegmatis transformation.
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10.1.9 Analysis of recovered plasmids
The various plasmids recovered from the M. smegmatis 
transformants and re-transformed into E. coli were analysed 
by restriction digests and Southern hybridization if 
necessary. The plasmids, and the parental pIJ656, were 
digested with various enzymes and electrophoresed through 
agarose gels (0.8%) for two to three hours at lOOV (H5 
horizontal gel apparatus). Restriction digest fragments of 
plasmids pSUSOO, pSUSOl and pSU502 were analyzed further by 
Southern hybridization. The results are shown and discussed 
in the next three sections.
10.1.9.1 Analysis of pIJ666 (a) and (b)
Analysis of the plasmid isolated from ZZlOO after 6 
passages through chloramphenicol suggest that this plasmid is 
very similar to the parental pIJ666 (see Section 10.1.6 and 
Figure IOC). The plasmid, after re-transformation into 
E. coli was extracted from two E, coli clones, digested with 
various enzymes and analysed by agarose electrophoresis. The 
restriction fragments of these two plasmids, designated 
pIJ666 (a) and (b) (Figure lOD, tracks 2, 3, 5, 6, 8 and 9) 
was indistinguishable from that of the parental pIJ666 
(Figure lOD, tracks 4, 7 and 10). This agrees with the
previous result described in Section 10.1,6.
Restriction digest with other enzymes {BamEI, EcoRI and 
SphI) also did not reveal any detectable difference between 
the two plasmids and the parental pIJ666 (results not shown).
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The E. coll clones were also able to grow on kanamycin 
(20ug/ml), as well as on chloramphenicol, indicating that 
both resistance genes are still intact and functioning. The 
inability of the M. smegmatis transformant, from which the 
plasmid used to transform E. coll was isolated, to grow on 
kanamycin even at low concentration was therefore surprising. 
The Aphll gene from Tn5 has been shown to be well expressed 
by a variety of bacterial species (Tobias Kieser, personal 
communication). The product of the Rphll gene was also not 
detectable when the transformants were screened with 
polyclonal antiserum raised against it (Section 10.1.4). This 
result suggest that the M. smegmatis strain ATCC607 may be 
unable to recognise the Rphll gene promoter.
Alternatively, the copy number of the plasmid in 
M. smegmatis may be too low to allow the product of the Aphll 
gene to be detected by Western blotting which may also 
explain the lack of kanamycin resistance. However, the fact 
that the chloramphenicol resistant gene ( CRT gene from Tn9 ) 
was expressed sufficiently to confer the resistance phenotype 
suggests that the copy number of the plasmid in the 
mycobacterial transformants is adequate.
The other possible explanation is that the CRT gene 
promoter is recognised more efficiently than the Rphll gene 
promoter. Some mycobacterial promoters are recognised more 
efficiently than others by E. coli (see Section 4.3.1). The 
reverse might also be true.
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Figure lOD Restriction digest analysis of
pIJ666 (a) and pIJ666 (b)
Track Plasmid Digest
1 Lambda Hindlll marker2 pIJ666 (a) Hlndlll3 pIJ666 (b) Hindlll4 parental pIJ666 Hindlll5 pIJ666 (a) BamHI+EcoRI6 pIJ666 (b) BamHI+EcoRI7 parental pIJ666 BamHl+EcoRI8 pIJ666 (a) PstI9 pIJ666 (b) PstI10 parental pIJ666 PstI
2 3 4  5 6 7 8  9 10
Electrophoresis was for lOOV for 2 hours on an H5 gel electrophoresis gel apparatus.
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10.1.9.2 Analysis of pSUSOO
Previous results (Section 10.1.6), although not 
conclusive, suggested that the plasmid from ZZlOO after 8 
passages was not identical to the parental pIJ666. 
Restriction digests of this plasmid (Figure lOE) isolated 
from the E. coli re-tranformants confirms that the 
restriction digest patterns of pSUSOO (tracks 2 to 7) and the 
parental plasmid (tracks 8 to 13) are not identical. Table 
lOE shows the sizes of the restriction fragments of pSUSOO 
and the parental pIJ666 (see Figure lOF) for comparison.
However, the pattern of the PvuII digests of pSUSOO 
(Figure lOE, track S) and pIJ666 (track 11) showed bands of 
similar size (see Table lOE) suggesting that pSUSOO is 
related to pIJ666 and not a totally different plasmid. Two 
bands (3.6 and 1.7kb) were found in this digest of pSUSOO but 
not in the same digest of pIJ666. However, the 1.367kb 
fragment present in the PvuII digest of pIJ666 was not seen 
in pSUSOO. The rest of the restriction fragments in pIJ666 
appear to be present in pSUSOO.
This result suggests that pSUSOO is a plasmid which has 
evolved from the original pIJ666 by the insertion of an extra 
DNA fragment whilst in the M. smegmatis host. The size of 
this extra DNA fragment and its location of insertion can be 
deduced by analysing the various restriction digests of 
pSUSOO and comparing the results with the restriction map of 
pIJ666 (Figure lOF).
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Figure lOE Restriction digest analysis of pSUSOO 
Track Plasmid Digest
1 Lambda Hindlll marker2 pSUSOO BamHI3 pSUSOO ECORI4 pSUSOO Hindlll5 pSUSOO PvuII6 pSUSOO PvuII+Clal7 pSUSOO Uncut8 pIJ666 BamHI9 pIJ666 EcoRI10 pIJ666 Hindlll11 pIJ666 PvuII12 pIJ666 PvuII+Clal13 pIJ666 Uncut
1 2  3 4 5 6 7 8 9 10 11 12 13•
Electrophoresis was for 2 hours at lOOV (HS gel apparatus)
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Table lOE Restriction fragments of pSUSOO
Fragment size(kb)
Enzyme(s) pSUSOO pIJ666*
BamHI 6.4S.O 6.36 0.3S6
EcoRI 6.4S.O
6.716
Hindlll 6.0 S.676 0.688 0.3S2
PvuII 3.62.31.7 2.3411.3671.1 1.1130.73 0.7620.412<0.3 0.3600.2680.093
PvuII+Clal 3.62.3 2.341
1.3671.0 1.0020.73 0.762<0.6 0.4120.3600.2680.1110.093
* The restriction sites and sizes of the fragments for pIJ666 
were determined from the deduced sequence of this plasmid 
(see Appendix A and B).
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Figure 10F Simplified Restriction Map of pXJ666
£bo RI . 1 Puu ï1,103
Fuu 11,515
CAT
BRI
pIJ 666
67 1 6 b p Puu II.1628 Puu 11,1721'LAC
'P u u 11/1989 
H i tr i 111,2087TER4584, P s t  4478, Puu NEO TER y  Vi?d/?î H! .2429 \  \ H i t r ï III.2439 \ Eco R i?d/î? 1-11,2785
3716. Peu II 3661, Pst I 127Puu II,3356
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The BamHI digest of pSUSOO (Figure lOE, track 2) 
resulted in the generation of two bands; one of 6.4kb and the 
other of S.Okb in size. The 6.4kb band is similar to the 
6.36kb BamHI fragment of pIJ665 (see Table lOE and Figure 
lOE, track 8), The 5kb fragment is not found in pU666. 
Furthermore, the 0.356kb band (which is the stuffer fragment; 
see Figure lOF) observed in pIJ666 (Figure lOE, track 8) is 
not present in pSUSOO (Figure lOE, track 2).
These results suggest that the stuffer fragment of 
pIJ666 has either been completely or partially removed and 
replaced with a Skb DNA fragment or that the extra Skb 
fragment has recombined with the original plasmid at a 
position within the stuffer region of pIJ666 resulting in the 
new plasmid pSUSOO.
The Hindlll digest of pU666 generated three fragments 
(Figure lOE, track 3) of 5.676, 0.688 and 0.3S2kb in size. 
The same digest of pSUSOO resulted in only one band (Figure 
lOE, track 4). The intensity of this band however, strongly 
suggests that this band is actually a doublet i.e this digest 
of pSUSOO has resulted in two fragments of similar sizes 
(about 6kb). A possible explanation for this result can be 
made by analysing the restriction map of pIJ666 (Figure 
lOF).
Firstly, the 352 basepair fragment in pIJ666 is 
generated by the Hindlll sites at positions 2087 and 2439 
(see Figure lOF). The next fragment, 688 basepairs in size.
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is located between the Hindlll sites at positions 2439 and 
3127. The fact that the two fragments are no longer seen in 
the digest of pSUSOO suggests that the common Hindlll site 
shared by the two fragments (position 2439) has been lost. 
This result therefore agrees with the previous deduction from 
the BamHI digest i.e. that the stuffer fragment has been 
removed and replaced with another DNA fragment. The Hindlll 
digest of pSUSOO did not generate any other observable 
fragments indicating that the inserted DNA fragment do not 
contain any site for this enzyme.
Assuming that some if not most of the stuffer region of 
the original plasmid is no longer present in pSUSOO, and that 
the size of the inserted DNA fragment is about Skb (as 
suggested by the BamHI digest) then the Hindlll digest would 
generate a fragment consisting of the two terminator regions 
(see Figure lOF), each of which is 342 bases in size, and the 
Skb insert. The total size of this fragment would therefore 
be in the region of S.7kb. Furthermore, the other large 
fragment originating from the parental plasmid would also be 
about S.7kb in size (see Table lOE). This predicted result 
therefore, agrees very well with the observed digest (Figure 
lOE, track 4).
If a sizable proportion of the stuffer fragment remains 
(3S6 basepairs) then the total size of the fragment 
containing the inserted DNA would be about 6kb. It would 
still be difficult to discern the two bands on the gel.
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Analyses of other restriction digests of pSUSOO is 
consistent with the hypothesis that a Skb DNA fragment has 
replaced the stuffer region in the original pIJ666. A 
hypothetical restriction map of pSUSOO is shown in 
Figure lOG.
e
Figure 100 Hypothetical restriction map of pSUSOO
600 bp
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E. coli clones containing this plasmid were also able to 
grow on kanamycin indicating that the kanamycin resistance 
gene has not been affected by the recombination event. This 
agrees with the analysis of the results of the restriction 
digests (Figure lOG).
One possible reason why the recombination may have 
occurred at this particular site could be that the presence 
of the two terminator sequences very close together could 
result in a recombinational hot-spot. However, the nature and 
significance of the fragment which have been inserted is 
still unknown at this stage. Further work will be required to 
determine whether the inserted DNA is a random fragment from 
the host genome, a phage or a resident plasmid (Jones and 
David, 1972) and whether this DNA fragment plays a part in 
the observed transformation phenomenon.
The fragments generated from the digests of pSUSOO were 
further analyzed by Southern hybridization using labelled 
pIJ666 as the probe. The results showed that the Skb fragment 
in the BamHI digest of pSUSOO (Figure lOE, track 2) did not 
hybridize with the probe (results not shown).
The 3.6kb fragment in the PvuII digest of pSUSOO also 
did not hybridize with the probe (Figure lOH). The 1. 7kb 
PvuII fragment of pSUSOO hybridized weakly with the probe 
indicating that it contained some pIJ666 sequences. This is 
consistent with the suggested location of the extra fragment 
in pSUSOO as shown by the hypothetical restriction map
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(Figure lOG). These results suggest that the inserted DNA 
fragment presumably originate from the M. smegmatis host.
Figure lOH Southern hybridization of pSUSOO PvuII digest.
Track Plasmid
1 pIJ666 (PvuJJ)2 pSUSOO {PvuII)
0.5 6—
1 2
0«56—
10H(2)- The probe was pIJ666. Autoradiography was for 2 hours at room temperature.
10.1.9.3 Analysis of pSUSOl and pSUS02
The E. coli clones transformed with plasmid DNA 
preparation from ZZlOO after 11 passages did not grow on 
kanamycin even at low antibiotic concentrations. This 
immediately suggests that the plasmid has undergone some 
modification.
Figure 101(1) shows that the digest patterns of pSUSOl 
(tracks 3, 6, 9,) and pSU502 (tracks 4, 1, 10) are completely
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Figure 101 Restriction digests of pSUSOl and pSUS02
1(1 )
Track DNA Digest
1 Lambda Hindlll marker2 pIJ666 uncut3 pSUSOl uncut4 pSUS02 uncut5 pIJ666 BamHI6 pSUSOl BamHI7 pSUS02 BamHI8 pIJ666 Hindlll9 pSUSOl Hindlll10 pSUS02 Hindlll11 pIJ666' EcoRV12 pSUSOl ECORV13 pSU502 EcoRV14 Lambda Hindlll marker
1(2 )
Track DNA Digest 
1 Lambda Hindlll marker2 pIJ666 PstI3 pSUSOl PstI4 pSUS02 PstI5 pIJ666 EcoRV+Bglll6 pSUSOl EcoRV+Bglll7 pSUS02 ECORV+Bglll8 pIJ666 Clal+PvuII9 pSUSOl Clal+PvuII10 pSU502 Clal+PvuII11 pIJ666 PvuII12 pSUSOl PvuII13 pSUS02 PvuII14 Lambda Hindlll marker
5 6 7 8 9 10 11 12 13 ,4
Electrophoresis was for 1.S hours at lOOV (HS gel horizontal gel apparatus with IX Tris-borate running buffer).
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different from that of pIJ566 (tracks 2, 5, 8) and pSUSOO
(Figure lOE), Differences in banding patterns between the two 
plasmids and pIJ666 can also be observed with other 
restriction digests as shown by Figure 101(2).
An analysis of the restriction fragments showed that 
pSUSOl and pSU502 appear to be smaller than pIJ666 by about 
SOO bases. The regions where changes have occurred can also 
be identified.
Firstly, the loss of the two BamHI sites (Figure 101(1); 
tracks 6 and 7), two of the three Hindlll sites (Figure 
101(1); tracks 9 and 10) and both PstI sites (Figure 10(2); 
tracks 3 and 4) in the two plasmids are indicated by 
comparison with similar digests of the parental pIJ666 
(Figure 101(1); tracks 5 and 8, Figure 101(2); track 2 
respectively). These results suggest that modifications have 
occurred somewhere in the region containing these restriction 
sites.
In the parental pIJ666, these restriction sites are 
located in the region between positions 2087 and 4617 (see 
Figure lOF). This region includes the kanamycin resistance 
gene. The fact that clones containing the recovered plasmids 
are sensitive to kanamycin therefore is consistent with 
modifications occurring in the kanamycin resistance gene and 
agrees with the restriction digest analysis discussed above.
Analysis of other restriction digests of the two 
plasmids indicated that regions containing the Lac,
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terminators and the kanamycin resistance gene sequences have 
undergone changes although the exact modification events 
which may have occurred (deletions, insertions, re­
arrangements or various recombinations of the three) could 
not be determined.
Southern hybridization showed that these plasmids 
hybridized very strongly with pIJ666 indicating that the two 
plasmids also originated from pIJ666 (results not shown). 
Furthermore, all the fragments generated by the enzymes 
used so far contained regions homologous to the pIJ666 probe 
(results not shown). Thus there is no evidence that the 
recovered plasmids contain any inserted foreign DNA such as 
that seen in pSUSOO. This however do not of course rule out 
the possibility of foreign DNA integration since the inserted 
DNA, if present, may be very small and it may not be possible 
to isolate and identify it.
The relationship between these plasmids and pSUSOO poses 
another interesting question; could these two plasmids have 
evolved from pSUSOO (or a similar plasmid) whilst in the 
M. smegmatis host?
When one of these plasmids (pSUSOl) was labelled and 
used as a probe, the S kb band from pSUSOO {BamHI digest; see 
Section 10.1.9.2) which did not hybridize at all with pIJ565, 
gave a positive signal although it was fairly weak (results 
not shown). This suggests that the plasmids recovered from 
the eleventh subculture of the M. smegmatis transformant.
2S1
ZZlOO, did evolve from a plasmid like pSUSOO and that some 
sequences present in the extra S kb fragment of pSUSOO has 
been retained. More evidence however would be required to 
ascertain this.
The analyses of the results for plasmid pSUSOO gives a 
clear and straightforward conclusion that the transforming 
DNA, pIJ666, has had a fragment of foreign inserted into the 
region between the two terminator sequences. There was no 
evidence of any further change.
The analyses of the results for plasmids pSUSOl and 
pSUS02 suggest firstly that they were derived from pSUSOO. 
Secondly, further changes have occurred to the original 
pIJ666 involving deletions, re-arrangements and possibly 
insertions. The major areas where these modifications have 
occurred seemed to be in the regions containing the Lac, 
terminators and the Aphll gene (kanamycin resistance gene).
10.1.10 Re-transformation of Mycobacterium smegmatis
The next step was to use the plasmids isolated during 
the various stages, to re-transform M. smegmatis. The methods 
used for this experiment were described previously.
The transformants were selected on chloramphenicol 
(40ug/ml). The details and the results of the transformation 
experiments are shown in Table lOF.
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Table 10F Re-transformation of M. smegmatis
Plasmid Amountused(ug) No. of colonies Transformation (cfu/ug DNA)
From E.coll
pIJ666(a) Clone A pIJ666(b) Clone B pSUSOO Clone E pSUSOl Clone F pSU502 Clone G
0.150.10.10.120.12
11320360014751750
7.532.036.001.231.46
X  10^ 
X  10^ 
X  10^ 
X  104 
X  10^
From M.smegmatis
pIJ666 6th passage pSUSOO 8th passage 0.00250.0024 3001000 1.204.17 X  105 X  10^
Control
No DNA 0 0 0
"Plasmid preparation" from untransformed M. smegmatis 0 0
Several Interesting observations can be derived from 
the results shown above. Firstly, pIJ666 isolated from 
M. smegmatis was apparently more effective in re-transforming 
M. smegmatis than the same plasmids extracted from E. coll. 
This could indicate a restriction modification barrier in 
M. smegmatis but the result could also be affected by the 
purity of the DNA samples. DNA from M. smegmatis was purified 
on CsCl gradient while those from E. coll (pIJ666(a), 
pIJ666(b) were from small scale alkaline lysis plasmid 
preparations). The results could also be due to the different 
amounts of DNA used.
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The DNA from the mycobacterial host also gave higher 
transformation frequencies than the modified plasmids 
(pSUSOO, pSUSOl, pSU502) isolated from E. coll.
pSUSOO and pIJ666 isolated from the mycobacterial host 
gave comparable results. The fact that the number of colonies 
from pSUSOO is approximately three times greater than that of 
pIJ666 (using similar amounts of DNA) may be significant 
although the difficulty in obtaining accurate transformation 
frequencies, due to the level of growth during regeneration, 
must also be taken into account.
The second interesting observation that can be made is 
by comparing the transformation frequencies of the various 
plasmids extracted from E. coll. The results (Table lOF) 
suggest that the transformation efficiency increases as the 
plasmid undergoes the observed modifications in the 
mycobacterial host. The low transformation frequencies 
obtained from pIJ666(a) and (b) may be due their lower purity 
but comparison of pSUSOO and pSUSOl as well as pSUS02 (all 
three purified by CsCl gradient) shows that the last two 
plasmids have higher transformation frequencies.
These results seem to indicate that the modifications 
which the original transforming plasmid had undergone 
improves the transformation efficiency in M. smegmatis. The 
nature of the inserted fragment in pSUSOO, pSUSOl and pSU502 
has to be investigated further.
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10.1.11 Probing of DNA from untransformed M. smegmatis.
The results of the analysis of the plasmids pSUSOO, 
pSUSOl and pSUS02 suggest that a fragment of DNA from the 
host has been inserted into the original plasmid used to 
transform M. smegmatis ATCC607. To confirm that the inserted 
DNA originated from the mycobacterial host, total DNA from 
the parental strain was probed with the labelled pSUSOl and 
the Skb BamHI fragment from pSUSOO.
Total DNA from untransformed M. smegmatis ATCC607 was 
digested with BamHI, EcoRI, Sail and Bglll. The digested and 
undigested DNA was electrophoresed through 0.8% agarose. 
After transferring to Hybond-N membrane the DNA was probed 
with labelled pSUSOl. Autoradiography showed the presence of 
bands in the digested samples after the filter was washed in
0.1 X SSC for 10 minutes at 68°C but these bands were no 
longer seen when the filter was rewashed in the same buffer 
for another 30 minutes at the same temperature (results not 
shown) even after extended autoradiography (S days at -70°C).
The same filter was then probed with the Skb fragment 
isolated from pSUSOO (BamHI digest, using the GENECLEAN 
procedure) after removal of the first probe. No bands were 
were seen after the filter was washed in O.IX SSC at 68°C for 
30 minutes even after extended autoradiography ( -70*^ C for 7 
days) (results not shown).
The results of this experiment did not give a clear
2SS
answer to the question of the origin of the inserted 
fragment. However, a hypothesis can be formulated to try and 
explain these results.
Firstly, the results showed quite definitely that the 
inserted fragment did not originate from the chromosomal DNA 
of M. smegmatis ATCC607. This suggests that the fragment came 
from another source. The source of the 5kb fragment in pSUSOO 
therefore, could be a resident low copy number plasmid or a 
mycobacteriophage in M. smegmatis ATCC 607.
The probes used in this experiment however, should still 
have been able to locate the hypothetical plasmid or phage 
even if is present at only one copy per cell. The fact that 
this was not observed suggest firstly that this plasmid or 
phage, if present, is not episomal and hence probably self- 
replicating. However, the results also seem to indicate that 
the plasmid/phage is present at less than one copy per cell 
which is not possible under normal circumstances.
Two possible explanations can be forwarded to account 
for the observations. One, the plasmid/phage cannot be 
isolated by the methods used to extract the DNA due to 
instability of the plasmid/phage or some other as yet unknown 
factors. Second, ATCC607 may be heterogenous (Jacobs et al,
1987) and the plasmid/phage may be present in only a small 
percentage of the population which was then enriched by the 
selection procedure for the transformants.
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There are of course other possible sources of the 
inserted fragment such as RNA or a linear plasmid. Further 
work will be required to determine the origin of the inserted 
fragment.
The general conclusion that can be drawn from the 
results however is that M. smegmatis can be transformed with 
an E. coli plasmid using a simple and reproducible method. 
Furthermore, the plasmids are stably maintained and the 
expression of a non-mycobacterial gene can be achieved in 
M. smegmatis ATCC607. Other mycobacterial species especially 
BCG could perhaps be transformed using this method. It may 
also be possible to use other E. coli cloning vectors to 
transform mycobacterial species.
The results from these experiments are very encouraging 
for the general advance of mycobacterial genetic research. 
More work however would be required to understand the 
genetical basis of the transformation phenomenon such as the 
mode of replication of the vector in the M. smegmatis host as 
well as the origin, nature and significance of the fragment 
that was found in pSUSOO.
A recent paper by Snapper et al (1988) reported the 
results of an electroporation-based transformation system 
using a similar pool of recombinant plasmids (pIJ666/pAL5000; 
T. Kieser). Some of their findings however, contrasted with 
that obtained in this study. The results of the two studies 
will be discussed further in Chapter 11.
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DISCUSSION
CHAPTER 11
DISCUSSION
Transformation in Mycobacteria
The study of Mycobacterial genetics has only really 
started in earnest during the last three to four years. 
Techniques and methods for the manipulation of mycobacterial 
DNA are still at an early stage and requires more work to be 
done to refine and perfect them.
One of the most important molecular biology techniques 
for genetic manipulation is transformation, involving the 
use of phage and plasmid vectors or a combination of both.
Transformation systems for Mycobacteria have been 
described (Tokunaga and Nakamura, 1967, Norgard and Imaeda 
1978) but have not proved to be consistently reproducible or 
versatile enough to be of general use. Recently, Jacobs et al
(1987) described a transformation system using a phasmid; a 
vector constructed by fusing an E. coll plasmid with a 
mycobacteriophage.
The transformation system described in Chapter 11 of 
this study uses a plasmid vector and may prove to be a more 
flexible and versatile system than those previously 
described. An electroporation-based transformation system 
using plasmid and temperate phage cloning vectors was 
recently reported by Snapper et al (1988).
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Section 11.1 Independent replication of an Es cheM chia coll 
plasmid in Mycobacterium smegmatls ATCC607
The original plan in the preliminary experiment was to 
create a shuttle vector by cloning fragments of a 
M. fortultum plasmid, pALSOOO, in an E. coll plasmid called 
pIJ666. This was done because it was not thought possible for 
the E. coll plasmid to replicate independently in 
M. smegmatls.
The results however, surprisingly showed that the non­
recombinant plasmid can replicate independently in this 
Mycobacterial species. Furthermore, the plasmid can be 
shuttled from M. smegmatls to E. coll and back again.
The suggestion that this plasmid is self-replicating in 
M. smegmatls was indicated by the Southern blotting results 
especially in the undigested samples. The partial instability 
of the selected phenotype (chloramphenicol resistance) 
supports the hypothesis that the plasmid is self-replicating 
and no recombination with the chromosome has occurred. 
Furthermore, the instability of the phenotype also indicates 
that the chloramphenicol resistance was conferred by the 
plasmid and not through chromosomal mutation. This was also 
verified by r e -tr ans format ion into E. coll and M. smegmatls.
The important question arising from this result is, how 
does pIJ666, containing an E. coll origin of replication 
(P15A replicon), replicate independently in Mycobacteria? 
Other results (Z.Kunze, this department, unpublished) have
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shown that a plasmid based on the ColEl replicon can also 
transform M. smegmatls and the data strongly suggest that 
this plasmid can also replicate independently.
There are three possible explanation for this 
phenomenon. Firstly, M. smegmatls can recognise the E. coll 
origin of replication. Secondly, pIJ666 can recombine with a 
resident M. smegmatls plasmid or phage, which exist in low 
copy number or in an episomal state, and pIJ666 is thus 
replicated with the help of this resident plasmid or phage.
Thirdly, some other mechanism yet to be discovered, may 
exist which is involved in the replication of pIJ666 in 
M. smegmatls.
The results that have been obtained so far appear to
indicate a combination of the first two possibilities.
Firstly, the fact that a plasmid identical to pIJ666 was 
obtained from the M. smegmatls transformant after six 
passages through antibiotic media seemed to suggest that the 
E. coll origin of replication itself was being used for 
replication.
The phenomenon of a plasmid replicating in widely 
different genera has been reported. Serworld-Davis et al
(1987) reported that a plasmid from
Corynebacterium dlptherlae was able to replicate in E. coll. 
Furthermore, this plasmid has a higher copy number in E. coll 
than in the original host. Plasmids that can replicate in
Staphylococcus and E. coll were reported by Zyskind et al
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(1979), Goze and Ehrlich (1980) and Barany et al (1982). Kok 
et al (1984) and Forough et al (1987) presented results which 
showed that some plasmids that replicate in Bacillus and 
E. coll. These observations however does not preclude the 
possibility of a transient recombination occurring between 
pIJ666 and a resident plasmid.
The isolation of a plasmid approximately 11 kilobases in 
size (pSUSOO) after eight passages followed by a plasmid of 
about 6.4kb (pSUSOl and 502) in size after the eleventh 
passage strongly suggest that pIJ666 has had an extra 
fragment of DNA, of about 5.0 kb, inserted into the plasmid 
which was then followed by a deletion giving rise to a 
plasmid smaller than pIJ666 itself.
The significance of the insertion and deletion phenomena 
is unknown. The apparent increase in the transformation 
efficiency when the modified plasmids were used leads to the 
speculation that a mycobacterial origin of replication had 
been fortuitously inserted into pIJ666 in vivo. However, no 
direct evidence is available at this time and therefore these 
modified plasmids need to be investigated further.
The origin of the extra 5kb fragment found in plasmid 
pSUSOO is still unknown. The negative result which was 
obtained when this fragment was used to probe untransformed 
M. smegmatls ATCC607 DNA merely confirmed that this fragment 
did not originate from the chromosome. It would be tempting 
to speculate that this DNA fragment is actually the
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hypothetical resident plasmid that has been put forward 
previously. There have been reports in the literature for the 
evidence of the existence of a plasmid in M. smegmatls 
ATCC607 (Jones and David 1972, Jones et al 1974) but not its 
isolation.
One possible explanation for the negative results 
however, is that M, smegmatls ATCC607 is a heterogenous 
population. Only a small part of the population carries the 
resident plasmid. If the replication of pIJ666 involves 
recombination with this plasmid then the selective procedure 
for the marker phenotype would naturally select those cells 
containing the plasmid.
An alternative explanation is recombination of pIJ666 
with a mycobacteriophage. The extra DNA could have come from 
a mycobacteriophage which is present in the lysogenic or 
pseudolysogenic state in only a small part of the population. 
At any one time only some of the population is involved with 
the mycobacteriophage lytic and lysogenic cycles and thus the 
phage is maintained within the population. This may also 
explain why the phage was not detected in parental strain 
when probed with the extra fragment from pSUSOO.
Many examples of lysogenic mycobacteriophages have been 
described (Redmond, 1953, Grange, 1975 for reviews) including 
those of M. smegmatls. Pseudolysogenic strains of 
M. fortultum and M. dlernhoferl have also been reported 
(Baess, 1971, Nordstrom and Grange, 1974) in which only a
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small proportion of the population carries the
mycobacteriophage. Lysogenic mycobacteriophages have been 
implicated with host conversion (Bonicke and Saito, 1970, 
Grange,1975) including colonial morphology in strains of 
M. smegmatls. Interestingly, colonial variation has been 
reported in M. smegmatls ATCC607 (Bloom and Godal, 1983).
Recently, a temperate phage was isolated from 
M. smegmatls ATCC607 (Françoise Haeseleer and P. Jacobs,
1988). Haeseleer and Jacobs further indicated that the phage 
may be present in only a small proportion of the ATCC607 
population. Further work however is required to determine 
whether the extra DNA fragment found in pSUSOO originated 
from this phage.
The results from the initial transformation experiment, 
in which the M. smegmatls transformants were probed with 
labelled pIJ666 suggest that the copy number of the plasmid 
pIJ656 vary from one transformant to another. One possible 
interpretation of the result is that pIJ665 is capable of 
self-replication in M. smegmatls ATCC607 even in those cells 
that do not contain the hypothetical resident plasmid (or 
phage). However, if the resident plasmid or phage is present, 
then co-replication involving recombination or some other 
unknown mechanism may result in a higher copy number of 
pIJ666 in the M. smegmatls host as observed in clone ZZIOO.
The difference in the copy number however, may be due to 
some other factors. For example it has been found that
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plasmids replicating from the chromosomal origin, oriC 
(E. coll and Salmonella typhlmurlum), have copy numbers that 
can vary widely even within a single population (Messer 
et al, 1978, Zyskind et al, 1979).
The control of plasmid replication is still not fully 
known even in a well characterised system such as E. coll 
(Nordstrom, 1981). Different types of replication control 
systems have been found and different principles appear to be 
involved (Nordstrom, 1983). In Mycobacterium, similar systems 
may be present enabling E. coll plasmids to be independently 
replicated.
Section 11.2 The expression of the Chloramphenicol
Acetyltransferase gene from Tn9
The successful isolation of M. smegmatls transformants 
with the chloramphenicol resistance phenotype and the 
evidence that the transforming plasmids were stably 
maintained indicated that the transcriptional and 
translational signals of this gene were recognised by 
M. smegmatls ATCC607.
Recently in the last few years, the cloning of 
mycobacterial DNA using E, coll plasmid, cosmid and lambda 
vectors have been reported (Bhattacharya and Bhattacharya, 
1984; Jacobs at al, 1986a and 1986b; Clark-Curtiss et al, 
1985; Thole et al, 1985; Khandekar et al, 1986; Kieser et al, 
1986 ). These workers have shown that mycobacterial promoters 
were mostly poorly recognised or not at all by the E. coll
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transcriptonal systems although evidence showed that 
translational signals were well expressed. Some mycobacterial 
promoters however, were recognised fairly efficiently by 
E. coll (Shinnick, 1987; Moss, 1988). Thus, it would not be 
too surprising if the reciprocal phenomena occurred in 
mycobacteria.
More recently, Rauzier et al (1988) have sequenced a 
mycobacterial plasmid and showed that this plasmid has 
homologies with various E. coll plasmids at both the DNA and 
the amino acid levels. Furthermore, they have shown evidence 
of the presence of typical Shine-Dalgarno sequences preceding 
the open reading frames found in this plasmid. This suggest 
that transcriptional and translational mechanisms in E. coll 
and M. smegmatls ATCC607 may share many similarities.
The fact that kanamycin resistance was not found may be 
due to the inability of M. smegmatls to recognise the 
particular promoter for this gene. The possibility that the 
result may be due to the low copy number of the plasmid in 
the mycobacterial host is not supported by the observation 
that the level of expression of the CAT gene, located on the 
same plasmid was sufficient to confer resistance to the 
mycobacterial transformants.
However, the recent report by Snapper et al (1988) 
indicated that this gene is well expressed in M. smegmatls 
ATCC607. The transformation experiment reported by Snapper 
et al was performed using a similar pool of hybrid plasmids
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(pIJ666/pAL5000 recombinants) prepared by T. Kieser as that 
used in this study (designated as the pTK pool in this 
thesis). However, they were unable to select their 
transformants on chloramphenicol due to the appearance of 
large numbers of chloramphenicol resistant colonies on their 
control plates. This phenomenon was not observed in the study 
reported in this thesis. Snapper et al (1988) were also 
unable to transform the mc^6 strain with the parental pIJ666.
The results obtained from the two studies therefore 
differ in many ways although transformants were obtained in 
both cases. Two possible reasons may account for the 
differences in the two results.
Firstly, the M. smegmatls ATCC607 strain used by Jacobs 
et al, (1987) was found to contain three different colonial 
types on a Streptomyces medium One colony which was 
pigmented and had a rough morphology was chosen and 
designated as mc^6. The mc^6 strain was used by Snapper et al
(1988) in their study.
The strain that was used in this study however, was not 
chosen in this way. The parental strain was streaked on 7H11 
agar to obtain single colonies. Colonial variation was not 
observed on this medium. One colony was chosen to prepare the 
culture from which sphaeroplasts were produced for 
transformation. Thus, the different results which were 
obtained from the two studies may be due to strain 
differences.
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For example, the positive result obtained in the 
transformation experiment in this study using the parental 
plasmid may be due to the presence of the speculated resident 
plasmid/phage in the host strain that was used. The negative 
result from the study by Snapper et al therefore, may be due 
to the absence of the plasmid/phage in the mc^6 strain.
Secondly, growth conditions may affect the outcome of 
the transformation experiment. For example, sodium alginate 
was shown by Baltimore et al (1987) to inhibit the action of 
two aminoglycoside antibiotics (amikacin and gentamicin) 
against Pseudomonas aeruginosa strains. Sodium alginate is a 
common polysaccharide of seaweed. The agar used in preparing 
most solid media are usually produced from seaweed. It is 
therefore possible to speculate that other substances may be 
present, in varying amounts in different agar preparations 
which may cause similar effects such as inhibiting the 
activity of chloramphenicol in mycobacteria. The colonies 
observed on the control plates in the study by Snapper at al
(1988) may not be chloramphenicol resistant mutants after all 
but were able to grow because the activity of chloramphenicol 
in their medium was inhibited.
Similarly, a substance or substances present in their 
medium may increase the rate of mutation to chloramphenicol 
resistance. Parental and transformed strains have been 
exchanged and investigations are being conducted in both 
laboratories to determine the possible causes of the 
contrasting results.
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The results from this work and others are very 
encouraging for further understanding of mycobacterial 
genetics. More work however needs to be done to optimize and 
understand the system of mycobacterial transformation. The 
next goal in this field would be to transform other 
mycobacterial species. By introducing and expressing genes in 
mycobacteria especially BCG, it may be possible to develop 
useful multivaccine vehicles for many different diseases.
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CHAPTER 12
DISCUSSION
Plasmid and Plasmid-Related DNA in Mycobacteria
The search for plasmids in M. tuberculosis was prompted 
by several reasons.
Firstly, several reports in the literature have 
suggested the presence of extrachromosomal DNA in 
M. tuberculosis. Plasmids have been suggested to be involved 
with DNA méthylation and virulence (Srivastava et al, 1981), 
and aminoglycoside resistance (Alberghina et al, 1973; 
Marshall et al 1948). The rapid acquisition of streptomycin 
resistance by clinical isolates of M. tuberculosis as 
reported by Marshall et al in 1947 as well as the observation 
that streptomycin resistance tended to be unstable (M. Yates, 
Regional Tuberculosis Reference Laboratory, Dulwich Hospital, 
personal communication) seemed to suggest that 
extrachromosomal determinants were involved in these 
phenomena. However, no reports of the isolation or even the 
evidence on agarose gels of plasmids in M. tuberculosis has 
been communicated thus far.
Secondly, plasmids have been reported in other 
mycobacterial species. In the MAIS complex, plasmids have 
been suggested to be implicated in antibiotic resistance 
(Mizuguchi et al, 1981 and 1983; Franzblau et al, 1986), 
heavy metal resistance (Erardi et al, 1987) and virulence
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(Crawford and Bates, 1986; Gangadharam et al, 1988). Crawford 
et al (1981) have also reported that restriction-modification 
in one strain of M. avtum-intracellulare was mediated by a 
plasmid. These reports however, were all based on indirect 
evidence such as analysis of plasmid profiles or the 
instability of a phenotype. The lack of a transformation 
system for mycobacteria has made it difficult to study each 
individual mycobacterial plasmid.
Thirdly, there is no indication in the literature of any 
attempts to do a large scale screening for plasmids in 
M. tuberculosis. A study of this kind was thought to be 
appropriate especially in the light of the importance of 
plasmids in many microbial systems (Broda, 1979; Ellwell and 
Falkow, 1980; Lyon and Skurray, 1987; Sugisaki et ai, 1984; 
Plasterk et al, 1985). Furthermore, this work would help to 
contribute towards the emerging field of mycobacterial 
genetics.
Section 12.1 Plasmid screening of M. tuberculosis
Although some evidence of extrachromosomal DNA were found 
in some strains of M. tuberculosis by agarose 
electrophoresis, its isolation was not successful. Four 
possible reasons could account for this result.
Firstly, the apparent bands, other than the chromosome, 
that were found in these strains could be artefacts produced 
during the running of the gel.
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Secondly, the plasmids if present, could be linear 
similar to those described in Streptomyces (Hirochika and 
Sakaguchi, 1982; Hirochika et al, 1984; Kinashi et al, 1987), 
and yeast (Gunge et al, 1981; Stark et al 1984). Linear 
plasmids would be difficult to separate from chromosomal DNA 
using conventional techniques.
Thirdly, the putative M. tuberculosis plasmids may be 
unstable and cannot be isolated by the methods used. Unstable 
plasmids have been reported in Pseudomonas (Duggleby et al, 
1978, Wheatcroft and Williams, 1981).
Finally, plasmids may be present in M. tuberculosis in 
an episomal state and thus not detectable or extractable by 
the usual means. It is possible that the extrachromosomal 
bands seen in some of the strains were the plasmids coming 
out of the episomal state.
Section 12.2 Plasmid-related sequences in
M. tuberculosis genomic DNA
Although, no firm evidence for the presence of 
extrachromosomal DNA was obtained, further work has shown the 
existence of plasmid-related sequences in the genomic DNA of 
M. tuberculosis as decribed in Chapter 9. Furthermore, this 
work has led to other unexpected bonuses in the form of two 
DNA probes with which restriction fragment length 
polymorphism was found in M. tuberculosis and related 
species.
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There have been many attempts to classify 
M. tuberculosis into various subdivisions for epidemiological 
studies (Grange, 1979). Methods such as phage typing (Baess, 
1966 and 1969), DNA homology (Bradley, 1972; Baess, 1979), 
immunodiffusion analysis (Stanford and Grange, 1974), 
biochemical differences (Collins et al, 1982), mycolic acid 
patterns (Minnikin and Goodfellow, 1980; Minnikin et al, 
1984a and 1984b) and DNA restriction analysis (Collins and 
De Lisle,1985) have been used.
M. avium-intracellulare strains isolated from patients 
suffering from AIDS have been found to contain plasmids. 
Relationship with virulence and the use of plasmids as 
epidemiological markers have been proposed (Crawford and 
Bates, 1986, Labidi et al, 1984).
Recently, the use of specific DNA probes to identify 
M. avium, M. intracellulare and M. tuberculosis have been 
reported (Kiehn and Edwards, 1987). The probe is specific for 
the ribosomal RNA of the target organisms and is produced 
commercially (Gen-Probe Corporation, San Diego, California). 
The probe for M. tuberculosis however does not differentiate 
between strains. Mcfadden et al (1987a, 1987b and 1988) have 
also reported the use of DNA probes for the identification of 
M. paratuberculosis.
The DNA probes found in this thesis may prove to be a 
useful addition to complement the various methods used for 
epidemiological studies of M. tuberculosis, although the
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probes require further analysis. The nature of the sequences 
of the probes as well as the functions if any in 
M. tuberculosis and related species, have to be elucidated. 
Mcfadden et al (1987a) reported the finding that 
M. paratuberculosis contains several copies of insertion 
sequences (IS) in its genome. This bears a striking 
similarity to the results found in this thesis, although they 
differ in the diversity of the banding patterns discovered 
within the M. tuberculosis species.
In conclusion, although many questions are still 
unanswered, future work will hopefully elucidate some of 
them. Application of the probes in clinical research is only 
one possibility. The profound difference between the human, 
bovine and the BCG species in the M. tuberculosis complex as 
indicated by the banding patterns when the 5 kb fragment was 
used as the probe, may be clinically significant. The 
repeated sequences may play a role in virulence or antigenic 
interactions with the host. Further study of the two probes 
should help in the greater understanding of the genetics of 
M. tuberculosis and perhaps the Mycobacterium genus as a 
whole.
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CONCLUSION
CONCLUSIONS
1. No self replicating plasmid was observed in M. tuberculosis.
2. Plasmid-related sequences were present in M, tuberculosis 
and closely related species.
3. Isolation of a DNA fragment from a strain of 
M. tuberculosis led to the discovery of two DNA probes which 
were highly specific for M. tuberculosis and related species.
4. One of the probes could be used to show the presence of 
restriction fragment polymorphism in M. tuberculosis,
5. The other probe gave strain specific banding patterns in 
M. tuberculosis DNA.
6. A method for introducing plasmid DNA into M. smegmatis 
ATCC 607 was found.
7. E. coli plasmid pIJ666 was able to replicate independently 
in M. smegmatis ATCC 607.
8. The plasmid pIJ666 was found to undergo modifications in 
vfwo leading to a plasmid which may be useful for the 
transformation of Mycobacterium,
FUTURE PROJECTS
1. Characterisation of the two DNA probes for M. tuberculosis 
and sequencing.
2. To determine the feasibility of using the probes for 
epidemiological studies of tuberculosis and as diagnostic 
reagents.
3. To elucidate further the phenomena of transformation in 
M. smegmatis.
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4, To investigate the replication of E. coll plasmids in 
M. smegmatls,
5, To investigate the use of various plasmids in 
transformation of other mycobacteria species such as 
M. tuberculosis and BCG.
6, Cloning of mycobacterial genes in mycobacterial host.
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APPENDIX
APPENDIX A
NUCLEOTIDE SEQUENCE OF pIJ666
pIJ666 is a plasmid based on the multicopy cloning 
vector pACYC184, pIJ666 was constructed by Dr. Tobias Kieser 
at the John Innes Institute, Norwich as a positive cloning 
vector,
During the course of the work for this thesis, it was 
noticed that the given restriction map did not correspond 
with some of the actual restriction digest experiments. An 
attempt was therefore made to determine the sequence and thus 
the restriction sites of the plasmid since all the various 
DNA fragments used to construct the plasmid have been 
sequenced. This work was done using the Beckman Microgenie 
Program and Database and reference was made to Gentz et al 
(1981) for the construction of the precursor plasmid, pLBUl, 
Kieser and Melton (1988) for the construction of pIJ666 
itself and R.E.Rose (1988) for the complete sequence of 
PACYC184.
Listed in Table API are the DNA fragments which together 
make up the plasmid pIJ666 and the source of the sequence of 
each fragment. From the compiled sequence a list of predicted 
restriction sites were obtained ( see Appendix B). Restriction 
digests were performed using selected enzymes and the 
generated fragments were compared with those predicted by the 
sequence.
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Table API Source of DNA fragments in pIJ666
Fragment Source of nucleotide sequence
fd terminator (strain 478) lac*RphII~PACYC184
Beckman Microgenie Database
Beckman Microgenie Database Beckman microgenie Database R.E.Rose (1988), Nucleic Acids Research, 16 (1), 355
* Promoter, operator and part of lacZ regions ~ Kanamycin resistance gene from Tn5
Figures API and AP2 shows the results of the digest 
after electrophoresis through agarose. Table AP2 shows the 
sizes of the generated and predicted fragments for 
comparison.
The results shows good correlation between the predicted 
and the actual restriction digest fragments. Digestions using 
other enzymes not included in the table also shows good 
correlation with the predicted fragments.
Although the compiled sequence cannot be considered as a 
true sequence of pIJ666, since no actual sequencing was done, 
the results shows that the compiled sequence is accurate 
enough to be used with a fairly high degree of confidence.
A restriction map of pIJ666 was constructed using the 
predicted restriction sites based on the sequence. This map 
will be used throughout the thesis where the use of pIJ666 
was involved.
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Table AP2 Generated and predicted restriction fragments of pIJ666
Enzyme(s) Sizes of fragments (kb)
Predicted Generated from actual digests'"
Figure API
(1) Bami 6,360 6,390356 391
(2) EcoRI 6,7 6,820
(3) Hindi 11 5,676 5,680688 710352 315
(4) PvuII 2,341 2,3501,367 1,4101,113 1,090762 749412 397360 340268 28893 -
Figure AP2
(2) Red 4,023 4,0072,693 2,701
(3) Rcd+Clal 3,100 3,1472,693 2,726923 978
(4) Rcd+Hindl 4.023 4,1401,627 1,6411,066 1,070
(5) EcoRI+BamHI 3,931 4,1012,429 2,520356 412
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Table AP2 (continued)
Enzyme(s) Sizes of fragments (kb)
Predicted Generated from actual digests'"
Figure AP2
(6)*EcoRI-f-SalI 4,617 4,7002,099 2,167
(7) HiJidlll+Sall 4,187 4,2221,490 1,550688 720352 340
* - The numbers in brackets refers to the track numbers on the respective Figures.
- The restriction fragments were measured using the Microgenie program connected to a digitizer.
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Figure API Restriction digests of pIJ666 
Track Digest
(1) 
(2 ) 
(3) 
(4 )
BamHl
EcoRI
Hindlll
PvuII
0»5 6—
Figure AP2 Restriction digests of pIJ666
Track Digest
(1) Lambda Hindlll marker
(2) AccI
(3) Accl+Clal
(4) AccI+HincII
(5) EcoRI+BamHI
(6) EcoRI+Sall
(7) Hindlll+Sall
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APPENDIX B
SELECTED RESTRICTION SITES OF pIJ666
R e d  (GTVWAC)
Aval (CQCGPG)
BamHJ(GGATCC)
Bglll (AGATCT)
Clal (ATCGAT)
BCORI (GAATTC)
ECORV (GATATC)
Haell (PGCGCQ)
NO. SITES
5944617
FRAGMENTS
11
44495391
24292785
3448
1517
2595
5801669206026423363361147415171583558895972
40232693
5774942
6360356
1324113010897216645824303912488354
(59.9)(40.1)
(86.0)(14.0)
(94.7) ( 5.3)
6716 (100.)
6716 (100.)
6716 (100.)
6716 (100.)
(19.7)(16.8) (16.2) (10.7) ( 9.9)8.7) 6.4)5.8) 3.7) 1.2) 0.8)
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NO SITES FRAGMENTS
HindiII (AAGCTT)
PstI (CTGCAG)
PVUII (CAGCTG)
Sail (GTCGAC)
208724393127
36614584
103515162817211989335637164478
4617
5676688352
5793923
23411367111376241236026893
(84.5) (10.2) ( 5.2)
(86.3)(13.7)
(34.9) (20.4) (16.6) (11.3) ( 6.1) ( 5.4) ( 4.0) ( 1.4)
6716 (100.)
Smal (CCCGGG) NO1
SITES
4449
Xbal (TCTAGA) 1 1424
The following do not appear;
Aatll Afin Apal Apa LlAvalII Avril BSt Eli BSt XIDrain Hpal Kpnl MlulNdel Notl NslI SadSfil SnaBI Spel StuI
FRAGMENTS
6716 (100.)
6716 (100.)
Xhol
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